RESULT_COUNT: 911,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics to Announce Third Quarter 2017 Financial Results and Recent Corporate Developments on October 25, 2017",2017-10-16 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announce-third-quarter-123000420.html?.tsrc=rss,"CAMBRIDGE, Mass., Oct. 16, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,Why These Biotech Players Look Poised To Crush Earnings Views,2017-10-13 22:16:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uYjC4ojl3iY/why-these-biotech-players-look-poised-to-crush-earnings-views-cm859687,Biogen BIIB Gilead Sciences GILD and Sarepta Therapeutics SRPT will build on momentum in the biotech sphere to beat Wall Street expectations for the third quarter an analyst predicted Friday ibd display video id 2359800 width 50 float
SRPT,SRPT:UW,BBG000BCJC58,SPDR S&P Biotech ETF Experiences Big Outflow,2017-10-13 16:12:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y2YeC8dLonY/spdr-sp-biotech-etf-experiences-big-outflow-cm859407,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 65 4 million dollar outflow that s a 1 5 decrease week over week from 49 500 000
SRPT,SRPT:UW,BBG000BCJC58,7 Essential Rules for Investing in Biotech Stocks,2017-10-12 10:04:00 +0000,https://finance.yahoo.com/news/7-essential-rules-investing-biotech-100400466.html?.tsrc=rss,"If you only master one of these rules, definitely focus on the last one."
SRPT,SRPT:UW,BBG000BCJC58,"These Biotech Stocks Are Pricey, but Investors Can Still Buy Them",2017-10-11 02:10:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jGQbSIqanjo/these-biotech-stocks-are-pricey-but-investors-can-still-buy-them-cm857879,Sarepta Therapeutics NASDAQ SRPT and Amicus Therapeutics NASDAQ FOLD 160 are two fast growing biotech stocks that are trading at price to sales multiples north of 50 yet biotech investors may still want to add them to their portfolios despite their sky high valuations
SRPT,SRPT:UW,BBG000BCJC58,"These Biotech Stocks Are Pricey, but Investors Can Still Buy Them",2017-10-11 01:00:00 +0000,https://finance.yahoo.com/news/biotech-stocks-pricey-investors-still-010000720.html?.tsrc=rss,"Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: A-OK from the FDA?,2017-10-09 17:23:00 +0000,http://finance.yahoo.com/r/33353bc6-0bc5-30a1-ab2c-e65d8d43f568/sarepta-an-ok-from-the-fda-1507569794?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Controversy dimmed the excitement over the FDA’s decision last year to approve Sarepta Therapeutics’s (SRPT) Duchenne muscular dystrophy drug Exondys51.  On Saturday, early-stage data regarding golodirsen was released at the 22nd International Annual Congress of the World Muscle Society.  Today, some analysts are offering their take on what might be in store for Sarepta and at the FDA."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta shares rise nearly 3% premarket after RBC sees 'compelling' argument for faster approval of DMD drug,2017-10-09 12:30:33 +0000,http://finance.yahoo.com/r/4b142d3c-d5f0-3f6a-85b1-f80c15118a15/Story.aspx?guid=4EDB3B64-2E96-4FB3-9954-2A535FF5DCF9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics Inc. shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a ""compelling argument"" for faster-than-normal approval ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta shares rise nearly 3% premarket after RBC sees 'compelling' argument for faster approval of DMD drug,2017-10-09 12:30:33 +0000,https://finance.yahoo.com/news/sarepta-shares-rise-nearly-3-123033161.html?.tsrc=rss,"Sarepta Therapeutics Inc. shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a ""compelling argument"" for faster-than-normal approval ..."
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-10-09 12:05:08 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120508041.html?.tsrc=rss,Sarepta Therapeutics Inc NASDAQ/NGS:SRPT
SRPT,SRPT:UW,BBG000BCJC58,"Catabasis' DMD Candidate Slows Disease Progression, Stock Up",2017-10-05 17:48:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OD5R5R9SzV0/catabasis-dmd-candidate-slows-disease-progression-stock-up-cm855887,Catabasis Pharmaceuticals Inc CATB announced data from a phase II study which showed that its pipeline candidate edasalonexent substantially slowed disease progression in male children with Duchenne muscular dystrophy DMD The company is planning to initiate a phase III study on
SRPT,SRPT:UW,BBG000BCJC58,"XBI, CLVS, SRPT, PBYI: Large Inflows Detected at ETF",2017-10-05 16:49:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gunbgtXORhM/xbi-clvs-srpt-pbyi-large-inflows-detected-at-etf-cm855842,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 101 6 million dollar inflow that s a 2 4 increase week over week in outstanding
SRPT,SRPT:UW,BBG000BCJC58,"Catabasis&apos; DMD Candidate Slows Disease Progression, Stock Up",2017-10-05 15:47:03 +0000,https://finance.yahoo.com/news/catabasis-apos-dmd-candidate-slows-154703511.html?.tsrc=rss,Catabasis&apos; (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
SRPT,SRPT:UW,BBG000BCJC58,What Caused Sarepta Therapeutics to Rally 12.6% in September,2017-10-05 00:47:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nz1FRxmTBmM/what-caused-sarepta-therapeutics-to-rally-126-in-september-cm855496,What happened After reporting early stage data from a drug candidate for the treatment of Duchenne muscular dystrophy DMD on September 6 shares in Sarepta Therapeutics NASDAQ SRPT 160 jumped 12 6 last month according to S amp P Global Market Intelligence So
SRPT,SRPT:UW,BBG000BCJC58,What Caused Sarepta Therapeutics to Rally 12.6% in September,2017-10-04 23:31:00 +0000,http://finance.yahoo.com/r/4b1a9c8e-fe41-3409-b17d-ebf80770bbe7/what-caused-sarepta-therapeutics-to-rally-126-in-s.aspx?yptr=yahoo&.tsrc=rss,Optimism is building for the company&apos;s potential to treat more Duchenne muscular dystrophy patients.
SRPT,SRPT:UW,BBG000BCJC58,"Armed with fresh trial data, Catabasis doubles down on Duchenne drug",2017-10-04 08:55:07 +0000,http://finance.yahoo.com/r/cc12170f-a8c0-3416-9d94-33ede4d621f9/armed-with-fresh-trial-data-catabasis-doubles-down.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Regrouping after a trial setback involving its lead drug for Duchenne muscular dystrophy, Cambridge-based Catabasis Pharmaceuticals is forging ahead with a late-stage study, touting new data on Wednesday hinting that the treatment can improve the lives of boys with the muscle-wasting disease.  Catabasis (CATB) previously announced in January that a Phase 2 study of the drug, called edasalonexent, had failed to meet its primary goal — significantly reducing leg muscle inflammation compared to placebo after 12 weeks.  On Wednesday, Catabasis released data from an extended portion of the Phase 2 trial, in which around half of the patients continued to receive edasalonexent for an additional 12 or 24 weeks."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Surges on Top-Line Beats: Morgan Stanley,2017-10-03 18:04:00 +0000,http://finance.yahoo.com/r/c2fa1c50-b248-3656-864e-2c2fa850759a/sarepta-surges-topline-beats-morgan-stanley?partner=YahooSA&yptr=yahoo&.tsrc=rss,Analysts lift their rating on the drug company based on positive indicators for two new therapies.
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Endo International,2017-10-03 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000052.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / October 3, 2017 / U.S. markets kicked off the fourth quarter in the green Monday as investors appear optimistic that the markets record run will continue. The Dow Jones Industrial ..."
SRPT,SRPT:UW,BBG000BCJC58,"ECYT On Fire After ABX Deal, Rigel's ITP Drug Skips Panel Review, MCRB On Watch",2017-10-02 21:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R6yRkYK0ZHc/ecyt-on-fire-after-abx-deal-rigels-itp-drug-skips-panel-review-mcrb-on-watch-20171002-01496,"ECYT On Fire After ABX Deal, Rigel's ITP Drug Skips Panel Review, MCRB On Watch"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Stock Soars Despite Adverse Event Worries,2017-10-02 20:48:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ii1x7W079bE/sarepta-therapeutics-stock-soars-despite-adverse-event-worries-cm854187,Late last week some Sarepta Therapeutics NASDAQ SRPT investors were worried Now the weekend is over and all of those worries seem to have dissipated Concerns arose after the U S Food and Drug Administration FDA made its database of prescription drug adverse events
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Stock Soars Despite Adverse Event Worries,2017-10-02 19:02:00 +0000,http://finance.yahoo.com/r/e1c0f415-b6af-346f-a0df-1117befc6bef/sarepta-therapeutics-stock-soars-despite-adverse-e.aspx?yptr=yahoo&.tsrc=rss,Worries about side effects for the biotech&apos;s DMD drug get swept away.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: Join the Club,2017-10-02 17:43:00 +0000,http://finance.yahoo.com/r/9f50372f-f299-3321-b1b5-178ef853ab06/sarepta-therapeutics-join-the-club-1506966206?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Barron's Andrew Bary has been a fan of Sarepta Therapeutics (SRPT) for a long time.  Bary has remained bullish nearly every step of the way, most recently last month, when he argued that ""soaring Sarepta can continue to stay hot,"" thanks to the possibility for an accelerated approval for a second Duchenne muscular dystrophy.  For instance, Morgan Stanley's Matthew Harrison and team upgraded Sarepta to Overweight from Equal Weight with a $60 price target today."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics shares surge 7.5% after Morgan Stanley upgrade,2017-10-02 14:25:47 +0000,http://finance.yahoo.com/r/af0824d3-a032-344d-98fc-0185436ae405/Story.aspx?guid=1D43B2FB-B8B0-4EC1-86F1-BA9CFC980487&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics Inc. shares surged 7.5% in heavy morning trade Monday after the company was upgraded to overweight by Morgan Stanley with a $60 price target. Sarepta shares were valued at $48.68 as ...
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-10-02 12:03:31 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120414879.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SRPT,SRPT:UW,BBG000BCJC58,Investors want PTC Therapeutics to be the next Sarepta,2017-10-01 21:11:01 +0000,http://finance.yahoo.com/r/99de522f-ed0e-3dfe-b9a9-9ccabca8614c/Story.aspx?guid=C64C9D46-A511-11E7-9C2E-5F86E81714D2&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Sarepta’s Duchenne muscular dystrophy drug was approved by the FDA despite a negative recommendation — sparking concerns about setting a precedent.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-09-29 22:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-223000215.html?.tsrc=rss,"CAMBRIDGE, Mass., Sept. 29, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Dives On Drug-Tied Deaths, Helping PTC Shares Spike",2017-09-29 21:33:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fk-5rw2jSrg/sarepta-dives-on-drug-tied-deaths-helping-ptc-shares-spike-cm853268,Sarepta Therapeutics SRPT flopped Friday after the Food and Drug Administration released details of patient deaths following treatment with a Duchenne muscular dystrophy drug Exondys 51 prodding rival PTC Therapeutics PTCT to pop ibd display video id
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Dives On Drug-Tied Deaths, Helping PTC Shares Spike",2017-09-29 20:50:15 +0000,http://finance.yahoo.com/r/75804477-f369-3833-aab5-cbf65138f6a0/sarepta-dives-on-drug-tied-deaths-helping-ptc-shares-spike?src=A00220&yptr=yahoo&.tsrc=rss,Sarepta flopped Friday after the FDA released details of patient deaths following treatment with its muscular dystrophy drug.
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy Friday Option Activity: AGO, SRPT, MTZ",2017-09-29 20:36:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fyewk3JvrbY/noteworthy-friday-option-activity-ago-srpt-mtz-cm853278,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Assured Guaranty Ltd Symbol AGO where a total of 4 681 contracts have traded so far representing approximately 468 100 underlying shares That amounts to about 53 1 of AGO s
SRPT,SRPT:UW,BBG000BCJC58,"The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Today",2017-09-29 18:35:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d4g6JEoX5jc/the-unusual-reason-ptc-therapeutics-inc-is-bouncing-back-today-cm853225,What happened Despite a 10 1 advisory committee vote against PTC Therapeutics Inc s NASDAQ PTCT experimental Duchenne muscular dystrophy DMD drug Thursday the stock is on the rise on Friday A slight glimmer of hope the FDA might ignore the panel s recommendation as
SRPT,SRPT:UW,BBG000BCJC58,Biotech stocks plunge after FDA makes it easier for public to search for drug side effects,2017-09-29 17:24:41 +0000,http://finance.yahoo.com/r/872ed6f8-3d88-30f7-8bc5-feeeca9eba73/104741133?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104741133&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen and Acadia Pharmaceuticals all traded lower after investors found reports on their drugs on a database."
SRPT,SRPT:UW,BBG000BCJC58,Biotech stocks plunge after FDA makes it easier for public to search for drug side effects,2017-09-29 17:24:41 +0000,https://finance.yahoo.com/news/biotech-stocks-plunge-fda-makes-172441898.html?.tsrc=rss,"Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen and Acadia Pharmaceuticals all traded lower after investors found reports on their drugs on a database."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics shares dive on safety issues in FDA database,2017-09-29 15:36:49 +0000,http://finance.yahoo.com/r/c5e8f9bc-e1f2-31bf-8651-5578312746d6/Story.aspx?guid=0637FEDA-4986-4A86-B2EE-570BC45FFA34&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics Inc. shares declined as much as 8% in morning trade Friday on safety issues reported in the Food and Drug Administration's Adverse Events Reporting System (FAERS) for the company's ...
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta: Patient Deaths Sink Stock, Company Says 'Not Related' to Drug",2017-09-29 15:27:00 +0000,http://finance.yahoo.com/r/089b7996-e5e1-34c1-9f98-5f36b90914c7/sarepta-patient-deaths-sink-stock-company-says-not-related-to-drug-1506698835?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Sarepeta Therapeutics shares are down 4% this morning at $45.38 after trading below $43 amid investor concerns about data on a Food and Drug Administration web site showing 11 serious events including ...
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Has Suddenly Spiked To The Downside,2017-09-29 10:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CoRuwV5p3PE/sarepta-therapeutics-srpt-has-suddenly-spiked-to-the-downside-20170929-00575,Sarepta Therapeutics (SRPT) Has Suddenly Spiked To The Downside
SRPT,SRPT:UW,BBG000BCJC58,PTCT's Quest For Approval Of DMD Drug Translarna,2017-09-29 04:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j7KQoiBw--4/ptcts-quest-for-approval-of-dmd-drug-translarna-20170929-00125,PTCT's Quest For Approval Of DMD Drug Translarna
SRPT,SRPT:UW,BBG000BCJC58,"DXCM Falls On CGM Rivalry, ZYNE Firms Up, SPPI In Limelight, Big Day Awaits MNKD",2017-09-28 22:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uvSFtVsY3ek/dxcm-falls-on-cgm-rivalry-zyne-firms-up-sppi-in-limelight-big-day-awaits-mnkd-20170928-01406,"DXCM Falls On CGM Rivalry, ZYNE Firms Up, SPPI In Limelight, Big Day Awaits MNKD"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics to Present at the 22nd International Annual Congress of the World Muscle Society,2017-09-28 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-present-22nd-international-123000767.html?.tsrc=rss,"CAMBRIDGE, Mass., Sept. 28, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-09-28 12:02:45 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120245764.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Trending Tickers: Finisar Corporation and Sarepta Therapeutics,2017-09-28 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000478.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 28, 2017 / Large-cap and small-cap stocks soared to new intra-day records Wednesday as financial stocks surged after Republicans released details on tax reform. The ..."
SRPT,SRPT:UW,BBG000BCJC58,"XBI, CLVS, EXEL, SRPT: Large Outflows Detected at ETF",2017-09-27 16:55:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jW-pUueK1X8/xbi-clvs-exel-srpt-large-outflows-detected-at-etf-cm851981,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 49 9 million dollar outflow that s a 1 2 decrease week over week from 48 950 000
SRPT,SRPT:UW,BBG000BCJC58,Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating,2017-09-27 14:56:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o6gKLKDVRVA/stocks-showing-market-leadership-sarepta-therapeutics-earns-91-rs-rating-cm851869,Sarepta Therapeutics SRPT had its Relative Strength RS Rating upgraded from 87 to 91 Wednesday ibd display video id 449433 width 50 float left autostart true IBD s unique RS Rating measures technical performance by showing how a stock s price action over the
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-09-27 12:02:56 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120256934.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SRPT,SRPT:UW,BBG000BCJC58,Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating,2017-09-27 07:00:00 +0000,http://finance.yahoo.com/r/f208b781-1549-3880-ab1c-6238b7e693cf/stocks-showing-market-leadership-sarepta-therapeutics-earns-91-rs-rating?src=A00220&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating."
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks With Major Catalysts in October,2017-09-26 13:52:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jrCSOvFQb3s/3-biotech-stocks-with-major-catalysts-in-october-cm850928,Every month brings plenty of catalysts for several biotech stocks October is no exception There are quite a few regulatory decisions and clinical results expected to be announced next month Three biotechs in particular could enjoy boosts to their stocks if all goes well Here are
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks With Major Catalysts in October,2017-09-26 13:32:00 +0000,http://finance.yahoo.com/r/8565200c-db91-3665-a6ed-d3a832666fe5/3-biotech-stocks-with-major-catalysts-in-october.aspx?yptr=yahoo&.tsrc=rss,These biotechs are hoping that October brings blue skies for their promising pipeline candidates.
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-09-26 12:02:48 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120248455.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SRPT,SRPT:UW,BBG000BCJC58,Here's Why Sarepta Stock is Up More Than 60% So Far in 2017,2017-09-25 15:53:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oAvlAfpG6Eo/heres-why-sarepta-stock-is-up-more-than-60-so-far-in-2017-cm850383,Shares of Sarepta Therapeutics Inc SRPT have been rising since the beginning of this year This biotech company is up 64 7 so far this year outperforming the 15 6 increase registered by the industry during this period Let s analyze the factors that have driven the rally so far
SRPT,SRPT:UW,BBG000BCJC58,Here's Why Sarepta Stock is Up More Than 60% So Far in 2017,2017-09-25 15:53:40 +0000,,Shares of Sarepta Therapeutics Inc SRPT have been rising since the beginning of this year This biotech company is up 64 7 so far this year outperforming the 15 6 increase registered by the industry during this period Let s analyze the factors that have driven the rally so far
SRPT,SRPT:UW,BBG000BCJC58,Health Care Sector Update for 09/25/2017: SRPT,2017-09-25 13:48:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wkep9b_uh_I/health-care-sector-update-for-09252017-srpt-cm850295,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE flatPFE flat ABT 0 4 ABT 0 4 MRK 0 2 MRK 0 2 AMGN flatAMGN flat Health care shares were mainly unchanged in pre market trade Monday Health care shares were mainly unchanged in pre market trade Monday In health
SRPT,SRPT:UW,BBG000BCJC58,Here&apos;s Why Sarepta Stock is Up More Than 60% So Far in 2017,2017-09-25 13:40:01 +0000,https://finance.yahoo.com/news/apos-why-sarepta-stock-more-134001241.html?.tsrc=rss,"Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51&apos;s strong performance. The settlement of a patent litigation also boosted the stock."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer",2017-09-25 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-appoints-guriqbal-basi-123000300.html?.tsrc=rss,"CAMBRIDGE, Mass., Sept. 25, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks With Major Catalysts Incoming,2017-09-21 23:35:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eYP4dU7oN1E/3-biotech-stocks-with-major-catalysts-incoming-cm849328,Axovant Sciences Ltd NASDAQ AXON 160 and PTC Therapeutics Inc NASDAQ PTCT 160 have drugs in late stage development that could propel them to profitability over the next few years Gilead Sciences Inc NASDAQ GILD is already one of the most profitable companies
SRPT,SRPT:UW,BBG000BCJC58,SPDR S&P Biotech ETF Experiences Big Outflow,2017-09-15 16:35:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gz3KhXTMUqg/spdr-sp-biotech-etf-experiences-big-outflow-cm846330,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 87 4 million dollar outflow that s a 2 1 decrease week over week from 49 600 000
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-09-12 12:05:59 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120559920.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SRPT,SRPT:UW,BBG000BCJC58,What Analysts Recommend for BioMarin Pharmaceuticals in September,2017-09-11 11:38:17 +0000,http://finance.yahoo.com/r/acfe4f97-5dd2-31ee-95b0-606c7b6e2104/what-analysts-recommend-for-biomarin-pharmaceuticals-in-september?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,About 77.2% of analysts tracking BioMarin Pharmaceuticals in September 2017 suggested some form of a “buy” rating.
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta's Golodirsen Positive in DMD Study, Shares Soar",2017-09-07 19:49:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-xjVg7LaJFM/sareptas-golodirsen-positive-in-dmd-study-shares-soar-cm842520,Sarepta Therapeutics Inc 160 SRPT announced positive results from a phase I II study 4053 101 evaluating its Exon 53 skipping candidate golodirsen for the treatment of Duchenne Muscular Dystrophy DMD patients DMD is a genetic disorder in which the absence of a protein
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Chart Patterns Look Good,2017-09-07 18:11:00 +0000,http://finance.yahoo.com/r/7e5968b5-2e1c-3573-9661-cc6ab2293c98/sarepta-therapeutics-chart-patterns-look-good?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Things have been looking better since January.
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta&apos;s Golodirsen Positive in DMD Study, Shares Soar",2017-09-07 17:23:05 +0000,https://finance.yahoo.com/news/sarepta-apos-golodirsen-positive-dmd-172305937.html?.tsrc=rss,"Sarepta&apos;s (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response."
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta: Turbocharge Returns With Options,2017-09-07 16:52:00 +0000,http://finance.yahoo.com/r/27006412-cff6-3934-9a4d-45a9fd8969d7/sarepta-turbocharge-returns-with-options-1504803143?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The basic nature of Sarepta Therapeutics’ stock trading pattern may have changed yesterday.  This is a very early call, and it could even prove premature, but just released positive clinical data suggest the stock (SRPT), which has naturally long traded like a typical biotech stock that moves sharply around events, may be turning into more of a thematic pharmaceutical stock.  The shift reflects Wednesday’s news of favorable clinical trial results for Sarepta’s second drug for DMD (Duchenne muscular dystrophy)."
SRPT,SRPT:UW,BBG000BCJC58,One Worry Off the Table (Until December),2017-09-07 13:48:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sajijbNHhIQ/one-worry-off-the-table-until-december-cm842024,The September episode of the Zacks Ultimate Strategy Session is now available for viewing Tune in to this popular event when Sheraz Mian David Bartosiak Tracey Ryniec Neena Mishra CFA FRM and Brian Bolan discussed the investment landscape from most every angle Don t miss your chance
SRPT,SRPT:UW,BBG000BCJC58,One Worry Off the Table (Until December),2017-09-07 13:15:01 +0000,https://finance.yahoo.com/news/one-worry-off-table-until-131501905.html?.tsrc=rss,One Worry Off the Table (Until December)
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Myriad Genetics,2017-09-07 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000834.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 7, 2017 / It was a big day for biotech companies Sarepta Therapuetics and Myriad Genetics on Wednesday. Both stocks soared, with Myriad even hitting a new 52-week ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta’s positive trial results for new DMD treatment could reopen rare disease drug controversy,2017-09-07 10:54:53 +0000,http://finance.yahoo.com/r/cf287cdc-7cf5-321a-8aba-2c87271e8a78/Story.aspx?guid=029EEBE4-9308-11E7-AE01-E113318215E9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Sarepta shares surged as much as 14% on hopes that a new Duchenne muscular dystrophy drug could get faster-than-normal approval.
SRPT,SRPT:UW,BBG000BCJC58,What Happened in the Stock Market Today,2017-09-06 22:50:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bRQMU96cvUI/what-happened-in-the-stock-market-today-cm841960,Stocks rebounded somewhat Wednesday with good news on a bipartisan agreement in Washington to raise the debt ceiling and fund the government through mid December apparently mitigating some of Tuesday s worries over North Korea and Hurricane Irma The Dow Jones Industrial
SRPT,SRPT:UW,BBG000BCJC58,"SRPT Walks The Talk, VSTM Grows, PULM Pulls Back, Smooth Sailing For VYGR",2017-09-06 22:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fqLoPBDwsL8/srpt-walks-the-talk-vstm-grows-pulm-pulls-back-smooth-sailing-for-vygr-20170906-01588,"SRPT Walks The Talk, VSTM Grows, PULM Pulls Back, Smooth Sailing For VYGR"
SRPT,SRPT:UW,BBG000BCJC58,What Happened in the Stock Market Today,2017-09-06 20:57:00 +0000,http://finance.yahoo.com/r/558a2d0f-b836-330d-8571-6e8f7c57e435/what-happened-in-the-stock-market-today.aspx?yptr=yahoo&.tsrc=rss,"On a day when stocks generally rose, Trivago fell on revised guidance, and Sarepta Therapeutics jumped after announcing a successful drug trial."
SRPT,SRPT:UW,BBG000BCJC58,This Controversial Biotech May Yet Defy Its Skeptics,2017-09-06 18:02:29 +0000,https://finance.yahoo.com/news/controversial-biotech-may-yet-defy-180229771.html?.tsrc=rss,Sarepta stock spiked 14% thanks to its experimental muscular dystrophy drug.
SRPT,SRPT:UW,BBG000BCJC58,Can you trust Facebook? It's in the Blitz,2017-09-06 17:59:00 +0000,https://finance.yahoo.com/video/trust-facebook-blitz-175900594.html?.tsrc=rss,Big movers in the blitz.
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Is Rising Today,2017-09-06 17:51:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g_zVSeonOkM/why-sarepta-therapeutics-stock-is-rising-today-cm841793,What happened Shares of mid cap biotech Sarepta Therapeutics NASDAQ SRPT marched almost 11 higher Wednesday morning on elevated volume The stock s rally was catalyzed by news of encouraging results from an early stage muscle biopsy study for its experimental Duchenne
SRPT,SRPT:UW,BBG000BCJC58,We May Soon Learn Just How Flexible Scott Gottlieb's FDA Is,2017-09-06 17:29:16 +0000,http://finance.yahoo.com/r/bdd0c888-e5d8-3030-943e-129e8aec3142/sarepta-dmd-drug-data-the-fda-faces-a-new-test?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Another new DMD drug could spark another approval controversy.
SRPT,SRPT:UW,BBG000BCJC58,Is There Now An Opportunity In Sarepta Therapeutics Inc (SRPT)?,2017-09-06 17:20:09 +0000,https://finance.yahoo.com/news/now-opportunity-sarepta-therapeutics-inc-172009812.html?.tsrc=rss,"Sarepta Therapeutics Inc (NASDAQ:SRPT), a pharmaceuticals, biotechnology and life sciences company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS in theRead More..."
SRPT,SRPT:UW,BBG000BCJC58,​Why Sarepta’s latest trial data may presage another FDA controversy,2017-09-06 16:30:10 +0000,http://finance.yahoo.com/r/05b7b012-132c-3ee2-948c-3d76569f6c8f/why-sarepta-s-latest-trial-data-may-presage.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"One year after scoring one of the most controversial FDA approvals in recent history, Cambridge-based Sarepta Therapeutics may again find itself at the center of a debate over the agency’s standards with a new experimental drug.  Sarepta (SRPT) on Wednesday unveiled data from a small, early-stage trial of one of its potential treatments for Duchenne muscular dystrophy, a genetic disorder in which the absence of a protein called dystrophin causes progressive muscle weakness.  One percent of normal dystrophin may not sound like much."
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Is Rising Today,2017-09-06 16:09:00 +0000,http://finance.yahoo.com/r/51263867-ee35-3e16-af9f-e3678b05ef71/why-sarepta-therapeutics-stock-is-rising-today.aspx?yptr=yahoo&.tsrc=rss,The biotech&apos;s high-value Duchenne muscular dystrophy pipeline hit another important milestone with a positive early-stage readout for treatment candidate golodirsen.
SRPT,SRPT:UW,BBG000BCJC58,[$$] Soaring Sarepta Can Continue to Stay Hot,2017-09-06 15:39:00 +0000,http://finance.yahoo.com/r/3927518e-0428-3d5a-9487-6792b69fc336/soaring-sarepta-can-continue-to-stay-hot-1504712377?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Sarepta Therapeutics (SRPT) are up 11% to $45.61, today following favorable news from the company this morning on a clinical trial for its second drug for Duchenne muscular dystrophy.  The stock could head even higher as Wall Street factors in the possibility of accelerated approval of the drug, golodirsen, and a rising chance that Sarepta will develop a family of approved drugs to treat DMD, a fatal muscle-wasting disease affecting an estimated 10,000 boys in the U.S. Analysts reacted favorably to the news, which showed the drug to be more potent at producing dystrophin, the muscle protein lacking in boys with DMD, than Exondys 51, Sarepta’s commercialized DMD drug that was approved by the Food and Drug Administration in September.  The eagerly anticipated results of the Phase 1/2 clinical trial showed that after 48 weeks of treatment with golodirsen, 25 boys showed a mean dystrophin level of 1.019% of normal, versus a baseline reading of 0.095%."
SRPT,SRPT:UW,BBG000BCJC58,"CEO defends $300,000-per-year cost for a drug for a rare form of muscular dystrophy",2017-09-06 14:30:05 +0000,http://finance.yahoo.com/r/938a1d8e-1419-3d48-bfa3-6bd06473419f/104692925?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104692925&yptr=yahoo&.tsrc=rss,Sarepta's Doug Ingram responds to a question about the high cost for a drug for Duchenne muscular dystrophy.
SRPT,SRPT:UW,BBG000BCJC58,"Stocks to Watch: Hewlett Packard Enterprise, Fiat Chrysler, Exxon Mobil, Sarepta Therapeutics, G-III Apparel Group",2017-09-06 13:21:12 +0000,http://finance.yahoo.com/r/95366e49-d6fb-3dd7-91d5-9da89ff64001/stocks-to-watch-hewlett-packard-enterprise-fiat-chrysler-exxon-mobil-sarepta-therapeutics-g-iii-apparel-group-1504704070?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Among the companies with shares expected to trade actively in Wednesday's session are Hewlett Packard Enterprise Co., Fiat Chrysler Automobiles N.V., Exxon Mobil Corp., Sarepta Therapeutics Inc. and G-III ..."
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Sep 6, 2017 :  HPE, SRPT, VSTM, AZN, GDDY, TRVG, BAC, NWL, LYG, TVIX, PULM, VOD",2017-09-06 12:59:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E2OI74ncKCg/pre-market-most-active-for-sep-6-2017-hpe-srpt-vstm-azn-gddy-trvg-bac-nwl-lyg-tvix-pulm-vod-cm841417,The NASDAQ 100 Pre Market Indicator is up 6 7 to 5 939 43 The total Pre Market volume is currently 6 885 778 shares traded The following are the most active stocks for the pre market session Hewlett Packard Enterprise Company HPE is 0 33 at 14 37 with 968 715
SRPT,SRPT:UW,BBG000BCJC58,Shares of drugmaker that targets gene mutations soar after positive study results,2017-09-06 12:41:28 +0000,https://finance.yahoo.com/news/shares-drugmaker-targets-gene-mutations-124128939.html?.tsrc=rss,Sarepta Therapeutics reports positive results from a clinical trial of an experimental medicine for Duchenne muscular dystrophy.
SRPT,SRPT:UW,BBG000BCJC58,Shares of drugmaker that targets gene mutations soar after positive study results,2017-09-06 12:41:28 +0000,http://finance.yahoo.com/r/c22aa4e4-35e8-3f6e-b7c9-d767cd0dbae1/104692729?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104692729&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics reports positive results from a clinical trial of an experimental medicine for Duchenne muscular dystrophy.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day,2017-09-06 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-ring-nasdaq-stock-123000930.html?.tsrc=rss,"CAMBRIDGE, Mass., Sept. 06, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta stock jumps on muscular dystrophy drug trial resu...,2017-09-06 12:14:00 +0000,https://finance.yahoo.com/video/sarepta-stock-jumps-muscular-dystrophy-121400364.html?.tsrc=rss,CNBC's Meg Tirrell reports Sarepta Therapeutics met its goals with muscular dystrophy drug study.
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-09-06 12:02:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120212690.html?.tsrc=rss,Sarepta Therapeutics Inc NASDAQ/NGS:SRPT
SRPT,SRPT:UW,BBG000BCJC58,Sarepta shares surge 14% on positive early/mid-stage clinical trial results in DMD,2017-09-06 11:32:43 +0000,http://finance.yahoo.com/r/dad7fd79-bc57-3c69-8999-91d5a07ea1f3/Story.aspx?guid=537FAD6B-5131-4492-BE2C-65AB000E9CA8&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics Inc. shares surged 14.4% in premarket trade Wednesday on positive early/mid-stage clinical trial results for its golodirsen therapy in Duchenne muscular dystrophy. In a phase 1/2 trial ...
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53 Treated with Golodirsen (SRP-4053)",2017-09-06 11:00:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-positive-results-110000605.html?.tsrc=rss,"--Study achieved statistical significance on all primary and secondary biological endpoints--. --Results further validate the Company’ s exon-skipping platform for the treatment of DMD--. CAMBRIDGE, Mass., ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Has Jumped To A 10-Month High On Study Results,2017-09-06 09:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YIhR_VNrJUY/sarepta-therapeutics-srpt-has-jumped-to-a-10month-high-on-study-results-20170906-00854,Sarepta Therapeutics (SRPT) Has Jumped To A 10-Month High On Study Results
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: Time to Buy?,2017-09-05 16:31:00 +0000,http://finance.yahoo.com/r/8b68ff46-cd26-37a4-b0b6-8361070015a7/sarepta-time-to-buy-1504629099?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"What could drive shares of Sarepta Therapeutics (SRPT) higher?  Back in July, my colleague Andrew Bary noted thatExondys 51, the company’s controversial drug for Duchenne muscular dystrophy (DMD), is gaining traction, which could push the stock price higher.  Credit Suisse analyst Alethia Young and her team say the company could release top-line data from an early stage study of its experimental drug SRP-4053 before releasing the full data later this year."
SRPT,SRPT:UW,BBG000BCJC58,These 3 'Strong Buy' Healthcare Stocks Are Seeing Big Insider Buying,2017-09-05 15:18:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6LWO5TNswVA/these-3-strong-buy-healthcare-stocks-are-seeing-big-insider-buying-cm840873,Which hot healthcare stocks are corporate insiders snapping up right now? Tracking informative insider transactions is a great way of finding compelling investment opportunities from those who know the company best. But be aware that uninformative transactions indicate that an insider is buying/selling shares for
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell",2017-09-05 14:00:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-inc-nasdaq-srpt-140000426.html?.tsrc=rss,"What: Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will visit the ..."
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-09-04 12:04:55 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120455832.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-08-31 22:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-223000754.html?.tsrc=rss,"CAMBRIDGE, Mass., Aug. 31, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,Edited Transcript of SRPT earnings conference call or presentation 19-Jul-17 8:30pm GMT,2017-08-30 20:11:04 +0000,https://finance.yahoo.com/news/edited-transcript-srpt-earnings-conference-065013380.html?.tsrc=rss,Q2 2017 Sarepta Therapeutics Inc Earnings Call
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : August 30, 2017",2017-08-30 02:40:26 +0000,http://finance.yahoo.com/r/c141c5f0-2769-3ee3-9401-c5000f6db22d/sarepta-therapeutics-inc-value-analysis-nasdaqsrpt-august-30-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Sarepta Therapeutics, Inc. a score of 25. Our analysis is based on comparing Sarepta Therapeutics, Inc. with the following peers – Hemispherx Biopharma, Inc., Novavax, Inc., Gilead Sciences, Inc., Ionis Pharmaceuticals, Inc., Newlink Genetics Corporation, Aviragen Therapeutics Inc, BioCryst Pharmaceuticals, Inc., Omega Protein Corporation, PTC Therapeutics, Inc. ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks That Could Soar in September,2017-08-27 12:49:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jii3x9r6Fc4/3-biotech-stocks-that-could-soar-in-september-cm837607,Winter seems to always be coming in Game of Thrones but here in the real world autumn is on the way While the leaves will start falling in September some biotech stocks could be set to soar Quite a few biotechs have important catalysts coming up in the next month Three
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks That Could Soar in September,2017-08-27 11:27:00 +0000,http://finance.yahoo.com/r/7c57af97-5681-3d49-954b-a35676515cd6/3-biotech-stocks-that-could-soar-in-september.aspx?yptr=yahoo&.tsrc=rss,"Alnylam, PTC Therapeutics, and Zogenix have major catalysts on the way."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics to Present at Three Upcoming Investor Conferences,2017-08-24 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-present-three-upcoming-123000308.html?.tsrc=rss,"CAMBRIDGE, Mass., Aug. 24, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-08-23 12:01:56 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120156776.html?.tsrc=rss,Sarepta Therapeutics Inc NASDAQ/NGS:SRPT
SRPT,SRPT:UW,BBG000BCJC58,Why Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report?,2017-08-22 13:39:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ACHeVGf09ok/why-is-sarepta-srpt-down-99-since-the-last-earnings-report-cm835240,A month has gone by since the last earnings report for Sarepta Therapeutics Inc SRPT Shares have lost about 9 9 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : August 22, 2017",2017-08-22 13:04:33 +0000,http://finance.yahoo.com/r/07851106-1b07-3f71-946d-d1abf2e5cc53/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-srpt-us-august-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sarepta Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,Why Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report?,2017-08-22 12:43:12 +0000,https://finance.yahoo.com/news/why-sarepta-srpt-down-9-124312944.html?.tsrc=rss,Sarepta (SRPT) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-08-16 12:01:51 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120143711.html?.tsrc=rss,"Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan.  ETFs that hold SRPT had net inflows of $306 million over the last one-month.  Index (PMI) data, output in the Healthcare sector is rising."
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc.,2017-08-16 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000861.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 16, 2017 / U.S. markets swung between gains and losses on Tuesday as disappointing earnings from major retailers were offset by positive U.S. retail sales data. The Dow ..."
SRPT,SRPT:UW,BBG000BCJC58,"What You See, and What You Get: The Neurology of Perception",2017-08-16 00:35:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pvFLqj7qJNY/what-you-see-and-what-you-get-the-neurology-of-perception-cm832527,1 00 Neuroscience The 4 Theaters Of The Brain 5 00 Investors Train Their Brains to Trade Assumption and Perception 10 00 Neurology Is The New Oncology The Boom In Brain Sciences 14 00 Biotech Companies With Breakthrough
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-08-12 12:03:40 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120340659.html?.tsrc=rss,"Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan.  Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $340 million."
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-08-11 12:03:38 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120338202.html?.tsrc=rss,"Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan.  Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $340 million."
SRPT,SRPT:UW,BBG000BCJC58,IHS Markit Score Update: Drop in demand for ETFs holding Sarepta Therapeutics Inc is a negative sign for its shares,2017-08-10 12:03:46 +0000,https://finance.yahoo.com/news/ihs-markit-score-drop-demand-120346413.html?.tsrc=rss,"Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan.  Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $665 million."
SRPT,SRPT:UW,BBG000BCJC58,See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.,2017-08-09 12:04:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120412156.html?.tsrc=rss,"Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan.  Investors are committing new capital to ETFs that hold SRPT at an increasing rate, with the one-month net inflow having reached $325 million."
SRPT,SRPT:UW,BBG000BCJC58,These 3 Biotechs Just Crushed Analyst Expectations,2017-08-07 15:41:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0b7j7jeHDs4/these-3-biotechs-just-crushed-analyst-expectations-cm828104,Earnings season is under way and biotech business appears to be booming But it takes more than just a good quarter to know if a biotech is poised for sustainable long term growth With many companies issuing conservative profit forecasts at the start of the year second quarter
SRPT,SRPT:UW,BBG000BCJC58,These 3 Biotechs Just Crushed Analyst Expectations,2017-08-07 13:31:00 +0000,http://finance.yahoo.com/r/fcd2ee6f-6d51-37f6-972d-03160858cd3c/these-3-biotechs-just-crushed-analyst-expectations.aspx?yptr=yahoo&.tsrc=rss,"But before you invest in any of them, you should read this."
SRPT,SRPT:UW,BBG000BCJC58,BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter,2017-08-04 19:01:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bpwi8J4vrs4/biomarin-pharmaceutical-inc-got-it-done-in-the-second-quarter-cm827439,BioMarin Pharmaceutical NASDAQ BMRN turned in a 160 second quarter report on Wednesday that showed it continuing to grow sales of its current drugs getting new drugs approved and producing promising clinical trial data on its pipeline candidates There isn t much else investors
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Gained 10.7% in July,2017-08-04 13:01:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CRc8A9O53Kc/why-sarepta-therapeutics-stock-gained-107-in-july-cm827051,What happened Sarepta Therapeutics NASDAQ SRPT a biotech developing novel treatments for rare disorders saw its shares rise by a healthy 10 7 last month according to S amp P Global Market Intelligence The primary catalyst behind this noteworthy move northward was
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Gained 10.7% in July,2017-08-04 11:40:00 +0000,http://finance.yahoo.com/r/1d673468-ecb9-35eb-b66b-6e14bab743b4/why-sarepta-therapeutics-stock-gained-107-in-july.aspx?yptr=yahoo&.tsrc=rss,Sarepta&apos;s shares bolted higher in July after the company posted stellar second quarter results.
SRPT,SRPT:UW,BBG000BCJC58,[$$] FDA Emails Offer Rare Look Into Internal Battle Over a Drug's Approval,2017-08-03 22:51:07 +0000,http://finance.yahoo.com/r/2e0a25ad-fb57-310f-8aeb-348d7b165f9b/fda-emails-offer-rare-look-into-internal-battle-over-a-drugs-approval-1501799291?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,The Food and Drug Administration provided a rare glimpse of an internal battle that erupted last year over efforts to modernize the agency’s efforts to approve and regulate new drugs.
SRPT,SRPT:UW,BBG000BCJC58,"BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates",2017-08-03 16:06:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mV3zY2Fgu1g/biomarin-bmrn-q2-loss-narrows-sales-surpass-estimates-cm826565,BioMarin Pharmaceutical Inc BMRN reported a narrower than expected loss in the second quarter of 2017 and also beat estimates for sales The biotech also raised its previously issued full year sales outlook The company also announced that it will take both evaluated doses of its hemophilia
SRPT,SRPT:UW,BBG000BCJC58,"BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates",2017-08-03 13:38:01 +0000,https://finance.yahoo.com/news/biomarin-bmrn-q2-loss-narrows-133801599.html?.tsrc=rss,BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Trending Tickers: Sarepta Therapeutics Inc. and GW Pharmaceuticals Plc,2017-08-01 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000709.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 1, 2017 / U.S. markets were mixed Monday as a strong performance by Boeing lifted the Dow to a new record high, while weakness from major tech stocks dragged the S&P ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-07-31 22:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-223000034.html?.tsrc=rss,"CAMBRIDGE, Mass., July 31, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares,2017-07-29 09:57:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4BFoB9DGsSA/sarepta-therapeutics-inc-srpt-president-ceo-douglas-s-ingram-bought-2-million-of-shares-cm823763,President amp CEO of Sarepta Therapeutics Inc SRPT Douglas S Ingram bought 47 058 shares of SRPT on 07 27 2017 at an average price of 42 5 a share The total cost of this purchase was 2 million President CEO of Sarepta Therapeutics Inc SRPT Douglas S Ingram bought 47 058 shares
SRPT,SRPT:UW,BBG000BCJC58,"Friday 7/28 Insider Buying Report: SRPT, ETFC",2017-07-28 16:01:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uJ9FCP_AysI/friday-728-insider-buying-report-srpt-etfc-cm823268,As the saying goes there are many possible reasons for an insider to sell a stock but only one reason to buy they expect to make money So let s look at two noteworthy recent insider buys At Sarepta Therapeutics SRPT a filing with the SEC revealed that on Thursday CEO Douglas
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications",2017-07-27 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-partner-genethon-123000338.html?.tsrc=rss,"CAMBRIDGE, Mass., July 27, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Jul 25, 2017 :  MU, STX, QQQ, CHL, CAT, C, SRPT, BTI, FTI, AKS, TVIX, USLV",2017-07-25 12:56:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iYT8dAQX1oo/pre-market-most-active-for-jul-25-2017-mu-stx-qqq-chl-cat-c-srpt-bti-fti-aks-tvix-uslv-cm820657,The NASDAQ 100 Pre Market Indicator is down 15 17 to 5 926 2 The total Pre Market volume is currently 5 732 081 shares traded The following are the most active stocks for the pre market session Micron Technology Inc MU is 0 7 at 30 97 with 699 171 shares
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks With MercadoLibre-Like Return Potential,2017-07-25 02:56:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RLmrw5e6AzY/3-stocks-with-mercadolibre-like-return-potential-cm820597,Shares of Argentinean e commerce giant MercadoLibre NASDAQ MELI have been setting the Latin world on fire this year up 75 since the start of January This is a stock we ve recommended here at The Motley Fool in the past and one we still recommend today But what will we do for
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks With MercadoLibre-Like Return Potential,2017-07-25 01:43:00 +0000,http://finance.yahoo.com/r/ad7b06aa-f972-39e2-8b32-ea500ba78674/3-stocks-with-mercadolibre-like-return-potential.aspx?yptr=yahoo&.tsrc=rss,MercadoLibre stock has returned 75% year-to-date. Can you beat that? Let&apos;s try.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock,2017-07-25 00:00:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-pricing-325-000000055.html?.tsrc=rss,"CAMBRIDGE, Mass., July 24, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"This Biotech Got A Price Hike, But Seesawed After A Three-Day Run",2017-07-24 20:55:50 +0000,http://finance.yahoo.com/r/5c46d3cc-36ea-3a57-8b91-7eece7925bd6/this-biotech-got-a-price-hike-but-seesawed-after-a-three-day-run?src=A00220&yptr=yahoo&.tsrc=rss,Sarepta stock toed the line Monday after a three-day run turned negative following its strong second-quarter report last week and a price-target hike.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta may look to bolster pipeline after $250M offering,2017-07-24 16:15:10 +0000,http://finance.yahoo.com/r/3e6d05e6-4411-3136-be0d-35917710cc3c/sarepta-may-look-to-bolster-pipeline-after-250m.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics is planning to raise up to $250 million in a new stock offering, and said it may use some of the proceeds to acquire or license additional drug candidates.  The company said that new CEO Douglas Ingram is interested in buying up to $2 million worth of the shares.  Proceeds from the offering could be used to license or acquire “complementary products and technologies,” or for a range of other purposes, including to fund clinical trials, commercialization activities and manufacturing, Sarepta said."
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Jul 24, 2017 :  WBMD, NDRM, QQQ, GNCA, TVIX, SRPT",2017-07-24 12:52:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3iagWTu56x0/pre-market-most-active-for-jul-24-2017-wbmd-ndrm-qqq-gnca-tvix-srpt-cm819956,The NASDAQ 100 Pre Market Indicator is up 99 to 5 922 51 The total Pre Market volume is currently 2 415 007 shares traded The following are the most active stocks for the pre market session WebMD Health Corp WBMD is 10 9 at 66 09 with 4 936 075 shares traded
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Proposed $250 Million Public Offering of Common Stock,2017-07-24 11:00:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-proposed-250-110000295.html?.tsrc=rss,"CAMBRIDGE, Mass., July 24, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta's Sales Ramp Up,2017-07-22 04:46:00 +0000,http://finance.yahoo.com/r/9b81fe89-b00f-3473-83a8-7b5660298063/sareptas-sales-ramp-up-1500698772?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The new CEO of Sarepta Therapeutics, pharma industry veteran Douglas Ingram, is bullish on the company’s prospects, and Wall Street is starting to see it his way. Sarepta shares (SRPT) surged 22% last ..."
SRPT,SRPT:UW,BBG000BCJC58,"William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)",2017-07-21 16:57:22 +0000,https://finance.yahoo.com/news/william-blair-bullish-biotech-sarepta-165722479.html?.tsrc=rss,"Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech firm to soar 20% yesterday in trading following a wow factor second-quarter earnings top-line performance.  While consensus had been angling for Sarepta's second full quarter of Exondys 51 to yield $22.5 million, the firm powered through with a 114% quarterly rise to a hefty $35 million, leading management to boost full year 2017 guidance now for the second time in a year, rising from ""exceeding 95 million"" to an even more bullish range of $125 million to $130 million.  William Blair analyst Tim Lugo highlights strong commercial trends that also led Sarepta to beat his own forecast of $20 million."
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Kite Pharma,2017-07-21 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000264.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 21, 2017 / Both Sarepta Therapeutics and Kite Pharma saw gains on Thursday. Kite hit a new high after highlighting positive results of an anti-CD19 chimeric antigen receptor ..."
SRPT,SRPT:UW,BBG000BCJC58,"Why Kinder Morgan, Ambac Financial, and Sarepta Therapeutics Jumped Today",2017-07-20 22:03:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/negxhhM8P2U/why-kinder-morgan-ambac-financial-and-sarepta-therapeutics-jumped-today-cm818968,Stocks didn t move much on Thursday and major benchmarks were narrowly mixed as earnings season kicked into full gear Healthcare and utility stocks were generally higher but the industrials and materials sectors held back gains in the overall market On the economic front a solid
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta Can Rally Further As Key Drug Gains Sales,2017-07-20 21:52:00 +0000,http://finance.yahoo.com/r/28a34124-00eb-34d9-b782-88033a0af70e/sarepta-can-rally-further-as-key-drug-gains-sales-1500587531?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics’ drug for Duchenne muscular dystrophy (DMD) is gaining traction and that could continue to lift its shares even after a strong gain today.  Sarepta shares (SRPT) surged $6.85, or 20%, to $40.93, after the company late Wednesday reported $35 million in second-quarter sales of its DMD drug, Exondys 51, versus the consensus of $22 million and lifted its full-year 2017 sales guidance to $125 million to $130 million from a previous $95 million.  The news prompted a flurry of positive notes from analysts, who are upbeat about several developments, including positive comments on the conference call yesterday from the company’s new CEO, Douglas Ingram, and the recent resolution of a patent dispute with former rival BioMarin Pharmaceutical that will involve royalty payments to BioMarin."
SRPT,SRPT:UW,BBG000BCJC58,"Gainers & Losers Of July 20: SRPT, AKCA, AGRX, INO, IRWD...",2017-07-20 21:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Eir5vxzbdyA/gainers--losers-of-july-20-srpt-akca-agrx-ino-irwd-20170720-01748,"Gainers & Losers Of July 20: SRPT, AKCA, AGRX, INO, IRWD..."
SRPT,SRPT:UW,BBG000BCJC58,"Why Kinder Morgan, Ambac Financial, and Sarepta Therapeutics Jumped Today",2017-07-20 20:24:00 +0000,http://finance.yahoo.com/r/22360e68-084e-37ea-9c03-87be61d436c3/why-kinder-morgan-ambac-financial-and-sarepta-ther.aspx?yptr=yahoo&.tsrc=rss,These stocks climbed on a quiet day for Wall Street. Find out why.
SRPT,SRPT:UW,BBG000BCJC58,This Biotech Just Blew Past Its Buy Point On A $13 Million Sales Beat,2017-07-20 20:14:26 +0000,http://finance.yahoo.com/r/2d57c0f5-7f2d-3fef-a42a-c77f0e051373/this-biotech-just-blew-past-its-buy-point-on-a-13-million-sales-beat?src=A00220&yptr=yahoo&.tsrc=rss,Sarepta broke out Thursday and flirted with an eight-month high after reporting consensus-crushing second-quarter sales and cutting loss expectations by half.
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Inc (SRPT) Soars on Q2 Revenue, Forecast",2017-07-20 20:05:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IqE9auuif-0/sarepta-therapeutics-inc-srpt-soars-on-q2-revenue-forecast-cm818942,InvestorPlace Stock Market News Stock Advice amp Trading Tips Sarepta Therapeutics Inc NASDAQ SRPT stock was flying high on Thursday following the release of its earnings report for the second quarter of 2017 Source Shutterstock One part of 160 Sarepta Therapeutics Inc
SRPT,SRPT:UW,BBG000BCJC58,"Health Care Sector Update for 07/20/2017: VNRX,SRPT,CFRX",2017-07-20 20:05:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MfBgIEOENo0/health-care-sector-update-for-07202017-vnrxsrptcfrx-cm818918,Top Health Care StocksTop Health Care Stocks JNJ 1 1 JNJ 1 1 PFE 0 04 PFE 0 04 ABT 3 1 ABT 3 1 MRK 0 7 MRK 0 7 AMGN 0 2 AMGN 0 2 Health care stocks finishing on top of Thursday s leaderboard with the NYSE Health Care Index NYP climbing almost 0 9 while shares of health
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why,2017-07-20 19:02:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5JodzM9eF0A/sarepta-therapeutics-srpt-stock-surged-24-today-heres-why-cm818866,On Thursday shares of Sarepta Therapeutics SRPT are surging up almost 24 to 42 14 per share in morning trading after the biotech company reported second quarter revenues that blew past expectations in its earnings report yesterday after the bell Sarepta reported quarterly revenue of
SRPT,SRPT:UW,BBG000BCJC58,"Thursday's ETF Movers: XBI, OIH",2017-07-20 18:04:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_npb8q5cF8E/thursdays-etf-movers-xbi-oih-cm818844,In trading on Thursday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 1 5 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics SRPT up about 27 2 and shares of Esperion Therapeutics ESPR up about 5 9
SRPT,SRPT:UW,BBG000BCJC58,"Health Care Sector Update for 07/20/2017: SBPH,GILD,SRPT,CFRX",2017-07-20 18:03:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U8H98bseol8/health-care-sector-update-for-07202017-sbphgildsrptcfrx-cm818858,Top Health Care StocksTop Health Care Stocks JNJ 1 29 JNJ 1 29 PFE 0 19 PFE 0 19 ABT 2 99 ABT 2 99 MRK 0 79 MRK 0 79 AMGN 0 60 AMGN 0 60 Health care stocks were on top of Thursday s leaderboard with the NYSE Health Care Index climbing almost 0 9 while shares of health
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here&apos;s Why,2017-07-20 17:09:05 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-srpt-stock-surged-170905691.html?.tsrc=rss,"On Thursday, shares of Sarepta Therapeutics (SRPT) are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations in its earnings report yesterday after the bell."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View",2017-07-20 17:06:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Levo9K_I7JY/sarepta-srpt-q2-loss-narrows-ups-exondys-51-sales-view-cm818801,Sarepta Therapeutics Inc SRPT reported narrower than expected loss in the second quarter of 2017 The biotech also increased its 2017 sales outlook for Exondys 51 a treatment for Duchenne muscular dystrophy DMD and its only marketed drug Shares were up almost 15 in after hours trading
SRPT,SRPT:UW,BBG000BCJC58,"Stocks Close Nearly Flat, Nasdaq Still Reaches New Record High - U.S. Commentary",2017-07-20 16:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xq9mNqi1W-I/stocks-close-nearly-flat-nasdaq-still-reaches-new-record-high--u.s.-commentary-20170720-01480,"Stocks Close Nearly Flat, Nasdaq Still Reaches New Record High - U.S. Commentary"
SRPT,SRPT:UW,BBG000BCJC58,"Stocks Close Nearly Flat, Nasdaq Still Reaches New Record High - U.S. Commentary",2017-07-20 16:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PHOo58zyV_Q/stocks-close-nearly-flat-nasdaq-still-reaches-new-record-high--us-commentary-20170720-01480,"Stocks Close Nearly Flat, Nasdaq Still Reaches New Record High - U.S. Commentary"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Remains Sharply Higher In Late-Day Trading,2017-07-20 15:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-86VmORuxO8/sarepta-therapeutics-remains-sharply-higher-in-lateday-trading-20170720-01315,Sarepta Therapeutics Remains Sharply Higher In Late-Day Trading
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Inc (SRPT) Soars on Q2 Revenue, Forecast",2017-07-20 15:36:03 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-inc-srpt-soars-153603942.html?.tsrc=rss,"One part of Sarepta Therapeutics Inc’s earnings report for the second quarter of the year that really helped SRPT stock was its revenue of $35 million.  This easily beat out Wall Street’s revenue estimate of $22.50 million for the second quarter of 2017.  On the news of strong revenue for the second quarter of 2017, Sarepta Therapeutics Inc announced that it is increasing its revenue forecast for the year."
SRPT,SRPT:UW,BBG000BCJC58,Story Stocks from Briefing.com,2017-07-20 15:29:35 +0000,https://finance.yahoo.com/news/story-stocks-briefing-com-175403381.html?.tsrc=rss,Story Stocks from Briefing.com
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View",2017-07-20 14:43:02 +0000,https://finance.yahoo.com/news/sarepta-srpt-q2-loss-narrows-144302559.html?.tsrc=rss,Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Rose After-Hours Wednesday,2017-07-20 14:07:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jq-phUmC56I/why-sarepta-therapeutics-stock-rose-after-hours-wednesday-cm818540,What happened Shares of the orphan drug specialist Sarepta Therapeutics NASDAQ SRPT rose by as much as 15 5 in after hours trading yesterday on heavy volume This double digit rally was sparked by a far better than expected second quarter earnings report that hit the wires
SRPT,SRPT:UW,BBG000BCJC58,"Biotech Movers: Sarepta, Inovio, Mylan",2017-07-20 13:38:00 +0000,http://finance.yahoo.com/r/1f27cf63-0a87-3115-92e6-846e068b7613/biotech-movers-sarepta-inovio-mylan.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics, Inovio Pharmaceuticals and Mylan were among the biotech movers in premarket trading on July 20."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta rockets 20% higher after 'powerhouse' biotech tops revenue expectations,2017-07-20 13:30:32 +0000,http://finance.yahoo.com/r/3eea4e55-8b9a-3ecd-95df-b06099b84131/104598332?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104598332&yptr=yahoo&.tsrc=rss,Wall Street believes the biopharma's focus on developing treatments for rare neuromuscular diseases is paying off.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta rockets 20% higher after 'powerhouse' biotech tops revenue expectations,2017-07-20 13:30:32 +0000,https://finance.yahoo.com/news/sarepta-rockets-20-higher-apos-133032502.html?.tsrc=rss,Wall Street believes the biopharma's focus on developing treatments for rare neuromuscular diseases is paying off.
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Jul 20, 2017 :  INO, MT, XPO, SRPT, USAT, FND, QQQ, ERIC, WES, WFM, NVO, FMSA",2017-07-20 12:52:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n_1eVs9jeBk/pre-market-most-active-for-jul-20-2017-ino-mt-xpo-srpt-usat-fnd-qqq-eric-wes-wfm-nvo-fmsa-cm818520,The NASDAQ 100 Pre Market Indicator is up 9 73 to 5 925 89 The total Pre Market volume is currently 4 035 604 shares traded The following are the most active stocks for the pre market session Inovio Pharmaceuticals Inc INO is 0 34 at 6 44 with 637 200 shares
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc’s (SRPT) Earnings Trigger Price Target Boost; Shares Soar 18%,2017-07-20 12:18:40 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-inc-srpt-earnings-121840452.html?.tsrc=rss,"Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring nearly 18% in pre-market trading Thursday, after the drug maker reported solid second-quarter earnings and provided a corporate update to investors. Sarepta handily beat consensus 2Q Exondys 51 sales estimates of $22 million by $13 million and raised FY17 guidance to a range of $125-$130 million, compared to consensus estimate of $104 million."
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Is Rising Today,2017-07-20 12:05:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j-XzIsKdH8g/why-sarepta-therapeutics-stock-is-rising-today-cm818504,What happened Shares of the orphan drug specialist Sarepta Therapeutics NASDAQ SRPT rose by as much as 15 5 in after hours trading yesterday on heavy volume This double digit rally was sparked by a far better than expected second quarter earnings report that hit the wires
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Rose After-Hours Wednesday,2017-07-20 11:30:00 +0000,http://finance.yahoo.com/r/38f5337b-c82f-3fb9-8073-3d9a5d799da2/why-sarepta-therapeutics-stock-rose-after-hours-we.aspx?yptr=yahoo&.tsrc=rss,Sarepta&apos;s strong second quarter sent its shares surging higher in after-hours trading.
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Is Rising Today,2017-07-20 11:30:00 +0000,http://finance.yahoo.com/r/07739247-61cf-38c3-aa5a-165051b4d4c6/why-sarepta-therapeutics-stock-is-rising-today.aspx?yptr=yahoo&.tsrc=rss,Sarepta&apos;s strong second quarter sent its shares surging higher in after-hours trading.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Has Jumped To An 8-Month High On Q2 Results,2017-07-20 09:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p66opyEbc4k/sarepta-therapeutics-srpt-has-jumped-to-an-8month-high-on-q2-results-20170720-00888,Sarepta Therapeutics (SRPT) Has Jumped To An 8-Month High On Q2 Results
SRPT,SRPT:UW,BBG000BCJC58,"SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz",2017-07-20 02:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mEEsv6xa56w/srpt-soars-on-q2-results--outlook-aeris-mercury1-does-an-encore-alim-abuzz-20170720-00099,"SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics reports 2Q loss,2017-07-20 01:16:25 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-reports-2q-loss-201310593.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.15. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta & BioMarin Settle Patent Litigation on Exon Skipping,2017-07-19 23:03:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ePfPMTgsXU/sarepta-biomarin-settle-patent-litigation-on-exon-skipping-cm818405,Sarepta Therapeutics Inc SRPT and BioMarin Pharmaceutical Inc BMRN have settled their ongoing global patent litigation regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy DMD therapies BioMarin has licensed the
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta shoots higher as sales of $300,000-a-year drug exceed expectations",2017-07-19 21:37:22 +0000,http://finance.yahoo.com/r/9fd83efe-1020-38bc-a75f-89b0725eff12/Story.aspx?guid=D8F4DF47-FB40-4584-9D3F-ED6DD89DD510&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics Inc. shares shot more than 13% higher in late trading Wednesday after the company reported sales of its $300,000-a-year drug for Duchenne muscular dystrophy were better than expected. ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta & BioMarin Settle Patent Litigation on Exon Skipping,2017-07-19 20:56:08 +0000,https://finance.yahoo.com/news/sarepta-biomarin-settle-patent-litigation-205608020.html?.tsrc=rss,"Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta hikes full-year sales estimate for Duchenne drug,2017-07-19 20:31:16 +0000,http://finance.yahoo.com/r/3c9dbbf3-7446-3dbd-97ca-c030d1936686/sarepta-hikes-full-year-sales-estimate-for.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics reported Wednesday that sales of its Duchenne muscular dystrophy drug have picked up momentum since the FDA's controversial approval of the treatment last year.  Cambridge-based Sarepta (SRPT) said that the drug, Exondys 51, had generated $35 million in sales in the second quarter of 2017.  Sarepta also raised its guidance for total revenue in 2017, from more than $95 million to between $125 million and $130 million."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Rockets On Consensus-Crushing Sales, Narrowing Losses",2017-07-19 20:22:14 +0000,http://finance.yahoo.com/r/91fc105a-2d85-3351-b2cc-7cc221d23a01/sarepta-rockets-on-consensus-crushing-sales-narrowing-losses?src=A00220&yptr=yahoo&.tsrc=rss,Sarepta stock bolted after the biotech smashed views for second-quarter sales and it reported narrower losses
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments,2017-07-19 20:01:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-second-quarter-200100150.html?.tsrc=rss,--Achieved net revenue of $35 million for the second quarter 2017--. --Increased revenue guidance range to $125– $130 million for the year–. --Entered into global settlement and license agreements resolving ...
SRPT,SRPT:UW,BBG000BCJC58,"Earnings Reaction History: Sarepta Therapeutics, Inc., 37.5% Follow-Through Indicator, 4.1% Sensitive",2017-07-19 19:42:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9NsQeRi0kpg/earnings-reaction-history-sarepta-therapeutics-inc-375-follow-through-indicator-41-sensitive-cm818307,Expected Earnings Release 07 19 2017 After hoursExpected Earnings Release 07 19 2017 After hours Avg Extended Hours Dollar Volume 5 119 028Avg Extended Hours Dollar Volume 5 119 028 Sarepta Therapeutics Inc SRPT is due to issue its quarterly earnings report in the
SRPT,SRPT:UW,BBG000BCJC58,​Sarepta skips over a Duchenne patent battle with $35M settlement,2017-07-19 17:45:10 +0000,http://finance.yahoo.com/r/7a303899-d504-39b9-b8f2-cc86b885841b/sarepta-skips-over-a-duchenne-patent-battle-with.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Cambridge-based Sarepta Therapeutics has agreed to pay $35 million plus royalties and potential milestones to a California biotech to resolve a dispute over patents on its Duchenne muscular dystrophy drug.  Sarepta (SRPT) said Tuesday that it had reached an agreement to license the intellectual property of San Rafael-based BioMarin Pharmaceutical (BMRN).  BioMarin had previously challenged key patents covering Sarepta’s approved Duchenne drug, Exondys 51, as well as other so-called “exon-skipping” treatments."
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy Wednesday Option Activity: SRPT, NTRS, WMB",2017-07-19 17:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f8n1fZzB8JM/noteworthy-wednesday-option-activity-srpt-ntrs-wmb-cm818177,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Sarepta Therapeutics Inc Symbol SRPT where a total volume of 7 033 contracts has been traded thus far today a contract volume which is representative of approximately 703
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Q2 17 Earnings Conference Call At 4:30 PM ET,2017-07-19 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l3zlJrrom4Q/sarepta-therapeutics-q2-17-earnings-conference-call-at-430-pm-et-20170719-01046,Sarepta Therapeutics Q2 17 Earnings Conference Call At 4:30 PM ET
SRPT,SRPT:UW,BBG000BCJC58,"Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call",2017-07-19 15:00:00 +0000,https://finance.yahoo.com/news/investor-network-sarepta-therapeutics-inc-150000110.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 19, 2017 / Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, July 19, 2017 at 4:30 ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2017-07-19 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-clinigen-launch-managed-123000995.html?.tsrc=rss,"CAMBRIDGE, Mass., July 19, 2017-- Sarepta Therapeutics, Inc., a U.S. biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Secures $100 Million in Debt Financing,2017-07-18 20:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-secures-100-million-203000355.html?.tsrc=rss,"CAMBRIDGE, Mass., July 18, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,​BioMarin snags cash as Sarepta skips Duchenne patent battle,2017-07-18 17:45:11 +0000,http://finance.yahoo.com/r/8768d65e-54cb-34c3-9e30-3244f178f836/biomarin-sarepta-bmrn-srpt-duchenne-exondys-51.html?ana=yahoo&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics Inc. agreed to pay $35 million plus royalties and potential milestones to BioMarin Pharmaceutical Inc. to resolve a dispute over patents on its Duchenne muscular dystrophy drug. Sarepta ...
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta, BioMarin Fall After Settling Patent Fight",2017-07-18 17:32:00 +0000,http://finance.yahoo.com/r/d00245f4-55ac-3311-be0a-22fd81c2bc7e/sarepta-biomarin-fall-after-settling-patent-fight-1500399152?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics (SRPT) and BioMarin Pharmaceutical (BMRN) are falling Tuesday, after announced they had reached a settlement regarding the exclusive license on a patent pertaining to exon skipping technology used in Duchenne muscular dystrophy (DMD) therapies.  The settlement is a long-awaited one, and the agreement means that Sarepta will pay BioMarin an upfront fee of $15 million, and owe a 5% royalty on US sales of drugs using the technology, as well as an 8% royalty on European sales through 2023 and 2024, respectively.  Leerink's Joseph Schwartz and Dae Gon Ha reiterated Outperform ratings on both Sarepta and BioMarin, but write that the news is better for the latter than the former."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation,2017-07-18 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-biomarin-pharmaceutical-inc-123000612.html?.tsrc=rss,"CAMBRIDGE, Mass. and SAN RAFAEL, Calif., July 18, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics ..."
SRPT,SRPT:UW,BBG000BCJC58,How These Biotechs Are Dodging Payor Pushback In Muscular Dystrophy,2017-07-17 20:33:24 +0000,http://finance.yahoo.com/r/2085093b-218c-3f6b-b0c7-0a17cf4ee4c9/how-these-biotechs-are-dodging-payor-pushback-in-muscular-dystrophy?src=A00220&yptr=yahoo&.tsrc=rss,"Duchenne muscular dystrophy drugs from Sarepta and PTC look strong despite early pushback over their hefty price tags, an analyst said Monday."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: Say Hello To The New CEO,2017-07-17 14:55:00 +0000,http://finance.yahoo.com/r/8a0662bd-7fd6-3e07-ae34-ab7a7cb38c22/sarepta-therapeutics-say-hello-to-the-new-ceo-1500303315?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When Sarepta Therapeutics (SRPT) unveils its second quarter financial results on July 19, investors will get a gander at more than profits and sales.  The after-market conference hosted by the drug maker for analysts and investors will mark the introduction of Douglas Ingram as the new chief executive.  In fact, it will be Wall Street’s first opportunity to hear about “his vision and strategies for the company going forward,” says Joseph P. Schwartz, an analyst at Leerink."
SRPT,SRPT:UW,BBG000BCJC58,Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD,2017-07-13 23:46:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ofwTRzDzmxY/mallinckrodts-mnk-1411-gets-orphan-drug-status-for-dmd-cm815916,Mallinckrodt plc MNK announced that the FDA has granted orphan drug designation to its pipeline candidate MNK 1411 which is being evaluated for the treatment of Duchenne muscular dystrophy DMD The candidate has received a Fast Track designation by the FDA for the same indication
SRPT,SRPT:UW,BBG000BCJC58,SRPT Makes Bullish Cross Above Critical Moving Average,2017-07-13 21:46:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KboWJFyjKe4/srpt-makes-bullish-cross-above-critical-moving-average-cm815865,In trading on Thursday shares of Sarepta Therapeutics Inc Symbol SRPT crossed above their 200 day moving average of 35 23 changing hands as high as 35 63 per share Sarepta Therapeutics Inc shares are currently trading up about 1 7 on the day The chart below shows the one year
SRPT,SRPT:UW,BBG000BCJC58,"The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta Therapeutics and EXACT Sciences",2017-07-12 15:51:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yA2sXL6d-20/the-zacks-analyst-blog-highlights-vertex-pharmaceuticals-alimera-sciences-enzo-biochem-sarepta-therapeutics-and-exact-sciences-cm815145,For Immediate Release Chicago IL July 12 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include
SRPT,SRPT:UW,BBG000BCJC58,"The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta Therapeutics and EXACT Sciences",2017-07-12 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-vertex-133001974.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta Therapeutics and EXACT Sciences"
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Picked Up Steam in June,2017-07-12 12:46:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w903iPGPnzo/why-sarepta-therapeutics-stock-picked-up-steam-in-june-cm814840,What happened Sarepta Therapeutics NASDAQ SRPT a rare disease drugmaker had a particularly good month in June with its shares rising by 9 8 according to S amp P Global Market Intelligence While the company capped the month by announcing the appointment of its new
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Picked Up Steam in June,2017-07-12 11:01:00 +0000,http://finance.yahoo.com/r/2bd5eac1-d607-3b94-a2b1-2f1344ec1826/why-sarepta-therapeutics-stock-picked-up-steam-in.aspx?yptr=yahoo&.tsrc=rss,"Sarepta&apos;s shares gained momentum last month, but it remains a speculative buy."
SRPT,SRPT:UW,BBG000BCJC58,5 Top Multibagger Biotech Stocks to Buy in the 2nd Half,2017-07-11 13:26:01 +0000,https://finance.yahoo.com/news/5-top-multibagger-biotech-stocks-132601282.html?.tsrc=rss,Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-06-30 22:00:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-220000428.html?.tsrc=rss,"CAMBRIDGE, Mass., June 30, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017,2017-06-30 16:44:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RMRcr4Eglv4/sarepta-looks-to-focus-on-exondys-51-dmd-pipeline-in-2017-cm810615,We issued an updated research report on Cambridge MA based Sarepta Therapeutics Inc SRPT on Jun 28 Sarepta is a commercial stage biopharmaceutical company that focuses on the discovery and development of RNA based therapeutics targeting rare and infectious diseases especially
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017,2017-06-30 14:47:02 +0000,https://finance.yahoo.com/news/sarepta-looks-focus-exondys-51-144702983.html?.tsrc=rss,"We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28."
SRPT,SRPT:UW,BBG000BCJC58,Could This Biotech Be Headed For A Deal After CEO Takes Reins?,2017-06-29 20:21:53 +0000,http://finance.yahoo.com/r/99c5c0ae-4e54-3876-818f-728876325b93/could-this-biotech-be-headed-for-a-deal-after-ceo-takes-reins?src=A00220&yptr=yahoo&.tsrc=rss,Sarepta stock popped on speculation it could be on the auction block after hiring a new merger-savvy chief executive.
SRPT,SRPT:UW,BBG000BCJC58,A Veteran CEO Might Be Just What Sarepta Therapeutics Needed,2017-06-29 17:20:47 +0000,https://finance.yahoo.com/news/veteran-ceo-might-just-sarepta-172047074.html?.tsrc=rss,"Credit Suisse analyst Alethia Young reiterated an Outperform rating on Sarepta Therapeutics Inc (NASDAQ: SRPT ) with a $64 price target, following the announcement of a new CEO and ahead of several other ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Appoints Ex-Allergan Executive as CEO and President,2017-06-29 17:06:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jytjtyU3rYU/sarepta-appoints-ex-allergan-executive-as-ceo-and-president-cm810094,Sarepta Therapeutics Inc 160 SRPT announced the appointment of Douglas S Ingram as the new chief executive officer CEO He will also serve as the company s president and will also be a member of the board of directors Ingram has a cumulative experience of more than 20 years as
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Appoints Ex-Allergan Executive as CEO and President,2017-06-29 14:25:02 +0000,https://finance.yahoo.com/news/sarepta-appoints-ex-allergan-executive-142502918.html?.tsrc=rss,"Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO)."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: A New CEO Goes a Long Way?,2017-06-29 14:12:00 +0000,http://finance.yahoo.com/r/11448022-ea75-3e14-aa2c-eaf23089cb98/sarepta-a-new-ceo-goes-a-long-way-1498745538?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics (SRPT) last night announced that it had appointed Douglas Ingram as its new CEO. Leerink's Joseph Schwartz and Dae Gon Ha applaud the choice for Sarepta's new CEO: Following Dr. Ed ...
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics names new CEO,2017-06-28 22:58:14 +0000,http://finance.yahoo.com/r/14933885-f1fc-3096-93dc-12a6e3b690a8/Story.aspx?guid=5D795F8E-5509-4B8B-B6D5-9A54D6D4ED07&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Drugmaker Sarepta Therapeutics Inc. on Wednesday named Douglas Ingram its next chief executive. Ingram, currently the president and CEO at Allergan PLC's Chase Pharmaceutics, will start Sept. 20, Sarepta ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Names Douglas Ingram As President And CEO,2017-06-28 22:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kzpAGihEzLM/sarepta-therapeutics-names-douglas-ingram-as-president-and-ceo-20170628-01323,Sarepta Therapeutics Names Douglas Ingram As President And CEO
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta Taps Chase Pharmaceuticals Chief as Next CEO,2017-06-28 22:37:52 +0000,http://finance.yahoo.com/r/8b4f5ecc-94ee-34af-bb44-4669c3b7b238/sarepta-taps-chase-pharmaceuticals-chief-as-next-ceo-1498687839?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Biopharmaceutical developer Sarepta Therapeutics Inc. named a company outsider as its new chief executive, tapping Douglas Ingram to lead the firm."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta appoints former Allergan executive Douglas Ingram as CEO,2017-06-28 21:14:17 +0000,https://finance.yahoo.com/news/sarepta-appoints-former-allergan-executive-211417848.html?.tsrc=rss,"Sarepta Therapeutics Inc said on Wednesday it appointed Douglas Ingram as president and chief executive officer. Ingram, who previously held a senior executive position in Allergan Plc, will also be a ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief Executive Officer,2017-06-28 20:01:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-appoints-douglas-ingram-200100218.html?.tsrc=rss,"CAMBRIDGE, Mass., June 28, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 28, 2017",2017-06-28 13:05:32 +0000,http://finance.yahoo.com/r/d53dbc53-91d8-343b-a03c-9fbdab8d1edd/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-srpt-us-june-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sarepta Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics to Announce Second Quarter 2017 Financial Results and Recent Corporate Developments on July 19, 2017",2017-06-28 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announce-second-quarter-123000490.html?.tsrc=rss,"CAMBRIDGE, Mass., June 28, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover,2017-06-27 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-grand-opening-123000648.html?.tsrc=rss,"CAMBRIDGE, Mass., June 27, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Shares Cross Above 200 DMA,2017-06-21 22:21:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2uHCuwdtets/sarepta-therapeutics-srpt-shares-cross-above-200-dma-cm806562,In trading on Wednesday shares of Sarepta Therapeutics Inc Symbol SRPT crossed above their 200 day moving average of 35 39 changing hands as high as 35 49 per share Sarepta Therapeutics Inc shares are currently trading up about 5 5 on the day The chart below shows the one year
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy Wednesday Option Activity: CLR, UNP, SRPT",2017-06-21 21:21:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AOqPtE3oLvw/noteworthy-wednesday-option-activity-clr-unp-srpt-cm806534,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Continental Resources Inc Symbol CLR where a total volume of 15 430 contracts has been traded thus far today a contract volume which is representative of approximately 1
SRPT,SRPT:UW,BBG000BCJC58,"Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc.",2017-06-21 17:30:00 +0000,https://finance.yahoo.com/news/scott-scott-attorneys-law-llp-173000842.html?.tsrc=rss,"Scott+Scott, Attorneys at Law, LLP , a national shareholder and consumer rights litigation firm, is investigating Sarepta Therapeutics, Inc. , a corporation headquartered in Cambridge, Massachusetts and incorporated in Delaware, and certain of its senior officers and executives."
SRPT,SRPT:UW,BBG000BCJC58,Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Gilead Sciences and Sarepta Therapeutics,2017-06-21 12:00:00 +0000,https://finance.yahoo.com/news/biotech-industry-showing-signs-revival-120000223.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 21, 2017 / The Biotech Industry has continued to outperform the broader markets in 2017. Biotech companies appear to be benefitting from a speedier FDA approval process ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics and Genethon Announce a Gene Therapy Research Collaboration for the Treatment of Duchenne Muscular Dystrophy,2017-06-21 11:00:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-genethon-announce-gene-110000551.html?.tsrc=rss,"CAMBRIDGE, Mass. and EVRY, France, June 21, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics ..."
SRPT,SRPT:UW,BBG000BCJC58,3 Most Wildly Overvalued Stocks in Biotech (At Least on Paper),2017-06-19 14:22:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3L3N3R3v8d4/3-most-wildly-overvalued-stocks-in-biotech-at-least-on-paper-cm804962,Biotech stocks aren t exactly known for being cheap While there are some bargains to be found most biotech stocks trade for more than their financial results justify And a few biotech stocks fall into the wildly overvalued category The most overpriced biotech stocks based on
SRPT,SRPT:UW,BBG000BCJC58,3 Most Wildly Overvalued Stocks in Biotech (At Least on Paper),2017-06-19 12:24:00 +0000,http://finance.yahoo.com/r/444c7831-8696-382a-ba62-65f35027ca98/3-most-wildly-overvalued-stocks-in-biotech.aspx?yptr=yahoo&.tsrc=rss,"Are Amgen, Illumina, and Sarepta Therapeutics really the most overvalued biotech stocks on the market?"
SRPT,SRPT:UW,BBG000BCJC58,3 Healthcare Stocks for Ambitious Investors,2017-06-15 22:08:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4ylDvwq050w/3-healthcare-stocks-for-ambitious-investors-cm804120,Healthcare stocks in general and biopharma stocks in particular are known for their volatile ways Having said that the rare gem within this hectic sector can produce jaw dropping gains quite literally overnight making it an appealing area for ambitious investors on the hunt
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : June 15, 2017",2017-06-15 20:33:14 +0000,http://finance.yahoo.com/r/1dbeff29-f394-30c8-acfc-7e9b0c1683a6/sarepta-therapeutics-inc-value-analysis-nasdaqsrpt-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Sarepta Therapeutics, Inc. a score of 25. Our analysis is based on comparing Sarepta Therapeutics, Inc. with the following peers – Hemispherx Biopharma, Inc., Novavax, Inc., Gilead Sciences, Inc., Ionis Pharmaceuticals, Inc., Newlink Genetics Corporation, Aviragen Therapeutics Inc, BioCryst Pharmaceuticals, Inc., Omega Protein Corporation, PTC Therapeutics, Inc. ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,3 Healthcare Stocks for Ambitious Investors,2017-06-15 20:23:00 +0000,http://finance.yahoo.com/r/70523203-8272-35b6-98b4-dada7e1a839f/3-healthcare-stocks-for-ambitious-investors.aspx?yptr=yahoo&.tsrc=rss,These three healthcare stocks should be on ambitious investors&apos; radars. Here&apos;s why.
SRPT,SRPT:UW,BBG000BCJC58,"ETFs with exposure to Sarepta Therapeutics, Inc. : June 15, 2017",2017-06-15 19:22:41 +0000,http://finance.yahoo.com/r/ae78d5d8-4d4d-38f8-af8b-565dc8e52da7/etfs-with-exposure-to-sarepta-therapeutics-inc-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sarepta Therapeutics, Inc. Here are 5 ETFs with the largest exposure to SRPT-US. Comparing the performance and risk of Sarepta Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : June 14, 2017",2017-06-14 12:20:59 +0000,http://finance.yahoo.com/r/339182c5-aad2-30d6-9ec6-014a9d43584a/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-srpt-us-june-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sarepta Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics To Present At Goldman Sachs Conference; Webcast At 1:40 PM,2017-06-13 12:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V0yLI5Ymndk/sarepta-therapeutics-to-present-at-goldman-sachs-conference-webcast-at-140-pm-20170613-00980,Sarepta Therapeutics To Present At Goldman Sachs Conference; Webcast At 1:40 PM
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy Friday Option Activity: HLF, SRPT, KW",2017-06-09 21:27:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/owfDKgTjPug/noteworthy-friday-option-activity-hlf-srpt-kw-cm801452,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Herbalife Ltd Symbol HLF where a total of 5 427 contracts have traded so far representing approximately 542 700 underlying shares That amounts to about 46 7 of HLF s average
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: Cheap For an Acquirer?,2017-06-08 14:06:00 +0000,http://finance.yahoo.com/r/2659c223-21b7-3a71-bed6-c0f3f1201cf8/sarepta-cheap-for-an-acquirer-1496930762?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics (SRPT) has gained more than 60% during the past 12 months, as investors have become increasingly bullish about the potential success of its Duchenne muscular dystrophy, or DMD, treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Imploded in May,2017-06-07 18:28:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XxCks2YTclY/why-sarepta-therapeutics-stock-imploded-in-may-cm800179,What happened Shares of the rare disease drugmaker Sarepta Therapeutics NASDAQ SRPT crashed and burned in May seemingly due to nothing more than a lawsuit filed by a reporter against the U S Food and Drug Administration The lawsuit pertains to Sarepta because the
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Stock Imploded in May,2017-06-07 16:21:00 +0000,http://finance.yahoo.com/r/89bfb9e1-788e-3d98-a72a-290f688bd71f/why-sarepta-therapeutics-stock-imploded-in-may.aspx?yptr=yahoo&.tsrc=rss,Investors are obviously nervous about the regulatory status of Sarepta&apos;s FDA-approved DMD drug.
SRPT,SRPT:UW,BBG000BCJC58,Cramer's lightning round: You're playing with fire with this heavily shorted stock,2017-06-06 22:48:15 +0000,http://finance.yahoo.com/r/c7209a64-6c02-3764-ae05-d0f288880bcc/104513372?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104513372&yptr=yahoo&.tsrc=rss,"Jim Cramer rattles off his take on callers' favorite stocks, including this hybrid health-tech play."
SRPT,SRPT:UW,BBG000BCJC58,Cramer&apos;s lightning round: You&apos;re playing with fire with this heavily shorted stock,2017-06-06 22:48:15 +0000,https://finance.yahoo.com/news/cramer-apos-lightning-round-apos-224815702.html?.tsrc=rss,"Jim Cramer rattles off his take on callers&apos; favorite stocks, including this hybrid health-tech play."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-05-31 22:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-223000135.html?.tsrc=rss,"CAMBRIDGE, Mass., May 31, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy Tuesday Option Activity: LMT, PVH, SRPT",2017-05-30 20:32:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N4JtBzgk0nc/noteworthy-tuesday-option-activity-lmt-pvh-srpt-cm796434,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Lockheed Martin Corp Symbol LMT where a total of 3 573 contracts have traded so far representing approximately 357 300 underlying shares That amounts to about 41 7 of LMT s
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics to Present Company Overview at the Goldman Sachs 38th Annual Global Healthcare Conference,2017-05-30 12:30:00 +0000,https://finance.yahoo.com/news/sarepta-therapeutics-present-company-overview-123000074.html?.tsrc=rss,"CAMBRIDGE, Mass., May 30, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : May 26, 2017",2017-05-26 12:28:44 +0000,http://finance.yahoo.com/r/baf680e8-1114-3453-8580-f2125e3ec2a9/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-srpt-us-may-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sarepta Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,Reporter sues FDA for documents related to Sarepta drug approval,2017-05-26 00:00:13 +0000,http://finance.yahoo.com/r/8cd270e8-703a-3fe2-a853-df05759e7b45/reporter-sues-fda-for-documents-related-to-sarepta.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"A journalist has filed a federal lawsuit against the FDA seeking documents related to the agency’s controversial approval last year of Exondys 51, a Duchenne muscular dystrophy treatment developed by Cambridge-based Sarepta Therapeutics.  Charles Seife, a journalist and professor at New York University, filed a complaint Thursday in Manhattan federal court challenging the FDA’s decision not to disclose records that he requested under the Freedom of Information Act.  The documents relate to the FDA’s approval of Exondys 51 in September."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's Most Famous Drugs and Medications,2017-05-24 20:03:00 +0000,http://finance.yahoo.com/r/daec7ece-7398-3189-9ce3-3687b183e4bd/sareptas-most-famous-drugs-and-medications-srpt?partner=YahooSA&yptr=yahoo&.tsrc=rss,Drugmaker Sarepta Therapeutics has developed two other medications with encouraging prospects.
SRPT,SRPT:UW,BBG000BCJC58,"Why Zoe's Kitchen, GOL, and Sarepta Therapeutics Slumped Today",2017-05-22 22:12:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4zl2JZ_GyEc/why-zoes-kitchen-gol-and-sarepta-therapeutics-slumped-today-cm792935,Overall stocks did well on Monday and the Dow climbed 90 points even as other major benchmarks posted similar or slightly larger percentage gains Market participants seemed to be heartened by President Trump s performance on the first overseas visit of his administration over
SRPT,SRPT:UW,BBG000BCJC58,"Why Zoe&apos;s Kitchen, GOL, and Sarepta Therapeutics Slumped Today",2017-05-22 20:55:25 +0000,http://finance.yahoo.com/r/e859ba85-b8d6-35fc-b1e0-d59e9cd078e6/why-zoes-kitchen-gol-and-sarepta-therapeutics-slum.aspx?yptr=yahoo&.tsrc=rss,"Despite a rising market, these stocks fell. Find out why."
SRPT,SRPT:UW,BBG000BCJC58,Top hedge fund managers shared these 5 trade ideas at the SALT Conference,2017-05-20 17:32:13 +0000,https://finance.yahoo.com/news/hedge-fund-managers-share-best-trade-ideas-173213844.html?.tsrc=rss,Some big name money managers shared their best long and short ideas at the SALT Conference.
SRPT,SRPT:UW,BBG000BCJC58,"Notable Friday Option Activity: LOGM, SRPT, CAB",2017-05-19 21:13:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OwbI2NvwiJ0/notable-friday-option-activity-logm-srpt-cab-cm792128,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in LogMeIn Inc Symbol LOGM where a total of 4 271 contracts have traded so far representing approximately 427 100 underlying shares That amounts to about 60 4 of LOGM s average
SRPT,SRPT:UW,BBG000BCJC58,SALT Spotlight: Why Sarepta is a Buy,2017-05-18 20:52:00 +0000,http://finance.yahoo.com/r/bdee84da-06ae-353c-b674-fd23719514e2/salt-spotlight-why-sarepta-is-a-buy-1495140766?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Barron's  Andrew Bary has been a Sarepta Therapeutics (SRPT) bull for a while now, most recently arguing that the stock could double.  Karp notes that Sarepta's treatment for Duchenne muscular dystrophy, though lacking the same kind of data that drugs with higher prevalence rates might have, appears to work quite well.  Patients on the drug have better respiratory function and a greater walking ability than they have without it."
SRPT,SRPT:UW,BBG000BCJC58,Big Fund Managers Offer Up Stock Pick Ideas,2017-05-18 19:04:00 +0000,http://finance.yahoo.com/r/7484dd77-943b-3a35-b8c4-e405b319397f/big-fund-managers-offer-up-stock-pick-ideas.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Hedge fund managers offer up some investment ideas.
SRPT,SRPT:UW,BBG000BCJC58,Tourbillon's Karp says Sarepta shares could surge 200 pct,2017-05-18 18:44:33 +0000,https://finance.yahoo.com/news/tourbillons-karp-says-sarepta-shares-184433909.html?.tsrc=rss,"Hedge fund manager Jason Karp  on Thursday said that shares of Sarepta Therapeutics Inc  could climb as much as 200 percent and noted the  biotech company could be an attractive takeover candidate.  ""If they can get to the sales levels in the next two years,  this thing should be 200 percent higher,"" Karp said at the  SkyBridge Capital SALT hedge fund conference.  The company treats  Duchenne muscular dystrophy which affects as many as 7,000  males."
SRPT,SRPT:UW,BBG000BCJC58,"How the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn't Believe Worked",2017-05-18 15:30:57 +0000,http://finance.yahoo.com/r/dde45370-a3a1-340a-a380-b4dda2bfec09/how-the-fda-approved-a-300-000-a-year-drug-its-own-experts-didnt-believe-worked-1495116544?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"After trial data for a new medicine proved inconclusive, Sarepta Therapeutics joined with the parents of sick boys to persuade officials it helped."
SRPT,SRPT:UW,BBG000BCJC58,​Former Sarepta CEO launches biotech accelerator with $25M backing,2017-05-18 15:15:51 +0000,http://finance.yahoo.com/r/87e2dd75-e850-39be-b01f-bed59786ef75/former-sarepta-ceo-launches-biotech-accelerator.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"The former CEO of Sarepta Therapeutics Inc., one of the most closely watched small biotechs over the past five years, has reemerged more than two years after his sudden resignation from the Cambridge company — with $25 million in hand and a plan to change how entrepreneurs develop new drugs.  Chris Garabedian, who renamed a 30-year-old Seattle-based company (SRPT) and moved it to Cambridge in 2012, says he started getting calls within days after he stepped down on March 31, 2015.  “Literally, the week after I left Sarepta, I got a calls from entrepreneurs ... who reached out and were inquiring if I were available to work with them and find a path forward for their technology,” Garabedian said this week."
SRPT,SRPT:UW,BBG000BCJC58,"Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71",2017-05-15 00:00:17 +0000,http://finance.yahoo.com/r/9c8b9b49-5646-328b-bf79-1f1a9c48020a/henri-termeer-giant-of-biotech-and-longtime-ceo-of.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Henri Termeer, the longtime chief executive of Genzyme, one of the most iconic biotechnology companies in the world, has died at the age of 71 in his Marblehead home, according to multiple reports.  In an interview Saturday, Josh Boger, founding CEO of Vertex Pharmaceuticals (VRTX), said that Termeer served as a example for how to run a biotech firm ever since he first met him in the early 1990s.  ""As a CEO, as Vertex became big enough that I could pay attention to things outside the company, Henri taught me the importance of caring about ... the community you're in,"" said Boger."
SRPT,SRPT:UW,BBG000BCJC58,Should You Buy Into the Hype Surrounding These Stocks?,2017-05-06 19:25:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eUBMu1EfsSo/should-you-buy-into-the-hype-surrounding-these-stocks-cm785453,Wall Street and investors are always looking toward the future But the question that has to be asked from time to time is whether Wall Street and investors have looked too far into the future and overvalued a company relative to its hype With this in mind we asked three of our
SRPT,SRPT:UW,BBG000BCJC58,Should You Buy Into the Hype Surrounding These Stocks?,2017-05-06 17:24:00 +0000,http://finance.yahoo.com/r/5a52a286-529a-302b-8705-417d4952b673/should-you-buy-into-the-hype-surrounding-these-sto.aspx?yptr=yahoo&.tsrc=rss,"This rare-disease drugmaker, luxury sports-car manufacturer, and chipmaker all have some lofty expectations to live up to."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc. Stock Rose 22.5% in April. Here's Why.,2017-05-06 12:25:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qZIi4VoOrvc/sarepta-therapeutics-inc-stock-rose-225-in-april-heres-why-cm785401,What happened Shares of Sarepta Therapeutics Inc NASDAQ SRPT a biopharma company in the middle of its first drug launch rose 22 5 in April according to data from S amp P Global Market Intelligence Stronger than expected sales of its Duchenne muscular dystrophy
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc. Stock Rose 22.5% in April. Here&apos;s Why.,2017-05-06 10:47:00 +0000,http://finance.yahoo.com/r/b8a2a7f9-61e7-3598-b1b0-1beb6579babc/sarepta-therapeutics-inc-stock-rose-225-in-april-h.aspx?yptr=yahoo&.tsrc=rss,Stronger-than-expected sales of Exondys 51 and a departing executive gave the biotech stock some lift last month.
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy ETF Inflows: XBI, VRTX, IONS, SRPT",2017-05-03 19:47:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NzBCx0d6KZg/noteworthy-etf-inflows-xbi-vrtx-ions-srpt-cm783570,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 129 9 million dollar inflow that s a 4 2 increase week over week in outstanding
SRPT,SRPT:UW,BBG000BCJC58,Edited Transcript of SRPT earnings conference call or presentation 27-Apr-17 8:30pm GMT,2017-05-03 12:05:57 +0000,http://finance.yahoo.com/news/edited-transcript-srpt-earnings-conference-052738406.html?.tsrc=rss,Q1 2017 Sarepta Therapeutics Inc Earnings Call
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-05-01 21:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-213000420.html?.tsrc=rss,"CAMBRIDGE, Mass., May 01, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,How Much Would Sarepta Therapeutics Fetch in a Buyout?,2017-05-01 18:28:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ksmyH9BVPQ/how-much-would-sarepta-therapeutics-fetch-in-a-buyout-cm782166,Sarepta Therapeutics NASDAQ SRPT stock ended last week up over 11 due to the better than expected first quarter sales of its Duchenne muscular dystrophy DMD drug 160 Exondys 51 combined with the rumor that the French drugmaker Sanofi NYSE SNY may be considering a
SRPT,SRPT:UW,BBG000BCJC58,How Much Would Sarepta Therapeutics Fetch in a Buyout?,2017-05-01 16:57:00 +0000,http://finance.yahoo.com/r/cb2dba58-c9a2-3371-b403-77ed7ea016ee/how-much-would-sarepta-therapeutics-fetch-in-a-buy.aspx?yptr=yahoo&.tsrc=rss,"If Sarepta is up for sale, it could fetch a handsome premium. Here&apos;s why."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: Forget a Takeover. This is Why Its CEO's Departure Could Be Good News,2017-05-01 15:44:00 +0000,http://finance.yahoo.com/r/f2a6306f-e853-351b-8e60-4cae7cb230dc/sarepta-forget-a-takeover-this-is-why-its-ceos-departure-could-be-good-news-1493653498?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Last week, Sarepta Therapeutics (SRPT) gained 4.4% last week after releasing better-than-expected sales, but it was the departure of its CEO--which led to rumblings of a potential merger--that caught the market's attention.  In a note released Friday, SunTrust Robinson Humphrey's Edward Nash and team, however, argued that the CEO departure--with a replacement being ""commercially focused""--bodes well for Sarepta.  Reiterate Buy and $45PT Shares of Sarepta Therapeutics have risen 1.4% to $36.75 at 11:38 a.m. today."
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Trending Tickers: Sanofi and Sarepta Therapeutics,2017-05-01 11:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-trending-tickers-113000851.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 1, 2017 / There has been speculation that a takeover could soon be in Sarepta's future after its CEO exited the company, pushing shares higher on Friday. Investors were ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Pops On Consensus-Topping Revenue, Boosts 2017 Guide",2017-04-28 20:37:51 +0000,http://finance.yahoo.com/r/dc2373da-99db-3925-87a7-09d8313e1539/sarepta-pops-on-consensus-topping-revenue-boosts-2017-guide?src=A00220&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics stock rocketed after the biotech topped sales expectations for its key muscular dystrophy drug.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Tests Biotech's CEO Vacuum Hypothesis,2017-04-28 17:37:24 +0000,http://finance.yahoo.com/r/25988d31-19b8-3e9a-90e5-6f28bcad4bc2/sarepta-ceo-departure-tests-buyout-hypothesis?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Buyouts don't always follow leadership changes, but might this time."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up",2017-04-28 16:29:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0i3IU07dbfM/sarepta-srpt-q1-loss-narrows-exondys-51-sales-pick-up-cm781173,Sarepta Therapeutics Inc SRPT reported narrower than expected loss in the first quarter of 2017 Meanwhile the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased in the first quarter coupled with progress in
SRPT,SRPT:UW,BBG000BCJC58,​Sarepta shares jump as CEO’s planned exit spurs takeover speculation,2017-04-28 15:00:14 +0000,http://finance.yahoo.com/r/ac311f7b-1407-3f45-989d-6bd54111b60c/sarepta-shares-jump-as-ceo-s-planned-exit-spurs.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Sarepta Therapeutics soared Friday morning amid speculation that the planned departure of CEO Ed Kaye makes the Cambridge biotech a prime takeover target.  Kaye made the surprise announcement on a conference call with analysts Thursday, saying that he will step down from his role as CEO of Sarepta (SRPT) by the end of the year, but will remain on the company’s board.  Meanwhile, TheStreet’s Adam Feuerstein speculated Friday  that Sanofi (SNY) could emerge as a suitor."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up",2017-04-28 14:43:02 +0000,http://finance.yahoo.com/news/sarepta-srpt-q1-loss-narrows-144302766.html?.tsrc=rss,"Sarepta Therapeutics, Inc. (SRPT) reported narrower-than-expected loss in the first quarter of 2017. Meanwhile, the biotech company increased its 2017 sales outlook for Exondys 51 as patient and physician interest for the drug increased"
SRPT,SRPT:UW,BBG000BCJC58,"Yes, Sarepta Reported Earnings…But That's Not Why It's Flying Today",2017-04-28 14:16:00 +0000,http://finance.yahoo.com/r/0b123b01-7616-3984-a26c-80a49429e014/yes-sarepta-reported-earningsbut-thats-not-why-its-flying-today-1493388970?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics (SRPT) reported a larger-than-expected loss but much better sales this morning, which had given its shares a small boost in pre-open trading.  Speculation that Sarepta could be taken over, however, have caused its shares to skyrocket.  Sarepta stated its prescriber base increased 30% from 4Q16 (30 physicians submitting forms) and all tier 1 centers having submitted start forms, and first start forms from tier 3 centers have begun to flow in."
SRPT,SRPT:UW,BBG000BCJC58,"Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares",2017-04-28 13:39:00 +0000,http://finance.yahoo.com/r/83fff216-3cf3-3c9f-aadb-32d16788f885/biotech-movers-ceo-exit-tea-leaf-reading-prompts-surge-in-sarepta-shares.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal",2017-04-28 12:34:00 +0000,http://finance.yahoo.com/r/1681ceba-e650-3222-99b5-ef36c44eff8e/sarepta-ceo-exits-along-with-a-sanofi-director-so-let-s-speculate-about-a-possible-deal.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics tops Street 1Q forecasts,2017-04-27 21:06:27 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-tops-street-1q-210627411.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of $1.50. Losses, adjusted for non-recurring gains, came to 73 cents per share. The results beat Wall Street expectations. ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments,2017-04-27 20:01:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-first-quarter-200100852.html?.tsrc=rss,"--First quarter 2017 EXONDYS 51 total net revenues of $16.3 million--. --Company anticipates net revenues for the year will exceed $95 million--. CAMBRIDGE, Mass., April 27, 2017-- Sarepta Therapeutics, ..."
SRPT,SRPT:UW,BBG000BCJC58,"Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call",2017-04-27 18:00:00 +0000,http://finance.yahoo.com/news/investor-network-sarepta-therapeutics-inc-180000881.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 27, 2017 / Sarepta Therapeutics, Inc. (NASDAQ: SRPT) will be discussing their earnings results in their Q1 Earnings Call to be held April 27, 2017 at 4:30 PM Eastern Time. ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: A Victim of High Expectations?,2017-04-26 15:43:00 +0000,http://finance.yahoo.com/r/09811ae2-4225-34f6-98f4-77d9085231e5/sarepta-a-victim-of-high-expectations?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Sarepta Therapeutics (SRPT) have gained 7% this week following a bullish take from Barron's Andrew Bary. But with Sarepta set to report earnings after tomorrow's close, can the company deliver ..."
SRPT,SRPT:UW,BBG000BCJC58,Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock?,2017-04-25 14:08:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F7TX6sEugtE/is-the-options-market-predicting-a-spike-in-sarepta-srpt-stock-cm778638,Investors in Sarepta Therapeutics Inc SRPT need to pay close attention to the stock based on moves in the options market lately That is because the April 28 th 2017 35 Call had some of the highest implied volatility of all equity options today What is Implied Volatility
SRPT,SRPT:UW,BBG000BCJC58,Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock?,2017-04-25 12:42:12 +0000,http://finance.yahoo.com/news/options-market-predicting-spike-sarepta-124212203.html?.tsrc=rss,"Investors in Sarepta Therapeutics, Inc. (SRPT) need to pay close attention to the stock based on moves in the options market lately."
SRPT,SRPT:UW,BBG000BCJC58,"D-Day For CAPR Today, OMED Hands Out Pink Slips, JAZZ Hits Right Notes...",2017-04-25 02:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0ZyM6Z7-rM0/dday-for-capr-today-omed-hands-out-pink-slips-jazz-hits-right-notes-20170425-00089,"D-Day For CAPR Today, OMED Hands Out Pink Slips, JAZZ Hits Right Notes..."
SRPT,SRPT:UW,BBG000BCJC58,SRPT Makes Bullish Cross Above Critical Moving Average,2017-04-24 17:02:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LnOEuPijPJs/srpt-makes-bullish-cross-above-critical-moving-average-cm777920,In trading on Monday shares of Sarepta Therapeutics Inc Symbol SRPT crossed above their 200 day moving average of 33 60 changing hands as high as 34 75 per share Sarepta Therapeutics Inc shares are currently trading up about 4 9 on the day The chart below shows the one year performance
SRPT,SRPT:UW,BBG000BCJC58,"5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included",2017-04-24 16:17:00 +0000,http://finance.yahoo.com/r/62b8760a-0f71-358e-8c69-24a15e9c79f1/5-earnings-short-squeeze-plays-twitter-sarepta-therapeutics-included.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,These heavily shorted stocks could get squeezed sharply higher if they report positive earnings this week.
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers",2017-04-24 15:03:00 +0000,http://finance.yahoo.com/r/3e89ca9a-7aee-391f-8c11-70f035c5d727/biotech-movers-sarepta-paratek-pdl-biopharma.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics, Paratek Pharmaceuticals and PDL BioPharma were among the biotech stock movers in premarket trading on Monday."
SRPT,SRPT:UW,BBG000BCJC58,"Barron's Picks And Pans: Bank Stocks, O'Reilly Automotive, Sarepta And More",2017-04-23 17:11:28 +0000,http://finance.yahoo.com/news/barrons-picks-pans-bank-stocks-171128013.html?.tsrc=rss,This weekend's Barron's takes a look at the unusual value stock picks at one off the radar hedge fund. Other featured articles offer the prospects for top banks now that they have pulled back and a biotech ...
SRPT,SRPT:UW,BBG000BCJC58,[$$] Drugmaker Sarepta's Stock Could Double,2017-04-22 04:50:00 +0000,http://finance.yahoo.com/r/5e9ac645-dc0e-3435-a848-fb2fcfab2922/drugmaker-sareptas-stock-could-double-or-more-1492836646?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biotechnology stocks often suffer after the launch of new drugs when initial sales don’t measure up to investors’ hopes at the time of regulatory approval.  Exondys 51 is designed to slow the progression of the disease, rather than cure it."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : April 19, 2017",2017-04-19 19:18:55 +0000,http://finance.yahoo.com/r/ab9d450a-5c37-3290-999d-82846dc1dd4b/sarepta-therapeutics-inc-value-analysis-nasdaqsrpt-april-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Sarepta Therapeutics, Inc. a score of 19. Our analysis is based on comparing Sarepta Therapeutics, Inc. with the following peers – Hemispherx Biopharma, Inc., Novavax, Inc., Gilead Sciences, Inc., Ionis Pharmaceuticals, Inc., Newlink Genetics Corporation, Aviragen Therapeutics Inc, BioCryst Pharmaceuticals, Inc., Omega Protein Corporation, PTC Therapeutics, Inc. ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,"Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc. (SRPT)",2017-04-18 15:20:00 +0000,http://finance.yahoo.com/news/scott-scott-attorneys-law-llp-152000961.html?.tsrc=rss,"NEW YORK, April 18, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP (""Scott+Scott""), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta Therapeutics, Inc. (SRPT) (""Sarepta"" or ""the Company""), a corporation headquartered in Cambridge, Massachusetts and incorporated in Delaware, and certain of its senior officers and executives.  If you purchased Sarepta stock between October 1, 2015 and January 15, 2016, you are encouraged to contact a Scott+Scott attorney toll free at (844) 818-6980 for more information.  Sarepta is a biopharmaceutical company focused on the discovery and development of therapeutics for the treatment of rare, infectious and other diseases.  The Company developed the drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease.  Eteplirsen is designed to increase the underlying cause of DMD by enabling production of the protein dystrophin."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : April 18, 2017",2017-04-18 12:32:52 +0000,http://finance.yahoo.com/r/ecfafe68-5096-3feb-99a5-173eb98a16e8/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-srpt-us-april-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sarepta Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics,2017-04-18 11:30:00 +0000,http://finance.yahoo.com/news/fda-drug-approvals-rise-2017-113000923.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 18, 2017 / The volatile Biotech Industry has continued to be home to some of the largest gainers on the market in 2017. President Trump's pledge for a faster FDA approval ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017",2017-04-17 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announce-first-quarter-123000720.html?.tsrc=rss,"CAMBRIDGE, Mass., April 17, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Shark Bites: You Don't Want to Play the Gambler Today,2017-04-13 16:21:00 +0000,http://finance.yahoo.com/r/0a959386-d4bc-3095-8654-9abf5e820ab4/shark-bites-you-dont-want-play-gambler-today?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,This is one of those days when it may pay to walk away.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride,2017-04-12 21:55:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_2v0H1crjPk/sarepta-therapeutics-stock-history-a-biotech-roller-coaster-ride-cm773499,Stocks in the biotech and pharmaceuticals industries can give investors a ride more intense than the wildest roller coasters A quick analysis of the stock history of Sarepta Therapeutics NASDAQ SRPT provides a great example of this For two decades Sarepta stock has soared
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride,2017-04-12 20:42:00 +0000,http://finance.yahoo.com/r/f7513c9b-c5f5-34fc-bf47-6f0f6a5646c6/sarepta-therapeutics-stock-history-a-biotech-rolle.aspx?yptr=yahoo&.tsrc=rss,Sarepta Therapeutics stock history through the years has given investors a wild ride.
SRPT,SRPT:UW,BBG000BCJC58,Why PTC Therapeutics Dropped 25.3% in March,2017-04-07 12:55:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mB8DSs7D3kc/why-ptc-therapeutics-dropped-253-in-march-cm771198,What happened Shares of PTC Therapeutics NASDAQ PTCT 160 a commercial stage biotech focused on rare diseases plunged 25 3 in March according to data from S amp P Global Market Intelligence Image source Getty Images So what Here s a
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax,2017-04-06 11:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-biotech-stocks-113000052.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 6, 2017 / Sarepta recently presented clinical trial data at the MDA Scientific conference and received some unexpected support, while Novovax is looking to meet FDA endpoint ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),2017-04-05 21:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grant-210000234.html?.tsrc=rss,"CAMBRIDGE, Mass., April 05, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"Health Care Sector Update for 04/05/2017: SRPT,GILD,NEOT,UNIS",2017-04-05 20:33:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YwrauUnC__g/health-care-sector-update-for-04052017-srptgildneotunis-cm770403,Top Health Care StocksTop Health Care Stocks JNJ 0 32 JNJ 0 32 PFE 0 42 PFE 0 42 MRK 0 97 MRK 0 97 ABT 0 17 ABT 0 17 AMGN 1 26 AMGN 1 26 Health care stocks were lower just before today s closing bell with the NYSE Health Care Index slipping almost 0 4 while shares of health
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Can Gain 45%,2017-04-05 15:17:00 +0000,http://finance.yahoo.com/r/5bf17b49-1f40-38ac-b303-33952140cfa4/why-sarepta-can-gain-45?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Nearly one year ago, shares of Sarepta Therapeutics (SRPT) traded as low as $8 a share after the Food and Drug Administration voted against giving its treatment for Duchenne muscular dystrophy accelerated approval, resulting in numerous downgrades.  Barron's  Andrew Bary  has been bullish every step of the way.  Might Sarepta be setting up for another run now?"
SRPT,SRPT:UW,BBG000BCJC58,"Biotech Movers: Sarepta, Bellicum, Novavax",2017-04-05 13:23:00 +0000,http://finance.yahoo.com/r/10cd65f1-a3dd-3f55-b0e9-b113e442d75a/biotech-movers-sarepta-bellicum-novavax.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics, Bellicum Pharmaceuticals and Novavax were among the biotech stock movers in premarket trading on Wednesday."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Gets An Upgrade; Cardiac, Pulmonary Function Could Provide Added Clinical Support For Exondys",2017-04-05 13:05:35 +0000,http://finance.yahoo.com/news/sarepta-gets-upgrade-cardiac-pulmonary-130535709.html?.tsrc=rss,Sarepta Therapeutics Inc (NASDAQ: SRPT ) presented encouraging long-term cardiac and pulmonary data at the MDA Scientific Conference. The data could provide “additional support for the clinical benefit ...
SRPT,SRPT:UW,BBG000BCJC58,Sarepta chief hands over CMO role to former Regeneron exec,2017-04-03 15:00:11 +0000,http://finance.yahoo.com/r/bcd7e00b-a7f3-3f5b-b61a-84261457c8ec/sarepta-chief-hands-over-cmo-role-to-former.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics has appointed a former Regeneron Pharmaceuticals executive to take over the chief medical officer role from CEO Ed Kaye as the Cambridge biotech seeks to build its pipeline of Duchenne muscular dystrophy drugs.  Sarepta (SRPT) on Monday announced the appointment of Catherine Stehman-Breen, who held various executive roles at Amgen (AMGN) for more than a decade before joining New York-based Regeneron (REGN) in 2015 as vice president of clinical development and regulatory affairs.  Kaye has served as CMO since joining Sarepta in 2011."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta chief hands over CMO role to former Regeneron exec,2017-04-03 15:00:11 +0000,http://www.bizjournals.com/boston/news/2017/04/03/sarepta-chief-hands-over-cmo-role-to-former.html?ana=yahoo,Sarepta chief hands over CMO role to former Regeneron exec
SRPT,SRPT:UW,BBG000BCJC58,"8:38 am Sarepta Therapeutics names Catherine Stehman-Breen, M.D., M.S., as Chief Medical Officer",2017-04-03 12:38:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#srpt,"8:38 am Sarepta Therapeutics names Catherine Stehman-Breen, M.D., M.S., as Chief Medical Officer"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer",2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-appointment-catherine-123000105.html?.tsrc=rss,"CAMBRIDGE, Mass., April 03, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer",2017-04-03 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-appointment-catherine-123000105.html,"[GlobeNewswire] - CAMBRIDGE, Mass., April 03, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-03-31 22:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-223000346.html?.tsrc=rss,"CAMBRIDGE, Mass., March 31, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-03-31 22:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-223000346.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 31, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets",2017-03-31 12:32:04 +0000,http://biz.yahoo.com/e/170331/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets"
SRPT,SRPT:UW,BBG000BCJC58,Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?,2017-03-31 09:00:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fautcCJipBI/why-is-sarepta-srpt-down-27-since-the-last-earnings-report-cm768106,It has been about a month since the last earnings report for Sarepta Therapeutics Inc SRPT Shares have lost about 2 7 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is its due for a breakout
SRPT,SRPT:UW,BBG000BCJC58,Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?,2017-03-31 07:44:07 +0000,http://finance.yahoo.com/news/why-sarepta-srpt-down-2-074407360.html?.tsrc=rss,Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SRPT,SRPT:UW,BBG000BCJC58,Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?,2017-03-31 07:44:07 +0000,http://finance.yahoo.com/news/why-sarepta-srpt-down-2-074407360.html,Why Is Sarepta (SRPT) Down 2.7% Since the Last Earnings Report?
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board",2017-03-30 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-addition-kenneth-123000048.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 30, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board",2017-03-30 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-addition-kenneth-123000048.html?.tsrc=rss,"CAMBRIDGE, Mass., March 30, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Market Is Home on the Range Again,2017-03-22 17:06:00 +0000,http://finance.yahoo.com/r/d10c5d70-a0b2-3d56-81f6-0c487c61efbb/market-home-range-again?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Emotion of yesterday's collapse is pretty much gone.
SRPT,SRPT:UW,BBG000BCJC58,Market Is Home on the Range Again,2017-03-22 17:06:00 +0000,http://realmoney.thestreet.com/articles/03/22/2017/market-home-range-again?puc=yahoo&cm_ven=YAHOO,Market Is Home on the Range Again
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics,2017-03-17 13:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-biotech-stocks-133000563.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 17, 2017 / There has been significant interest in both companies by investment rating firms and individual investors over the past quarter. The interest is not necessarily ..."
SRPT,SRPT:UW,BBG000BCJC58,Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics,2017-03-17 13:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-biotech-stocks-133000563.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / March 17, 2017 / There has been significant interest in both companies by investment rating firms and individual investors over the past quarter. The interest is not necessarily ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference,2017-03-17 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-presentations-2017-123000062.html?.tsrc=rss,"CAMBRIDGE, Mass., March 17, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference,2017-03-17 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-presentations-2017-123000062.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 17, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : March 17, 2017",2017-03-17 12:16:42 +0000,http://www.capitalcube.com/blog/index.php/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-srpt-us-march-17-2017/,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : March 17, 2017"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : March 17, 2017",2017-03-17 12:16:42 +0000,http://finance.yahoo.com/r/187e184a-89d6-3e13-9b1d-a9446af1e873/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-srpt-us-march-17-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sarepta Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
SRPT,SRPT:UW,BBG000BCJC58,"Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought",2017-03-16 20:40:23 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=E4CF5596-0A71-11E7-A5EA-6FDC3BFE3CC3&siteid=yhoof2,"Why PTC Therapeutics may have to lower the price on a $89,000-a-year drug it just bought"
SRPT,SRPT:UW,BBG000BCJC58,PTC Therapeutics Buys Duchenne Drug for $140M,2017-03-16 19:33:00 +0000,http://www.investopedia.com/news/ptc-therapeutics-buys-duchenne-drug-140m-ptct/?partner=YahooSA,PTC Therapeutics Buys Duchenne Drug for $140M
SRPT,SRPT:UW,BBG000BCJC58,PTC Therapeutics Buys Duchenne Drug for $140M,2017-03-16 19:33:00 +0000,http://finance.yahoo.com/r/1323dfe9-8809-3a38-b3fc-bd79cc3f3d86/ptc-therapeutics-buys-duchenne-drug-140m-ptct?partner=YahooSA&yptr=yahoo&.tsrc=rss,Marathon Pharmaceuticals is selling its Duchenne muscular dystrophy drug amid uproar over its high cost.
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's DMD Drug Launch Slow; What's in Store for 2017?,2017-03-13 15:09:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZnLMwZQgnmo/sareptas-dmd-drug-launch-slow-whats-in-store-for-2017-cm759915,We issued an updated research report on Sarepta Therapeutics Inc SRPT on Mar 9 2016 Sarepta is a commercial stage biopharmaceutical company that focuses on the discovery and development of RNA based therapeutics targeting rare and infectious diseases It concentrates on the development
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's DMD Drug Launch Slow; What's in Store for 2017?,2017-03-13 13:32:01 +0000,http://finance.yahoo.com/news/sareptas-dmd-drug-launch-slow-133201127.html,Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's DMD Drug Launch Slow; What's in Store for 2017?,2017-03-13 13:32:01 +0000,http://finance.yahoo.com/news/sareptas-dmd-drug-launch-slow-133201127.html?.tsrc=rss,"We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016."
SRPT,SRPT:UW,BBG000BCJC58,"Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ...",2017-03-11 00:11:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EnI2WYygFWA/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-cm759336,Perceptive Advisors Llc New Purchases GLPG AVDL ACOR IRTC CTMX BCRX ATRS JAZZ ALNY PPHMP Added Positions NBIX ACRS FOLD ANIP AVXS GBT ARDX VBIV ZGNX XNCR Reduced Positions SRPT AERI CRBP ABMD SUPN AGEN BPMC NDRM AGTC
SRPT,SRPT:UW,BBG000BCJC58,Trump nominates FDA head with deep ties to drug companies,2017-03-10 22:57:57 +0000,http://finance.yahoo.com/news/trump-poised-tap-scott-gottlieb-175321839.html?.tsrc=rss,"U.S. President Donald Trump  has chosen Dr. Scott Gottlieb, a conservative health policy  expert with deep ties to the pharmaceutical industry, to lead  the U.S. Food and Drug Administration, a White House official  said on Friday.  If confirmed by the Senate, Gottlieb would be in charge of  implementing Trump's plan to dramatically cut regulations  governing food, drugs, cosmetics, dietary supplements and  tobacco."
SRPT,SRPT:UW,BBG000BCJC58,Trump nominates FDA head with deep ties to drug companies,2017-03-10 22:57:57 +0000,http://finance.yahoo.com/news/trump-poised-tap-scott-gottlieb-175321839.html,"[Reuters] - U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, a White House official said on Friday. If confirmed by the Senate, Gottlieb would be in charge of implementing Trump's plan to dramatically cut regulations governing food, drugs, cosmetics, dietary supplements and tobacco."
SRPT,SRPT:UW,BBG000BCJC58,Payor Re-Evaluation On Exondys Positive For Sarepta,2017-03-10 20:21:11 +0000,http://finance.yahoo.com/news/payor-evaluation-exondys-positive-sarepta-202111118.html?.tsrc=rss,"Cowen sees positive trends over payor evaluation and re-evaluation of Sarepta Therapeutics Inc (NASDAQ: SRPT )’s Exondys 51, which was approved in last September for the treatment Duchenne Muscular Dystrophy. ..."
SRPT,SRPT:UW,BBG000BCJC58,Payor Re-Evaluation On Exondys Positive For Sarepta,2017-03-10 20:21:11 +0000,http://finance.yahoo.com/news/payor-evaluation-exondys-positive-sarepta-202111118.html,Payor Re-Evaluation On Exondys Positive For Sarepta
SRPT,SRPT:UW,BBG000BCJC58,"Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease",2017-03-10 19:33:42 +0000,http://finance.yahoo.com/news/adam-feuerstein-weighs-novo-gbt-193342974.html,"Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease"
SRPT,SRPT:UW,BBG000BCJC58,"Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease",2017-03-10 19:33:42 +0000,http://finance.yahoo.com/news/adam-feuerstein-weighs-novo-gbt-193342974.html?.tsrc=rss,"The pharmaceutical industry, rich with innovative players and shaken by impending regulatory changes, is a well-worn topic on Wall Street. Adam Feuerstein joined Benzinga’s Pre-Market Prep radio show to ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta To Present At Cowen Health Care Conference; Webcast At 8:00 AM ET,2017-03-08 06:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/11vWwlSvSHA/sarepta-to-present-at-cowen-health-care-conference-webcast-at-800-am-et-20170308-00271,Sarepta To Present At Cowen Health Care Conference; Webcast At 8:00 AM ET
SRPT,SRPT:UW,BBG000BCJC58,Vetr Advises Hold On Sarepta,2017-03-07 11:48:17 +0000,http://finance.yahoo.com/news/vetr-advises-hold-sarepta-114817199.html,Vetr Advises Hold On Sarepta
SRPT,SRPT:UW,BBG000BCJC58,Vetr Advises Hold On Sarepta,2017-03-07 11:48:17 +0000,http://finance.yahoo.com/news/vetr-advises-hold-sarepta-114817199.html?.tsrc=rss,"The Vetr crowd on Monday upgraded their rating for Sarepta Therapeutics Inc (NASDAQ: SRPT ) from 1.5 stars (Strong Sell), issued eight days ago, to 3 stars (Hold). At the time of the upgrade, crowd sentiment ..."
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Financials",2017-03-04 18:04:15 +0000,http://finance.yahoo.com/q/is?s=srpt,"SAREPTA THERAPEUTICS, INC. Financials"
SRPT,SRPT:UW,BBG000BCJC58,2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump,2017-03-03 18:14:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3BtnfZ7DdDE/2-reasons-behind-sarepta-therapeutics-incs-69-february-jump-cm756074,What happened Shares of Sarepta Therapeutics NASDAQ SRPT a commercial stage biotech focused on rare diseases gained 6 9 in February according to data from S amp P Global Market Intelligence So what Sarepta s jump can be traced to two main
SRPT,SRPT:UW,BBG000BCJC58,Market Action Is Boring but Necessary,2017-03-03 16:54:00 +0000,http://realmoney.thestreet.com/articles/03/03/2017/market-action-boring-necessary?puc=yahoo&cm_ven=YAHOO,Market Action Is Boring but Necessary
SRPT,SRPT:UW,BBG000BCJC58,2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump,2017-03-03 16:11:00 +0000,http://www.fool.com/investing/2017/03/03/2-reasons-behind-sarepta-therapeutics-incs-69-febr.aspx,2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump
SRPT,SRPT:UW,BBG000BCJC58,Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta Therapeutics and BioCryst Pharmaceuticals,2017-03-03 14:30:00 +0000,http://finance.yahoo.com/news/biotechs-outlook-strengthens-president-trumps-143000791.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / March 3, 2017 / The Biotech's Post-Election rally gained some steam this week after President Trump labeled the U.S. Food and Drug Administration's drug approval process as ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : March 3, 2017",2017-03-03 12:23:48 +0000,http://www.capitalcube.com/blog/index.php/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-srpt-us-march-3-2017/,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : March 3, 2017"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc (SRPT) Stock Heads Higher on Analyst Upgrade,2017-03-02 23:14:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bBltdaPYmEI/sarepta-therapeutics-inc-srpt-stock-heads-higher-on-analyst-upgrade-cm755734,InvestorPlace Stock Market News Stock Advice amp Trading Tips Sarepta Therapeutics Inc NASDAQ SRPT stock was up on Thursday following an upgrade from Leerink Swann Leerink Swann analysts Joseph Schwartz and Dae Gon Ha 160
SRPT,SRPT:UW,BBG000BCJC58,"Why Abercrombie & Fitch, W&T Offshore, and Sarepta Therapeutics Jumped Today",2017-03-02 23:13:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9k25MvzxHc8/why-abercrombie-fitch-wt-offshore-and-sarepta-therapeutics-jumped-today-cm755686,Thursday was a down day for the stock market but major market benchmarks gave back only a portion of their extensive gains from Wednesday Losses were generally limited to around half a percent and the Dow Jones Industrials just barely managed to stay above the 21 000 mark despite
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference,2017-03-02 23:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-present-company-overview-230000866.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 02, 2017-- Sarepta Therapeutics, Inc., a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the Cowen and Company ..."
SRPT,SRPT:UW,BBG000BCJC58,"Why Abercrombie & Fitch, W&T Offshore, and Sarepta Therapeutics Jumped Today",2017-03-02 21:30:00 +0000,http://www.fool.com/investing/2017/03/02/why-abercrombie-fitch-wt-offshore-and-sarepta-ther.aspx,"Why Abercrombie & Fitch, W&T Offshore, and Sarepta Therapeutics Jumped Today"
SRPT,SRPT:UW,BBG000BCJC58,"Thursday's ETF Movers: XBI, GDXJ",2017-03-02 20:13:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iaRx5qcGgp8/thursdays-etf-movers-xbi-gdxj-cm755594,In trading on Thursday the SPDR S amp P Biotech ETF is outperforming other ETFs up about 1 2 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics up about 12 2 and shares of Acceleron Pharma up about 9 9 on the day And
SRPT,SRPT:UW,BBG000BCJC58,Why PTC Therapeutics Is Plunging Today,2017-03-02 19:13:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-0R0VvjMXa0/why-ptc-therapeutics-is-plunging-today-cm755562,What happened In response to reporting disappointing top line results from an important phase 3 trial shares of PTC Therapeutics NASDAQ PTCT a commercial stage biotech focused on rare diseases fell by 10 as of 11 a m EST Thursday So what PTC announced the results of
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: What Goes Down Must Go Up,2017-03-02 16:41:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/02/sarepta-therapeutics-what-goes-down-must-go-up/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: What Goes Down Must Go Up
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. :SRPT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017",2017-03-02 15:42:14 +0000,http://www.capitalcube.com/blog/index.php/sarepta-therapeutics-inc-srpt-us-earnings-analysis-q4-2016-by-the-numbers-march-2-2017/,"Sarepta Therapeutics, Inc. :SRPT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017"
SRPT,SRPT:UW,BBG000BCJC58,"Morning Movers: Shake Shack Sinks, Abercrombie & Fitch Jumps, Valeant Climbs",2017-03-02 14:23:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/02/morning-movers-shake-shack-sinks-abercrombie-fitch-jumps-valeant-climbs/?mod=yahoobarrons&ru=yahoo,"Morning Movers: Shake Shack Sinks, Abercrombie & Fitch Jumps, Valeant Climbs"
SRPT,SRPT:UW,BBG000BCJC58,Coverage initiated on Sarepta Therapeutics by Instinet,2017-03-02 13:43:30 +0000,http://finance.yahoo.com/q/ud?s=SRPT,Coverage initiated on Sarepta Therapeutics by Instinet
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Stock Seesaws On 2017 Duchenne Muscular Dystrophy Guide,2017-03-01 21:13:20 +0000,http://www.investors.com/news/technology/sarepta-stock-walloped-on-2017-duchenne-muscular-dystrophy-guide/,Sarepta Stock Seesaws On 2017 Duchenne Muscular Dystrophy Guide
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Stock Tanks 7% on 4Q Loss,2017-03-01 18:00:00 +0000,http://www.investopedia.com/news/sarepta-stock-tanks-7-4q-loss-srpt/?partner=YahooSA,Sarepta Stock Tanks 7% on 4Q Loss
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutic shares waver amid concerns over 2017 guidance,2017-03-01 17:56:24 +0000,http://www.cnbc.com/id/104312795?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104312795,Sarepta Therapeutic shares waver amid concerns over 2017 guidance
SRPT,SRPT:UW,BBG000BCJC58,Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow,2017-03-01 17:13:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SLgBT9VSx04/sarepta-srpt-q4-loss-widens-sales-of-duchenne-drug-slow-cm754878,Sarepta Therapeutics Inc SRPT reported wider than expected loss in the fourth quarter of 2016 Meanwhile the biotech company s 2017 sales outlook fell largely short of expectations as the commercial launch of its only approved drug Exondys 51 has been slower than expected Sarepta
SRPT,SRPT:UW,BBG000BCJC58,Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options,2017-03-01 16:17:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nFwq5N8la9g/implied-volatility-surging-for-sarepta-therapeutics-srpt-stock-options-cm754818,Investors in Sarepta Therapeutics Inc SRPT need to pay close attention to the stock based on moves in the options market lately That is because the March 3 rd 2017 27 Call had some of the highest implied volatility of all equity options today What is Implied Volatility
SRPT,SRPT:UW,BBG000BCJC58,Sarepta predicts slower sales of Duchenne drug than many investors hoped,2017-03-01 16:13:18 +0000,http://www.bizjournals.com/boston/news/2017/02/28/sarepta-predicts-slower-sales-of-duchenne-drug.html?ana=yahoo,Sarepta predicts slower sales of Duchenne drug than many investors hoped
SRPT,SRPT:UW,BBG000BCJC58,Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow,2017-03-01 15:05:03 +0000,http://finance.yahoo.com/news/sarepta-srpt-q4-loss-widens-150503068.html,Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow
SRPT,SRPT:UW,BBG000BCJC58,The Street Is Misreading Sarepta's Guidance,2017-03-01 14:57:50 +0000,http://finance.yahoo.com/news/street-misreading-sareptas-guidance-145750542.html,The Street Is Misreading Sarepta's Guidance
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Mar 1, 2017 :  BAC, BBY, TVIX, SRPT, PANW, MU, LOW, WTW, ISF, CLNE, DLTR, XIV",2017-03-01 13:51:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rEoXg_shur4/pre-market-most-active-for-mar-1-2017-bac-bby-tvix-srpt-panw-mu-low-wtw-isf-clne-dltr-xiv-cm754674,The NASDAQ 100 Pre Market Indicator is up 23 3 to 5 353 61 The total Pre Market volume is currently 10 308 252 shares traded The following are the most active stocks for the pre market session Bank of America Corporation BAC is 0 625 at 25 23 with 2 037 071
SRPT,SRPT:UW,BBG000BCJC58,Edited Transcript of SRPT earnings conference call or presentation 28-Feb-17 9:30pm GMT,2017-03-01 13:50:26 +0000,http://finance.yahoo.com/news/edited-transcript-srpt-earnings-conference-135026407.html,Edited Transcript of SRPT earnings conference call or presentation 28-Feb-17 9:30pm GMT
SRPT,SRPT:UW,BBG000BCJC58,Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options,2017-03-01 13:50:01 +0000,http://finance.yahoo.com/news/implied-volatility-surging-sarepta-therapeutics-135001243.html,Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options
SRPT,SRPT:UW,BBG000BCJC58,"RBC: Sarepta's Setting The Bar Low, Buy On This Weakness",2017-03-01 12:40:32 +0000,http://finance.yahoo.com/news/rbc-sareptas-setting-bar-low-124032805.html,"RBC: Sarepta's Setting The Bar Low, Buy On This Weakness"
SRPT,SRPT:UW,BBG000BCJC58,"AKRX, LXRX Get FDA Nod, KITE Flies Higher, SRPT Plunges On Dull Outlook",2017-03-01 02:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U1g_1km_G0w/akrx-lxrx-get-fda-nod-kite-flies-higher-srpt-plunges-on-dull-outlook-20170301-00110,"AKRX, LXRX Get FDA Nod, KITE Flies Higher, SRPT Plunges On Dull Outlook"
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an",2017-03-01 00:53:37 +0000,http://biz.yahoo.com/e/170228/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-02-28 23:46:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-234600402.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on February 28, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to four individuals hired by Sarepta in February 2017."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics reports 4Q loss,2017-02-28 21:41:28 +0000,http://sg.finance.yahoo.com/news/sarepta-therapeutics-reports-4q-loss-214128383.html,Sarepta Therapeutics reports 4Q loss
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today,2017-02-28 21:30:00 +0000,http://biz.yahoo.com/cc/2/155712.html,Sarepta Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments,2017-02-28 21:03:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-fourth-quarter-210300630.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today reported financial results for the three and twelve months ended December 31, 2016."
SRPT,SRPT:UW,BBG000BCJC58,"​At rare disease panel, ex-FDA new drug head preaches evidence over empathy",2017-02-28 19:10:08 +0000,http://www.bizjournals.com/boston/news/2017/02/28/at-rare-disease-panel-ex-fda-new-drug-head.html?ana=yahoo,"​At rare disease panel, ex-FDA new drug head preaches evidence over empathy"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Q4 16 Earnings Conference Call At 4:30 PM ET,2017-02-28 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9XXZxRxguQ/sarepta-therapeutics-q4-16-earnings-conference-call-at-430-pm-et-20170228-01514,Sarepta Therapeutics Q4 16 Earnings Conference Call At 4:30 PM ET
SRPT,SRPT:UW,BBG000BCJC58,Q4 2016 Sarepta Therapeutics Inc Earnings Release - After Market Close,2017-02-28 12:07:03 +0000,http://biz.yahoo.com/research/earncal/20170228.html?t=srpt,Q4 2016 Sarepta Therapeutics Inc Earnings Release - After Market Close
SRPT,SRPT:UW,BBG000BCJC58,Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?,2017-02-27 15:54:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sOFpzABNOVM/is-a-surprise-coming-for-sarepta-therapeutics-srpt-this-earnings-season-cm753511,Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics Inc SRPT may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Sarepta Therapeutics is
SRPT,SRPT:UW,BBG000BCJC58,Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?,2017-02-27 13:42:01 +0000,http://finance.yahoo.com/news/surprise-coming-sarepta-therapeutics-srpt-134201764.html,Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season?
SRPT,SRPT:UW,BBG000BCJC58,How the state’s newest Duchenne biotechs are getting a boost from patient groups,2017-02-27 12:50:11 +0000,http://www.bizjournals.com/boston/news/2017/02/27/how-the-state-s-newest-duchenne-biotechs-are.html?ana=yahoo,How the state’s newest Duchenne biotechs are getting a boost from patient groups
SRPT,SRPT:UW,BBG000BCJC58,Biotech Stocks Facing FDA Decision In March,2017-02-27 05:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uBycQmSKtBM/biotech-stocks-facing-fda-decision-in-march-20170227-00289,Biotech Stocks Facing FDA Decision In March
SRPT,SRPT:UW,BBG000BCJC58,5 Stocks Set for Explosive Breakouts,2017-02-24 18:17:00 +0000,https://www.thestreet.com/story/14015553/1/5-stocks-set-for-explosive-breakouts.html?puc=yahoo&cm_ven=YAHOO,5 Stocks Set for Explosive Breakouts
SRPT,SRPT:UW,BBG000BCJC58,"More Selling Pressure, But No Rush for the Exits",2017-02-24 16:44:00 +0000,http://realmoney.thestreet.com/articles/02/24/2017/more-selling-pressure-no-rush-exits?puc=yahoo&cm_ven=YAHOO,"More Selling Pressure, But No Rush for the Exits"
SRPT,SRPT:UW,BBG000BCJC58,Bullish Two Hundred Day Moving Average Cross - SRPT,2017-02-23 18:52:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ufyqtSQkksk/bullish-two-hundred-day-moving-average-cross-srpt-cm752220,In trading on Thursday shares of Sarepta Therapeutics Inc Symbol SRPT crossed above their 200 day moving average of 31 10 changing hands as high as 31 29 per share Sarepta Therapeutics Inc shares are currently trading down about 2 1 on the day The chart below shows the one
SRPT,SRPT:UW,BBG000BCJC58,"Commit To Purchase Sarepta Therapeutics At $18, Earn 16.7% Using Options",2017-02-23 18:50:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1EPkwMlaUG0/commit-to-purchase-sarepta-therapeutics-at-18-earn-167-using-options-cm752218,Investors considering a purchase of Sarepta Therapeutics Inc Symbol SRPT stock but tentative about paying the going market price of 29 74 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
SRPT,SRPT:UW,BBG000BCJC58,[2/23] This Week’s Earnings Revisions Movers,2017-02-23 14:39:09 +0000,http://finance.yahoo.com/tumblr/blog-223-this-weeks-earnings-revisions-movers-143916542.html,[2/23] This Week’s Earnings Revisions Movers
SRPT,SRPT:UW,BBG000BCJC58,The Contrary Indicators Are Piling Up,2017-02-22 18:52:00 +0000,http://realmoney.thestreet.com/articles/02/22/2017/contrary-indicators-are-piling?puc=yahoo&cm_ven=YAHOO,The Contrary Indicators Are Piling Up
SRPT,SRPT:UW,BBG000BCJC58,Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics,2017-02-22 14:30:00 +0000,http://finance.yahoo.com/news/bull-market-ahead-biotech-industry-143000739.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 22, 2017 / The Biotech Industry's rally does not appear to be losing any steam in 2017. Both the iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF ..."
SRPT,SRPT:UW,BBG000BCJC58,"Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising",2017-02-22 11:43:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-alexion-reports-114311834.html,"Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising"
SRPT,SRPT:UW,BBG000BCJC58,Did Gilead's new tool for speeding drug approval come at bargain-basement price?,2017-02-21 19:00:11 +0000,http://www.bizjournals.com/sanfrancisco/news/2017/02/21/gilead-sarepta-priority-review-voucher-gild-srpt.html?ana=yahoo,Did Gilead's new tool for speeding drug approval come at bargain-basement price?
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Sells Priority Review Voucher for $125M,2017-02-21 16:03:00 +0000,http://www.investopedia.com/news/sarepta-sells-priority-review-voucher-125m-srpt/?partner=YahooSA,Sarepta Sells Priority Review Voucher for $125M
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Leads Biotech Movers on Voucher Deal News,2017-02-21 15:09:00 +0000,https://www.thestreet.com/story/14009119/1/sarepta-leads-biotech-movers-on-voucher-deal-news.html?puc=yahoo&cm_ven=YAHOO,Sarepta Leads Biotech Movers on Voucher Deal News
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta sells FDA review voucher for $125M, but analyst questions price",2017-02-21 15:05:09 +0000,http://www.bizjournals.com/boston/news/2017/02/21/sarepta-sells-fda-review-voucher-for-125m-but.html?ana=yahoo,"Sarepta sells FDA review voucher for $125M, but analyst questions price"
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E",2017-02-21 12:28:41 +0000,http://biz.yahoo.com/e/170221/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M,2017-02-21 12:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-agrees-sale-priority-120000277.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher ."
SRPT,SRPT:UW,BBG000BCJC58,Congressman Keating calls pricy Duchenne drug an example of 'gouging',2017-02-17 19:30:08 +0000,http://www.bizjournals.com/boston/news/2017/02/17/congressman-keating-calls-pricy-duchenne-drug-an.html?ana=yahoo,Congressman Keating calls pricy Duchenne drug an example of 'gouging'
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks to Buy in February,2017-02-17 16:11:41 +0000,http://www.fool.com/investing/2017/02/16/3-biotech-stocks-to-buy-in-february.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks to Buy in February
SRPT,SRPT:UW,BBG000BCJC58,Santhera opens Mass. office as local Duchenne ecosystem grows,2017-02-17 12:05:06 +0000,http://www.bizjournals.com/boston/news/2017/02/17/santhera-opens-mass-office-as-local-duchenne.html?ana=yahoo,Santhera opens Mass. office as local Duchenne ecosystem grows
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks to Buy in February,2017-02-16 16:55:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EEmloK-YTMw/3-biotech-stocks-to-buy-in-february-cm748960,The biotech industry can aptly be described as Wall Street s roulette wheel The odds are against drugmakers succeeding in clinical trials but if they do the rewards can be enormous Keeping in mind the risks involved with investing in biotech stocks as well as the huge potential
SRPT,SRPT:UW,BBG000BCJC58,Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl,2017-02-16 14:50:13 +0000,http://finance.yahoo.com/news/oppenheimer-stays-bullish-sarepta-concerns-145013095.html,Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017",2017-02-15 13:31:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announce-fourth-quarter-133100088.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a developer of innovative RNA-targeted therapeutics, will report fourth quarter and full-year 2016 financial results after the NASDAQ Global Market closes on Tuesday, February 28, 2017."
SRPT,SRPT:UW,BBG000BCJC58,The Fed's Dilemma Is Quite Obvious,2017-02-14 15:48:00 +0000,http://realmoney.thestreet.com/articles/02/14/2017/feds-dilemma-quite-obvious?puc=yahoo&cm_ven=YAHOO,The Fed's Dilemma Is Quite Obvious
SRPT,SRPT:UW,BBG000BCJC58,Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal,2017-02-14 15:02:00 +0000,https://www.thestreet.com/story/14001431/1/defending-sarepta-against-blowback-from-the-marathon-pharma-steroid-price-gouging-scandal.html?puc=yahoo&cm_ven=YAHOO,Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal
SRPT,SRPT:UW,BBG000BCJC58,"Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000 price",2017-02-13 21:12:45 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=0150F7C4-B995-4FEE-8007-D893C0C15D5E&siteid=yhoof2,"Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000 price"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Muscular Dystrophy Drug Faces Competition,2017-02-10 17:04:00 +0000,http://www.investopedia.com/news/sarepta-muscular-dystrophy-drug-gets-competition-srpt/?partner=YahooSA,Sarepta Muscular Dystrophy Drug Faces Competition
SRPT,SRPT:UW,BBG000BCJC58,FDA approves Marathon Pharma's Duchenne muscular dystrophy drug,2017-02-09 20:51:38 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=7E5A9FFC-4685-4EF2-A540-48F30B9DD7D3&siteid=yhoof2,FDA approves Marathon Pharma's Duchenne muscular dystrophy drug
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment,2017-02-09 20:13:20 +0000,http://finance.yahoo.com/news/sarepta-under-pressure-fda-approves-201320433.html,Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment
SRPT,SRPT:UW,BBG000BCJC58,Dunkin Brands Pulls Back Off Best Levels But Holding On To Strong Gain,2017-02-09 14:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rfvJqvcpby8/dunkin-brands-pulls-back-off-best-levels-but-holding-on-to-strong-gain-20170209-01354,Dunkin Brands Pulls Back Off Best Levels But Holding On To Strong Gain
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Therapeutics, Inc. Stock Rose 13.2% in January",2017-02-07 21:12:03 +0000,http://www.fool.com/investing/2017/02/06/why-sarepta-therapeutics-inc-stock-rose-132-in-jan.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Sarepta Therapeutics, Inc. Stock Rose 13.2% in January"
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Therapeutics, Inc. Stock Rose 13.2% in January",2017-02-06 22:17:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6XCihXEDZDM/why-sarepta-therapeutics-inc-stock-rose-132-in-january-cm743853,What happened Shares of Sarepta Therapeutics Inc NASDAQ SRPT a biotech that earned a controversial new drug approval last year rose 13 2 last month according to 160 data from S amp P Global Market Intelligence Management eased concerns that payer pushback would
SRPT,SRPT:UW,BBG000BCJC58,Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys,2017-02-02 16:34:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8wLR44vzXPQ/forget-gw-pharmaceuticals-these-2-stocks-are-better-buys-cm742231,Britain s GW Pharmaceuticals NASDAQ GWPH has certainly captured the market s imagination with its cannabidiol drug development platform Over the past three years its stock is up by an astounding 1200 GWPH data by YCharts Although
SRPT,SRPT:UW,BBG000BCJC58,Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys,2017-02-02 15:53:57 +0000,http://www.fool.com/investing/2017/02/02/forget-gw-pharmaceuticals-these-2-stocks-are-bette.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys
SRPT,SRPT:UW,BBG000BCJC58,Catabasis Hits 52-Week Low on Poor DMD Drug Study Data,2017-02-02 13:33:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JJpG3fc33zM/catabasis-hits-52-week-low-on-poor-dmd-drug-study-data-cm742023,Cambridge MA based Catabasis Pharmaceuticals Inc s CATB shares tumbled to a new 52 week low of 1 08 on Feb 1 after the company announced disappointing top line safety and efficacy data from part B of the MoveDMD study phase I II on edasalonexent CAT 1004 The company s shares
SRPT,SRPT:UW,BBG000BCJC58,Catabasis Hits 52-Week Low on Poor DMD Drug Study Data,2017-02-02 12:21:12 +0000,http://finance.yahoo.com/news/catabasis-hits-52-week-low-122112062.html,Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: It's Not Whether Insurers Will Pay. It's How Much They'll Pay,2017-02-01 18:28:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/01/sarepta-its-not-whether-insurers-will-pay-its-how-much-theyll-pay/?mod=yahoobarrons&ru=yahoo,Sarepta: It's Not Whether Insurers Will Pay. It's How Much They'll Pay
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results,2017-02-01 16:55:33 +0000,http://finance.yahoo.com/news/sarepta-under-pressure-amid-concerning-165533894.html,Sarepta Under Pressure Amid Concerning Exondys 51 Survey Results
SRPT,SRPT:UW,BBG000BCJC58,Catabasis shares plummet on Duchenne trial failure,2017-02-01 00:55:06 +0000,http://www.bizjournals.com/boston/news/2017/01/31/catabasis-shares-plummet-on-duchenne-trial-failure.html?ana=yahoo,Catabasis shares plummet on Duchenne trial failure
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-01-31 22:15:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-221500693.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on January 31, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to ten individuals hired by Sarepta in January 2017."
SRPT,SRPT:UW,BBG000BCJC58,"This Was, Unquestionably, the Most Disappointing Drug Launch of 2016",2017-01-31 13:32:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N1B4BuiNUd4/this-was-unquestionably-the-most-disappointing-drug-launch-of-2016-cm740608,Image source Getty Images According to the U S Food and Drug Administration 22 new molecular entities wound up being approved in 2016 Mind you this figure excludes approvals tied to label expansion opportunities and generic drugs that the regulatory body oversaw in
SRPT,SRPT:UW,BBG000BCJC58,Is BioMarin (BMRN) Well Poised for Growth in 2017?,2017-01-26 17:34:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5eLgf7DCyGg/is-biomarin-bmrn-well-poised-for-growth-in-2017-cm738794,We issued an updated research report on BioMarin Pharmaceutical Inc BMRN on Jan 25 BioMarin should continue to see growth in both its orphan disease drugs Vimizim and Kuvan in 2017 Vimizim sales continue to be driven by robust patient growth and penetration in additional markets
SRPT,SRPT:UW,BBG000BCJC58,SRPT Crosses Below Key Moving Average Level,2017-01-25 23:30:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0QUr6QNZ0w0/srpt-crosses-below-key-moving-average-level-cm738360,In trading on Wednesday shares of Sarepta Therapeutics Inc Symbol SRPT crossed below their 200 day moving average of 30 00 changing hands as low as 29 88 per share Sarepta Therapeutics Inc shares are currently trading off about 1 6 on the day The chart below shows the one year
SRPT,SRPT:UW,BBG000BCJC58,"Keep Politics Out Of Science, Says Departing FDA Chief",2017-01-23 16:12:00 +0000,http://www.forbes.com/sites/matthewherper/2017/01/23/keep-politics-out-of-science-says-departing-fda-chief/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"Keep Politics Out Of Science, Says Departing FDA Chief"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : January 23, 2017",2017-01-23 13:25:40 +0000,http://www.capitalcube.com/blog/index.php/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-srpt-us-january-23-2017/,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : January 23, 2017"
SRPT,SRPT:UW,BBG000BCJC58,Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug,2017-01-19 14:08:35 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=BEDA5CF6-7191-4B92-99E8-160018E8F2EC&siteid=yhoof2,Catabasis Pharma surges 17% on positive early-stage clinical trial results for DMD drug
SRPT,SRPT:UW,BBG000BCJC58,Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential,2017-01-19 13:40:50 +0000,http://finance.yahoo.com/news/baird-4-red-hot-biotechs-134050054.html,Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential
SRPT,SRPT:UW,BBG000BCJC58,5 Healthcare Stocks Poised for Maximum Gains in 2017,2017-01-17 22:38:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XgjiyxvpJcg/5-healthcare-stocks-poised-for-maximum-gains-in-2017-cm734458,The healthcare sector s drop in the past year means that investors can buy many healthcare stocks on sale including these five stocks All five could experience explosive growth in 2017 and they are trading at share prices that are below 2016 s peak Read on to find out if now is
SRPT,SRPT:UW,BBG000BCJC58,5 Healthcare Stocks Poised for Maximum Gains in 2017,2017-01-17 21:20:06 +0000,http://www.fool.com/investing/2017/01/17/5-healthcare-stocks-poised-for-maximum-gains-in-20.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Healthcare Stocks Poised for Maximum Gains in 2017
SRPT,SRPT:UW,BBG000BCJC58,FDA 101: What Does 'Orphan Drug Designation' Mean?,2017-01-17 19:56:48 +0000,http://finance.yahoo.com/news/fda-101-does-orphan-drug-195648734.html,FDA 101: What Does 'Orphan Drug Designation' Mean?
SRPT,SRPT:UW,BBG000BCJC58,Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns,2017-01-17 17:52:00 +0000,http://realmoney.thestreet.com/articles/01/17/2017/heres-new-list-stocks-show-bullish-or-bearish-reversal-patterns?puc=yahoo&cm_ven=YAHOO,Here's a New List of Stocks That Show Bullish or Bearish Reversal Patterns
SRPT,SRPT:UW,BBG000BCJC58,Bullish and Bearish Reversals in the Market,2017-01-17 17:35:00 +0000,http://realmoney.thestreet.com/articles/01/17/2017/bullish-and-bearish-reversals-market?puc=yahoo&cm_ven=YAHOO,Bullish and Bearish Reversals in the Market
SRPT,SRPT:UW,BBG000BCJC58,Cramer lists the stocks that you should take the cash and run on,2017-01-14 00:23:38 +0000,http://www.cnbc.com/id/104218478?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104218478,Cramer lists the stocks that you should take the cash and run on
SRPT,SRPT:UW,BBG000BCJC58,Surge From Bank Earnings Doesn't Last,2017-01-13 21:36:00 +0000,http://realmoney.thestreet.com/articles/01/13/2017/surge-bank-earnings-doesnt-last?puc=yahoo&cm_ven=YAHOO,Surge From Bank Earnings Doesn't Last
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : January 12, 2017",2017-01-12 15:12:39 +0000,http://www.capitalcube.com/blog/index.php/sarepta-therapeutics-inc-value-analysis-nasdaqsrpt-january-12-2017/,"Sarepta Therapeutics, Inc. – Value Analysis (NASDAQ:SRPT) : January 12, 2017"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen,2017-01-11 19:17:09 +0000,http://www.insidermonkey.com/blog/sarepta-therapeutics-inc-srpt-gets-off-to-a-running-start-with-eteplirsen-516827/,Sarepta Therapeutics Inc (SRPT) Gets Off To A Running Start With Eteplirsen
SRPT,SRPT:UW,BBG000BCJC58,Is This Going To Be Sarepta Therapeutics' Year?,2017-01-11 18:58:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ML1WVgGTmSM/is-this-going-to-be-sarepta-therapeutics-year-cm732341,Sarepta Therapeutics NASDAQ SRPT found itself embroiled in controversy last year when top FDA regulators publicly debated the efficacy of its Duchenne muscular dystrophy DMD drug Exondys 51 When the dust settled Sarepta Therapeutics was awarded a green light to begin
SRPT,SRPT:UW,BBG000BCJC58,Is This Going To Be Sarepta Therapeutics' Year?,2017-01-11 17:25:42 +0000,http://www.fool.com/investing/2017/01/11/is-this-going-to-be-sarepta-therapeutics-year.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is This Going To Be Sarepta Therapeutics' Year?
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: Reports of Its Demise Appear 'Greatly Exaggerated',2017-01-11 15:38:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/11/sarepta-therapeutics-reports-of-its-demise-appear-greatly-exaggerated/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: Reports of Its Demise Appear 'Greatly Exaggerated'
SRPT,SRPT:UW,BBG000BCJC58,Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?,2017-01-11 15:01:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mwfI7LmUvd0/are-options-traders-betting-on-a-big-move-in-sarepta-therapeutics-srpt-stock-cm732175,Investors in Sarepta Therapeutics Inc SRPT need to pay close attention to the stock based on moves in the options market lately That is because the January 13 th 2017 35 Call had some of the highest implied volatility of all equity options today What is Implied Volatility
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Muscular Dystrophy Drug Posts Solid Sales,2017-01-11 14:46:00 +0000,http://www.investopedia.com/news/sarepta-muscular-dystrophy-drug-sales-rise-srpt/?partner=YahooSA,Sarepta Muscular Dystrophy Drug Posts Solid Sales
SRPT,SRPT:UW,BBG000BCJC58,Latest Reports on Sarepta Therapeutics and Cempra as the NASDAQ Continues to Hit Record Highs,2017-01-11 14:30:00 +0000,http://finance.yahoo.com/news/latest-reports-sarepta-therapeutics-cempra-143000328.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 11, 2017 / The Nasdaq Composite Index has gained 2.76 percent over the first five trading session of the year, its best five day period to begin the year in a decade ..."
SRPT,SRPT:UW,BBG000BCJC58,7 Stocks Making Big Moves With Unusual Volume,2017-01-11 14:20:00 +0000,https://www.thestreet.com/story/13950001/1/7-stocks-making-big-moves-with-unusual-volume.html?puc=yahoo&cm_ven=YAHOO,7 Stocks Making Big Moves With Unusual Volume
SRPT,SRPT:UW,BBG000BCJC58,Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?,2017-01-11 13:35:01 +0000,http://finance.yahoo.com/news/options-traders-betting-big-move-133501861.html,Are Options Traders Betting on a Big Move in Sarepta Therapeutics (SRPT) Stock?
SRPT,SRPT:UW,BBG000BCJC58,5 Biotech Stocks That Are Catching Fire,2017-01-11 13:00:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KEeF4-1CeeA/5-biotech-stocks-that-are-catching-fire-cm731920,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips While U S equities continue their sideways skid just below the Dow 20 000 threshold a level that has provided intractable for the last five weeks buyers aren t sitting still Since the New Year
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : January 11, 2017",2017-01-11 12:28:28 +0000,http://www.capitalcube.com/blog/index.php/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bullish-manner-srpt-us-january-11-2017/,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : January 11, 2017"
SRPT,SRPT:UW,BBG000BCJC58,What Sarepta Therapeutics' CEO Said That Made the Stock Soar,2017-01-10 23:51:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dagDyz7GNoQ/what-sarepta-therapeutics-ceo-said-that-made-the-stock-soar-cm731933,A half hour of Sarepta Therapeutics NASDAQ SRPT CEO Ed Kaye s time speaking at the J P Morgan Healthcare Conference paid off big time The biotech s shares soared over 15 as Kaye spoke at the conference and went even higher afterwards Here s what he said that caused Sarepta
SRPT,SRPT:UW,BBG000BCJC58,What Sarepta Therapeutics' CEO Said That Made the Stock Soar,2017-01-10 22:09:30 +0000,http://www.fool.com/investing/2017/01/10/what-sarepta-therapeutics-ceo-said-that-made-the-s.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What Sarepta Therapeutics' CEO Said That Made the Stock Soar
SRPT,SRPT:UW,BBG000BCJC58,"Gainers & Losers Of The Day: BIOC, CUR, ONTX, EGLT, ABAX...",2017-01-10 22:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rx0tCOEqBwQ/gainers--losers-of-the-day-bioc-cur-ontx-eglt-abax-20170110-01107,"Gainers & Losers Of The Day: BIOC, CUR, ONTX, EGLT, ABAX..."
SRPT,SRPT:UW,BBG000BCJC58,Tuesday’s Top Biopharma Movers,2017-01-10 20:30:54 +0000,http://finance.yahoo.com/news/tuesday-top-biopharma-movers-203054644.html,Tuesday’s Top Biopharma Movers
SRPT,SRPT:UW,BBG000BCJC58,Sarepta gains $300M in value as Duchenne drug launch beats expectations,2017-01-10 17:55:06 +0000,http://www.bizjournals.com/boston/news/2017/01/10/sarepta-gains-300m-in-value-as-duchenne-drug.html?ana=yahoo,Sarepta gains $300M in value as Duchenne drug launch beats expectations
SRPT,SRPT:UW,BBG000BCJC58,"For Sarepta, Today's Good News Might Be Just The Beginning",2017-01-10 17:49:26 +0000,http://finance.yahoo.com/news/sarepta-todays-good-news-might-174926896.html,"For Sarepta, Today's Good News Might Be Just The Beginning"
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Has Soared 20%,2017-01-10 16:54:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/10/sarepta-therapeutics-bears-on-the-run/?mod=yahoobarrons&ru=yahoo,Why Sarepta Therapeutics Has Soared 20%
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Soars Following Encouraging Exondys 51 News,2017-01-10 16:38:52 +0000,http://finance.yahoo.com/news/sarepta-soars-following-encouraging-exondys-163852264.html,Sarepta Soars Following Encouraging Exondys 51 News
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears,2017-01-10 16:22:00 +0000,http://www.thestreet.com/video/13948848/sarepta-provides-details-about-its-duchenne-drug-launch-and-eases-some-fears.html?puc=yahoov&cm_ven=YAHOOV,Sarepta Provides Details About its Duchenne Drug Launch and Eases Some Fears
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur",2017-01-10 15:33:01 +0000,http://biz.yahoo.com/e/170110/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears",2017-01-10 15:33:00 +0000,https://www.thestreet.com/story/13948568/1/sarepta-opens-up-about-duchenne-drug-launch-allays-investors-worst-fears.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta eyes a different approach to Duchenne: gene therapy,2017-01-10 15:20:08 +0000,http://www.bizjournals.com/boston/news/2017/01/10/sarepta-eyes-a-different-approach-to-duchenne-gene.html?ana=yahoo,Sarepta eyes a different approach to Duchenne: gene therapy
SRPT,SRPT:UW,BBG000BCJC58,3 Tempting Stocks We're Avoiding,2017-01-10 14:52:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fxdlxe0-6YY/3-tempting-stocks-were-avoiding-cm731451,Image source Getty Images Have you ever come across a company that seemed like too good of a value to pass up If you re a long term investor the answer to this question is almost assuredly yes On occasion these perceived to be tempting stocks can deliver handsome returns over
SRPT,SRPT:UW,BBG000BCJC58,3 Tempting Stocks We're Avoiding,2017-01-10 13:38:33 +0000,http://www.fool.com/investing/2017/01/10/3-tempting-stocks-were-avoiding.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Tempting Stocks We're Avoiding
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Enters into License Agreement with Nationwide Children’s Hospital for Galgt2 Gene Therapy Program,2017-01-10 13:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-enters-license-agreement-133000869.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered an exclusive license agreement with Nationwide Children’s Hospital, for their Galgt2 gene therapy program developed by researcher Dr."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program,2017-01-10 13:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-enters-research-agreement-133000690.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research and option agreement with Nationwide Children’s Hospital on their microdystrophin gene therapy program."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics To Present At J.P.Morgan Conference; Webcast At 10:30 AM ET,2017-01-10 09:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3UGvM35SJWY/sarepta-therapeutics-to-present-at-jpmorgan-conference-webcast-at-1030-am-et-20170110-00617,Sarepta Therapeutics To Present At J.P.Morgan Conference; Webcast At 10:30 AM ET
SRPT,SRPT:UW,BBG000BCJC58,Biotech Industry Off to a Strong Start in 2017 Latest Reports on Sarepta Therapeutics and Momenta Pharmaceuticals,2017-01-09 14:15:00 +0000,http://finance.yahoo.com/news/biotech-industry-off-strong-start-141500019.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 9, 2017 / The Biotech Industry has had a strong start to the year after a rocky 2016. The iShares NASDAQ Biotechnology Index ETF ( IBB ) and the SPDR S&P Biotech ETF ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2017-01-07 02:05:04 +0000,http://www.publicnow.com/view/F553A1F52F9241B4ECC67B226230E14434EFCFEC,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 30, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on December 30, ..."
SRPT,SRPT:UW,BBG000BCJC58,Cambridge's Akashi plans clinical tests of three Duchenne drugs this year,2017-01-06 12:20:08 +0000,http://www.bizjournals.com/boston/news/2017/01/06/cambridges-akashi-plans-clinical-tests-of-three.html?ana=yahoo,Cambridge's Akashi plans clinical tests of three Duchenne drugs this year
SRPT,SRPT:UW,BBG000BCJC58,Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference,2017-01-05 19:40:11 +0000,http://www.bizjournals.com/boston/news/2017/01/05/heres-what-to-expect-from-mass-biotechs-at-this.html?ana=yahoo,Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: How Shares Could Double Despite the Hurdles,2017-01-05 16:25:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/05/sarepta-therapeutics-how-shares-could-double-despite-the-hurdles/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: How Shares Could Double Despite the Hurdles
SRPT,SRPT:UW,BBG000BCJC58,Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified,2017-01-05 12:21:00 +0000,http://realmoney.thestreet.com/articles/01/05/2017/revs-forum-fed-isnt-convinced-trump-rally-justified?puc=yahoo&cm_ven=YAHOO,Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified
SRPT,SRPT:UW,BBG000BCJC58,What Biotech Investors Can Expect from the J.P. Morgan Healthcare Conference 2017,2017-01-05 11:21:00 +0000,https://www.thestreet.com/story/13942459/1/what-biotech-investors-can-expect-from-the-j-p-morgan-healthcare-conference-2017.html?puc=yahoo&cm_ven=YAHOO,What Biotech Investors Can Expect from the J.P. Morgan Healthcare Conference 2017
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: Slow Going?,2017-01-04 16:39:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/04/sarepta-therapeutics-slow-going/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: Slow Going?
SRPT,SRPT:UW,BBG000BCJC58,"Trying to Knock Out Some Individual Trades, but it Is not Easy",2017-01-04 15:56:00 +0000,http://realmoney.thestreet.com/articles/01/04/2017/trying-knock-out-some-individual-trades-it-not-easy?puc=yahoo&cm_ven=YAHOO,"Trying to Knock Out Some Individual Trades, but it Is not Easy"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference,2017-01-03 13:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-present-company-overview-133000285.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the 35th Annual J.P."
SRPT,SRPT:UW,BBG000BCJC58,[$$] The FDA’s Rigged Drug Committees,2017-01-03 04:46:54 +0000,http://www.wsj.com/articles/the-fdas-rigged-drug-committees-1483140671?ru=yahoo?mod=yahoo_itp,[$$] The FDA’s Rigged Drug Committees
SRPT,SRPT:UW,BBG000BCJC58,[$$] The FDA's Rigged Drug Committees,2016-12-31 00:15:28 +0000,http://www.wsj.com/articles/the-fdas-rigged-drug-committees-1483140671?mod=yahoo_hs,[$$] The FDA's Rigged Drug Committees
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2016-12-30 22:05:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-220500278.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on December 30, 2016, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to five individuals hired by Sarepta in December 2016."
SRPT,SRPT:UW,BBG000BCJC58,"Why health insurers won’t cover this $300,000-a-year rare disease drug",2016-12-30 17:58:47 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=8BCE1A8E-CD2E-11E6-BC29-4D3093487538&siteid=yhoof2,"Why health insurers won’t cover this $300,000-a-year rare disease drug"
SRPT,SRPT:UW,BBG000BCJC58,3 Sleeper Biotechs That Could Bounce Back Strong in 2017,2016-12-30 16:15:37 +0000,http://finance.yahoo.com/news/3-sleeper-biotechs-could-bounce-161537373.html,3 Sleeper Biotechs That Could Bounce Back Strong in 2017
SRPT,SRPT:UW,BBG000BCJC58,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,2016-12-27 19:32:56 +0000,http://finance.yahoo.com/news/expect-availability-biogens-newly-approved-193256344.html,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
SRPT,SRPT:UW,BBG000BCJC58,The Year That Was: Novel Drug Approvals Of 2016,2016-12-25 02:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eutJfQ074C8/the-year-that-was-novel-drug-approvals-of-2016-20161225-00001,The Year That Was: Novel Drug Approvals Of 2016
SRPT,SRPT:UW,BBG000BCJC58,"Shark Bites: We Knew Today Would Be Slow, but Come On…",2016-12-23 16:42:00 +0000,http://realmoney.thestreet.com/articles/12/23/2016/shark-bites-we-knew-today-would-be-slow-come-...?puc=yahoo&cm_ven=YAHOO,"Shark Bites: We Knew Today Would Be Slow, but Come On…"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics: 'Rare Diseases Launches, Always Complex'",2016-12-23 16:41:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/23/sarepta-therapeutics-rare-diseases-launches-always-complex/?mod=yahoobarrons&ru=yahoo,"Sarepta Therapeutics: 'Rare Diseases Launches, Always Complex'"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Shares Cross Below 200 DMA,2016-12-22 22:56:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BvHPzrVKJSU/sarepta-therapeutics-srpt-shares-cross-below-200-dma-cm725400,In trading on Thursday shares of Sarepta Therapeutics Inc Symbol SRPT crossed below their 200 day moving average of 28 57 changing hands as low as 28 08 per share Sarepta Therapeutics Inc shares are currently trading down about 4 5 on the day The chart below shows the one year
SRPT,SRPT:UW,BBG000BCJC58,Biotech buying opportunity?,2016-12-22 22:52:00 +0000,http://finance.yahoo.com/video/biotech-buying-opportunity-225200149.html,Biotech buying opportunity?
SRPT,SRPT:UW,BBG000BCJC58,2 Opposing Views On The Future Of Sarepta,2016-12-22 17:47:54 +0000,http://finance.yahoo.com/news/2-opposing-views-future-sarepta-174754843.html,2 Opposing Views On The Future Of Sarepta
SRPT,SRPT:UW,BBG000BCJC58,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016,2016-12-22 16:20:00 +0000,https://www.thestreet.com/story/13935497/1/what-adam-feuerstein-got-right-and-wrong-about-biotech-stock-in-2016.html?puc=yahoo&cm_ven=YAHOO,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: Poised for a Rebound?,2016-12-22 15:27:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/22/sarepta-therapeutics-poised-for-a-rebound/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: Poised for a Rebound?
SRPT,SRPT:UW,BBG000BCJC58,2016 Was a Terrible Year for Biotech but the Tweets Were on Point,2016-12-22 14:24:00 +0000,https://www.thestreet.com/story/13925755/1/2016-was-a-terrible-year-for-biotech-but-the-tweets-were-on-point.html?puc=yahoo&cm_ven=YAHOO,2016 Was a Terrible Year for Biotech but the Tweets Were on Point
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51,2016-12-21 20:32:06 +0000,http://www.publicnow.com/view/C91C66ABB753F79FD0CFF580B962027C4F8AB425,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 19, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced that the European Medicines ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: An Appropriate Selloff?,2016-12-21 15:36:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/21/sarepta-therapeutics-an-appropriate-selloff/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: An Appropriate Selloff?
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's (SRPT) Application for DMD Drug Accepted in the EU,2016-12-20 22:45:10 +0000,http://finance.yahoo.com/news/sareptas-srpt-application-dmd-drug-224510649.html,Sarepta's (SRPT) Application for DMD Drug Accepted in the EU
SRPT,SRPT:UW,BBG000BCJC58,"For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51",2016-12-20 18:06:23 +0000,http://finance.yahoo.com/news/sarepta-goldman-adopts-wait-watch-180623474.html,"For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics: Watch and Wait, Goldman Sachs Says",2016-12-20 15:01:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/20/sarepta-therapeutics-watch-and-wait-goldman-sachs-says/?mod=yahoobarrons&ru=yahoo,"Sarepta Therapeutics: Watch and Wait, Goldman Sachs Says"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51,2016-12-19 22:23:00 +0000,http://uk.finance.yahoo.com/news/sarepta-therapeutics-announces-ema-validation-222300955.html,Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51
SRPT,SRPT:UW,BBG000BCJC58,The Best Biopharma CEOs of 2016 Are...,2016-12-19 14:10:00 +0000,https://www.thestreet.com/story/13930531/1/the-best-biopharma-ceos-of-2016-are.html?puc=yahoo&cm_ven=YAHOO,The Best Biopharma CEOs of 2016 Are...
SRPT,SRPT:UW,BBG000BCJC58,Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups,2016-12-15 16:03:24 +0000,http://finance.yahoo.com/news/citron-research-avexis-one-2017s-160324347.html,Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
SRPT,SRPT:UW,BBG000BCJC58,"Anthem, Humana, United Push Back On Sarepta's FDA-Approved DMD Drug",2016-12-14 21:17:25 +0000,http://www.investors.com/news/technology/anthem-humana-united-push-back-on-sareptas-fda-approved-dmd-drug/,"Anthem, Humana, United Push Back On Sarepta's FDA-Approved DMD Drug"
SRPT,SRPT:UW,BBG000BCJC58,Will Insurers Pay For Sarepta's DMD Drug?,2016-12-14 19:13:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/14/will-insurers-pay-for-sareptas-dmd-drug/?mod=yahoobarrons&ru=yahoo,Will Insurers Pay For Sarepta's DMD Drug?
SRPT,SRPT:UW,BBG000BCJC58,FDA's Woodcock speaks out about one of the agency's most controversial decisions,2016-12-14 17:51:04 +0000,http://www.cnbc.com/id/104166523?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104166523,FDA's Woodcock speaks out about one of the agency's most controversial decisions
SRPT,SRPT:UW,BBG000BCJC58,[$$] Gormley's Take: Biotech Startups Heed Tough Lessons from a Drugmaker's Controversy,2016-12-14 12:30:32 +0000,http://www.wsj.com/articles/gormleys-take-biotech-startups-heed-tough-lessons-from-a-drugmakers-controversy-1481718629?mod=yahoo_hs,[$$] Gormley's Take: Biotech Startups Heed Tough Lessons from a Drugmaker's Controversy
SRPT,SRPT:UW,BBG000BCJC58,Should You Be Concerned That Smart Money Is Fleeing ALLETE Inc (ALE)?,2016-12-09 20:02:27 +0000,http://www.insidermonkey.com/blog/should-you-be-concerned-that-smart-money-is-fleeing-allete-inc-ale-504279/,Should You Be Concerned That Smart Money Is Fleeing ALLETE Inc (ALE)?
SRPT,SRPT:UW,BBG000BCJC58,"PTC Therapeutics, Inc. in 3 Charts",2016-12-07 23:49:09 +0000,http://www.fool.com/investing/2016/12/07/ptc-therapeutics-inc-in-3-charts.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"PTC Therapeutics, Inc. in 3 Charts"
SRPT,SRPT:UW,BBG000BCJC58,"PTC Therapeutics, Inc. in 3 Charts",2016-12-07 22:57:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y8CFIUF5o7M/ptc-therapeutics-inc-in-3-charts-cm718308,While Sarepta Therapeutics NASDAQ SRPT gained a lot of attention this year with its U S approval of Duchenne muscular dystrophy DMD drug Exondys 51 another biotech holds the honor of having the first DMD drug on the market elsewhere in the world PTC Therapeutics
SRPT,SRPT:UW,BBG000BCJC58,"Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally",2016-12-07 19:46:00 +0000,https://www.thestreet.com/story/13917873/1/dow-looks-again-at-a-record-as-wall-street-shakes-off-biotech-slump.html?puc=yahoo&cm_ven=YAHOO,"Dow, S&P 500 Trade at Session Highs in Broad Wall Street Rally"
SRPT,SRPT:UW,BBG000BCJC58,Hedge Funds Are Crazy About Sarepta Therapeutics Inc (SRPT),2016-12-07 09:03:49 +0000,http://www.insidermonkey.com/blog/hedge-funds-are-crazy-about-sarepta-therapeutics-inc-srpt-500399/,Hedge Funds Are Crazy About Sarepta Therapeutics Inc (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,Is This Why Sarepta Therapeutics Fell 14.5% in November?,2016-12-05 14:23:06 +0000,http://www.fool.com/investing/2016/12/05/is-this-why-sarepta-therapeutics-fell-145-in-novem.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is This Why Sarepta Therapeutics Fell 14.5% in November?
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH)",2016-12-02 20:24:00 +0000,http://www.investopedia.com/news/sarepta-dmd-drug-covered-unitedhealth-srpt-unh/?partner=YahooSA,"Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH)"
SRPT,SRPT:UW,BBG000BCJC58,New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51,2016-12-02 16:33:18 +0000,http://finance.yahoo.com/news/aetna-clinical-policy-bulletin-details-163318992.html,New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
SRPT,SRPT:UW,BBG000BCJC58,5 Medical Tech Stocks You Should Be Investing In,2016-12-01 16:47:21 +0000,http://www.insidermonkey.com/blog/5-medical-tech-stocks-you-should-be-investing-in-495916/,5 Medical Tech Stocks You Should Be Investing In
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: UnitedHealth Induced Selloff a Buying Opportunity?,2016-12-01 16:05:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/01/sarepta-unitedhealth-induced-selloff-a-buying-opportunity/?mod=yahoobarrons&ru=yahoo,Sarepta: UnitedHealth Induced Selloff a Buying Opportunity?
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Enters Oversold Territory (SRPT),2016-11-30 23:15:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iTjsd_bQ-dA/sarepta-therapeutics-enters-oversold-territory-srpt-cm716041,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2016-11-30 23:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-230000035.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on November 30, 2016, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seven individuals hired by Sarepta in November 2016."
SRPT,SRPT:UW,BBG000BCJC58,"Notable Wednesday Option Activity: GWRE, SRPT, ATHN",2016-11-30 21:15:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7TYuK6RHa7s/notable-wednesday-option-activity-gwre-srpt-athn-cm715995,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Guidewire Software Inc Symbol GWRE where a total volume of 4 114 contracts has been traded thus far today a contract volume which is representative of approximately 411
SRPT,SRPT:UW,BBG000BCJC58,The 21st Century Cures Act Will Not Fix The FDA,2016-11-30 21:10:00 +0000,http://www.forbes.com/sites/kenkam/2016/11/30/the-21st-century-cures-act-will-not-fix-the-fda/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,The 21st Century Cures Act Will Not Fix The FDA
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics: A Mistake to Underestimate Its Sales, Baird Says",2016-11-29 18:55:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/29/sarepta-therapeutics-a-mistake-to-underestimate-its-sales-baird-says/?mod=yahoobarrons&ru=yahoo,"Sarepta Therapeutics: A Mistake to Underestimate Its Sales, Baird Says"
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Nov 28, 2016 :  VALE, BAC, MT, NOK, LXK, CHK, TVIX, CTSH, XIV, SQQQ, QQQ, SRPT",2016-11-28 14:00:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WWrAuMWDEEQ/pre-market-most-active-for-nov-28-2016-vale-bac-mt-nok-lxk-chk-tvix-ctsh-xiv-sqqq-qqq-srpt-cm714395,The NASDAQ 100 Pre Market Indicator is down 8 03 to 4 861 99 The total Pre Market volume is currently 4 365 260 shares traded The following are the most active stocks for the pre market session VALE S A VALE is 0 05 at 8 47 with 388 938 shares traded VALE s
SRPT,SRPT:UW,BBG000BCJC58,What Happened in Biotech in 2016?,2016-11-22 23:19:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jc0QNGC1rY8/what-happened-in-biotech-in-2016-cm713018,Image source Getty Images It s been a rollercoaster of a year for the biotech industry with the decline that started in the middle of last year continuing into this year a recovery from those lows after a few gyrations a pre election decline on fears of price controls and
SRPT,SRPT:UW,BBG000BCJC58,"Commit To Purchase Sarepta Therapeutics At $20, Earn 18% Using Options",2016-11-22 18:17:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_yxIiNlnN_k/commit-to-purchase-sarepta-therapeutics-at-20-earn-18-using-options-cm712788,Investors considering a purchase of Sarepta Therapeutics Inc Symbol SRPT shares but tentative about paying the going market price of 36 84 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
SRPT,SRPT:UW,BBG000BCJC58,Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment,2016-11-21 19:19:47 +0000,http://finance.yahoo.com/news/aetna-still-undecided-coverage-sareptas-191947884.html,Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment
SRPT,SRPT:UW,BBG000BCJC58,"XBI, IONS, TSRO, SRPT: Large Inflows Detected at ETF",2016-11-18 17:51:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UkTMtKeoK_8/xbi-ions-tsro-srpt-large-inflows-detected-at-etf-cm711315,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 456 0 million dollar inflow that s a 15 7 increase week over week in
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise,2016-11-17 13:56:01 +0000,http://finance.yahoo.com/news/3-stocks-add-portfolio-biotech-135601225.html,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise
SRPT,SRPT:UW,BBG000BCJC58,Why PTC Therapeutics Is Soaring Again,2016-11-14 18:31:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T3ytbuYQG2c/why-ptc-therapeutics-is-soaring-again-cm708855,IMAGE SOURCE GETTY IMAGES What happened Investors in PTC Therapeutics NASDAQ PTCT a biotech focused on rare diseases are having a pleasant start to the trading week S hares are up by 10 as of 10 45 a m EST on Monday So what Shareholders can thank analysts at
SRPT,SRPT:UW,BBG000BCJC58,Why PTC Therapeutics Is Soaring Again,2016-11-14 17:10:08 +0000,http://www.fool.com/investing/2016/11/14/why-ptc-therapeutics-is-soaring-again.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why PTC Therapeutics Is Soaring Again
SRPT,SRPT:UW,BBG000BCJC58,How Donald Trump May Impact The FDA,2016-11-14 12:58:00 +0000,http://www.forbes.com/sites/johnlamattina/2016/11/14/donald-trump-and-the-fda/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,How Donald Trump May Impact The FDA
SRPT,SRPT:UW,BBG000BCJC58,​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug,2016-11-11 18:25:52 +0000,http://www.bizjournals.com/boston/news/2016/11/11/why-not-everyone-is-buying-the-market-hype.html?ana=yahoo,​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug
SRPT,SRPT:UW,BBG000BCJC58,3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High',2016-11-11 15:30:43 +0000,http://finance.yahoo.com/news/3-reasons-2017-launch-expectations-153043287.html,3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
SRPT,SRPT:UW,BBG000BCJC58,PTC Therapeutics Duchenne Drug Wins Extended European Approval,2016-11-11 13:10:00 +0000,https://www.thestreet.com/story/13889941/1/ptc-therapeutics-duchenne-drug-wins-extended-european-approval.html?puc=yahoo&cm_ven=YAHOO,PTC Therapeutics Duchenne Drug Wins Extended European Approval
SRPT,SRPT:UW,BBG000BCJC58,Buy the SPDR S&P Biotech (ETF) (XBI) TODAY – Here’s Why,2016-11-09 15:53:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ujFvmFFX-2A/buy-the-spdr-sp-biotech-etf-xbi-today-heres-why-cm706398,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The SPDR S amp P Biotech ETF 160 NYSEARCA XBI and a host of biotech stocks and funds are surging this morning and that makes them stick out like a sore thumb Source Pixelbay Modified
SRPT,SRPT:UW,BBG000BCJC58,Why Cempra Inc Fell Over the Last 2 Days,2016-11-09 00:55:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hKqSPevHKPQ/why-cempra-inc-fell-over-the-last-2-days-cm706030,Image source Getty Images What happened Cempra NASDAQ CEMP fell 13 9 today after falling 9 3 yesterday Investors are clearly worried about the likelihood of a Food and Drug Administration approval of Cempra s antibiotic solithromycin So what Last week the
SRPT,SRPT:UW,BBG000BCJC58,Why Cempra Inc Fell Over the Last 2 Days,2016-11-08 22:40:19 +0000,http://www.fool.com/investing/2016/11/08/why-cempra-inc-fell-over-the-last-2-days.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Cempra Inc Fell Over the Last 2 Days
SRPT,SRPT:UW,BBG000BCJC58,Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed,2016-11-08 17:53:44 +0000,http://www.insidermonkey.com/blog/big-bet-on-sarepta-therapeutics-inc-srpt-lifts-perceptive-advisors-q3-returns-see-how-other-investments-performed-485488/,Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics To Participate In Credit Suisse Conference At 5:30 PM ET,2016-11-07 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EgxFwEIVthk/sarepta-therapeutics-to-participate-in-credit-suisse-conference-at-530-pm-et-20161107-01086,Sarepta Therapeutics To Participate In Credit Suisse Conference At 5:30 PM ET
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report",2016-11-07 13:33:27 +0000,http://biz.yahoo.com/e/161107/srpt10-q.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference,2016-11-04 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-present-company-overview-123000329.html,"[Business Wire] - Sarepta Therapeutics , a commercial-stage developer of innovative RNA-targeted therapeutics, announced today that it is scheduled to present at the Credit Suisse 25th Annual Healthcare Conference in Phoenix, Arizona on Monday, November 7, 2016 at 5:30 PM, Eastern Time. Edward Kaye, Sarepta's chief executive officer, will be the presenter at the fireside chat."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2016-11-02 12:10:14 +0000,http://www.publicnow.com/view/F0FF51E242E8146F1B4FC793BF3E4C015CC155F7,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on October 31, 2016, ..."
SRPT,SRPT:UW,BBG000BCJC58,4 Stocks I'd Avoid at All Costs,2016-11-01 17:13:44 +0000,http://www.fool.com/investing/2016/10/31/4-stocks-id-avoid-at-all-costs.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Stocks I'd Avoid at All Costs
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments,2016-10-31 21:43:05 +0000,http://www.publicnow.com/view/B6FA73955BC63C89A25954D1B70FC6C771CE6DE9,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 27, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today reported financial results for the ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2016-10-31 21:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-inducement-grants-213000606.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on October 31, 2016, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to three individuals hired by Sarepta in October 2016."
SRPT,SRPT:UW,BBG000BCJC58,4 Stocks I'd Avoid at All Costs,2016-10-31 19:16:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/34mHo_A6wQI/4-stocks-id-avoid-at-all-costs-cm701310,Developing and commercializing new drugs involves so many uncertainties that even the finest biotech stocks are relatively risky Some are so deep in the danger zone though that anyone would be well advised to leave them alone For a variety of reasons I d avoid Sarepta
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks to Avoid in Biotech,2016-10-29 12:16:29 +0000,http://www.fool.com/investing/2016/10/28/3-stocks-to-avoid-in-biotech.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks to Avoid in Biotech
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc. (SRPT) Stock: Jason Karp Is A Shareholder Again And Has A Larger Position Than Ever,2016-10-28 16:56:06 +0000,http://www.insidermonkey.com/blog/sarepta-therapeutics-inc-srpt-stock-jason-karp-is-a-shareholder-again-and-has-a-larger-position-than-ever-483741/,Sarepta Therapeutics Inc. (SRPT) Stock: Jason Karp Is A Shareholder Again And Has A Larger Position Than Ever
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy ETF Inflows: XBI, SRPT, TSRO, INCY",2016-10-28 16:32:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2tRE81Bhb0w/noteworthy-etf-inflows-xbi-srpt-tsro-incy-cm700265,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 111 4 million dollar inflow that s a 5 0 increase week over week in outstanding
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3,2016-10-28 14:33:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I91QFyOccf0/sarepta-therapeutics-srpt-incurs-narrower-yy-loss-in-q3-cm700177,Sarepta Therapeutics Inc SRPT posted a loss of 1 15 per share in the third quarter of 2016 narrower than the year ago loss of 1 25 The Zacks Consensus Estimate reported a loss of 1 35 per share No revenue was recorded by the company in the reported quarter as was the case a year
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : October 28, 2016",2016-10-28 14:04:06 +0000,http://www.capitalcube.com/blog/index.php/sarepta-therapeutics-inc-breached-its-50-day-moving-average-in-a-bearish-manner-srpt-us-october-28-2016/,"Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : October 28, 2016"
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks to Avoid in Biotech,2016-10-28 13:44:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PGrRKcj4tmE/3-stocks-to-avoid-in-biotech-cm700023,Image source Getty Images Public outrage over escalating drug prices made the biotechnology industry generally toxic to plenty of portfolios to begin the year and fear of political backlash isn t helping The iShares Nasdaq Biotechnology index which 160 tracks over 180
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3,2016-10-28 13:35:01 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-srpt-incurs-narrower-133501322.html,Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta is Sinking,2016-10-27 18:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/27/why-sarepta-is-sinking/?mod=yahoobarrons&ru=yahoo,Why Sarepta is Sinking
SRPT,SRPT:UW,BBG000BCJC58,Edited Transcript of SRPT earnings conference call or presentation 27-Oct-16 12:00pm GMT,2016-10-27 17:24:52 +0000,http://finance.yahoo.com/news/edited-transcript-srpt-earnings-conference-172452134.html,Edited Transcript of SRPT earnings conference call or presentation 27-Oct-16 12:00pm GMT
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics reports 3Q loss,2016-10-27 12:41:25 +0000,http://sg.finance.yahoo.com/news/sarepta-therapeutics-reports-3q-loss-124125839.html,Sarepta Therapeutics reports 3Q loss
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today,2016-10-27 12:00:00 +0000,http://biz.yahoo.com/cc/4/154434.html,Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an",2016-10-27 11:28:36 +0000,http://biz.yahoo.com/e/161027/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an"
SRPT,SRPT:UW,BBG000BCJC58,"Earnings Reaction History: Sarepta Therapeutics, Inc., 71.4% Follow-Through Indicator, 10.5% Sensitive",2016-10-27 11:10:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cTdhVMZPKlc/earnings-reaction-history-sarepta-therapeutics-inc-714-follow-through-indicator-105-sensitive-cm699104,Expected Earnings Release 10 27 2016 PremarketExpected Earnings Release 10 27 2016 Premarket Avg Extended Hours Dollar Volume 7 375 419Avg Extended Hours Dollar Volume 7 375 419 Sarepta Therapeutics Inc SRPT is due to issue its quarterly earnings report in the
SRPT,SRPT:UW,BBG000BCJC58,Q3 2016 Sarepta Therapeutics Inc Earnings Release - Before Market Open,2016-10-27 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20161027.html?t=srpt,Q3 2016 Sarepta Therapeutics Inc Earnings Release - Before Market Open
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments,2016-10-27 11:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-third-quarter-110000427.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, today reported financial results for the three and nine months ended September 30, 2016."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Q3 16 Earnings Conference Call At 8:00 AM ET,2016-10-27 07:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2I2eVyoisGg/sarepta-therapeutics-q3-16-earnings-conference-call-at-800-am-et-20161027-00408,Sarepta Therapeutics Q3 16 Earnings Conference Call At 8:00 AM ET
SRPT,SRPT:UW,BBG000BCJC58,"Notable Wednesday Option Activity: SRPT, BOFI, ORLY",2016-10-26 20:49:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SR-5-8St_mQ/notable-wednesday-option-activity-srpt-bofi-orly-cm698897,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Sarepta Therapeutics Inc Symbol SRPT where a total volume of 13 928 contracts has been traded thus far today a contract volume which is representative of approximately 1
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: 'Setting Aside the Controversy Around the Questionable Data…',2016-10-25 17:34:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/25/sarepta-setting-aside-the-controversy-around-the-questionable-data/?mod=yahoobarrons&ru=yahoo,Sarepta: 'Setting Aside the Controversy Around the Questionable Data…'
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016",2016-10-25 05:51:07 +0000,http://www.publicnow.com/view/D084EEF4ACAF41A11F122740715EC7FECEA895A0,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2016-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, will report third quarter 2016 financial ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016",2016-10-24 12:30:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announce-third-quarter-123000837.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, will report third quarter 2016 financial results before the NASDAQ Global Market opens on Thursday, October 27, 2016."
SRPT,SRPT:UW,BBG000BCJC58,Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry,2016-10-21 12:00:22 +0000,http://www.investors.com/etfs-and-funds/etfs/the-best-and-worst-biotech-etfs-of-2016-tell-a-tale-about-this-industry/,Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry
SRPT,SRPT:UW,BBG000BCJC58,SPDR S&P Biotech ETF Experiences Big Outflow,2016-10-20 16:25:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MYrlh9Yd0kM/spdr-sp-biotech-etf-experiences-big-outflow-cm696022,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 70 6 million dollar outflow that s a 3 0 decrease week over week from 40 200 000
SRPT,SRPT:UW,BBG000BCJC58,"Trader Be Nimble, Trader Be Quick",2016-10-20 14:45:00 +0000,http://realmoney.thestreet.com/articles/10/20/2016/trader-be-nimble-trader-be-quick?puc=yahoo&cm_ven=YAHOO,"Trader Be Nimble, Trader Be Quick"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Muscular Dystrophy Drug Interrupts 5-Day Biotech Slump,2016-10-18 20:43:39 +0000,http://www.investors.com/news/technology/sarepta-muscular-dystrophy-drug-interrupts-five-day-biotech-slump/,Sarepta Muscular Dystrophy Drug Interrupts 5-Day Biotech Slump
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: If You Approve It They Will Come,2016-10-18 15:20:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/18/sarepta-therapeutics-if-you-approve-it-they-will-come/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: If You Approve It They Will Come
SRPT,SRPT:UW,BBG000BCJC58,PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal,2016-10-18 14:50:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LBmxdRBP8-g/ptc-therapeutics-falls-on-fda-denial-of-dmd-drug-appeal-cm694642,PTC Therapeutics Inc s PTCT shares fell almost 40 after it provided a regulatory update on its lead pipeline candidate Translarna ataluren for the treatment of patients with nonsense genetic mutation Duchenne muscular dystrophy nmDMD PTC Therapeutics declared that its first appeal
SRPT,SRPT:UW,BBG000BCJC58,PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal,2016-10-18 12:59:12 +0000,http://finance.yahoo.com/news/ptc-therapeutics-falls-fda-denial-125912250.html,PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics' Greatest Threat: Anthem?,2016-10-17 21:21:46 +0000,http://www.fool.com/investing/2016/10/17/sarepta-therapeutics-greatest-threat-anthem.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Sarepta Therapeutics' Greatest Threat: Anthem?
SRPT,SRPT:UW,BBG000BCJC58,"Why PTC Therapeutics, Inc. Is Crashing Today",2016-10-17 16:48:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yz3mZDYuIMM/why-ptc-therapeutics-inc-is-crashing-today-cm694294,Image source Getty Images What happened After providing investors with two regulatory updates related to its nonsense mutation Duchenne muscular dystrophy nmDMD drug Translarna shares of PTC Therapeutics NASDAQ PTCT fell by 31 as of 12 00 p m EDT on Monday So
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics' Greatest Threat: Anthem?,2016-10-17 14:43:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-DEgvCoVYn8/sarepta-therapeutics-greatest-threat-anthem-cm694069,Image source Getty Images Sarepta Therapeutics NASDAQ SRPT now knows its biggest threat It s not the risk that confirmatory testing for recently approved Duchenne muscular dystrophy DMD drug 160 Exondys 51 won t go well It s not that rival BioMarin might prevail
SRPT,SRPT:UW,BBG000BCJC58,Short Interest In Sarepta Therapeutics Moves 21% Lower,2016-10-13 19:40:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ge7Wli8Ya_E/short-interest-in-sarepta-therapeutics-moves-21-lower-cm693067,The most recent short interest data has been released for the 09 30 2016 settlement date which shows a 2 995 824 share decrease in total short interest for Sarepta Therapeutics Inc Symbol SRPT to 11 282 680 a decrease of 20 98 since 09 15 2016 Total short interest is just one way to look
SRPT,SRPT:UW,BBG000BCJC58,"Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics",2016-10-13 15:39:00 +0000,https://www.thestreet.com/story/13852472/1/pardon-me-but-i-have-a-few-things-to-say-seattle-genetics-biomarin-sarepta-tg-therapeutics.html?puc=yahoo&cm_ven=YAHOO,"Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics"
SRPT,SRPT:UW,BBG000BCJC58,"Today’s Trending Stocks: Sarepta, Humana, HTG Molecular Diagnostics, and More",2016-10-12 17:22:08 +0000,http://www.insidermonkey.com/blog/todays-trending-stocks-sarepta-humana-htg-molecular-diagnostics-and-more-480844/,"Today’s Trending Stocks: Sarepta, Humana, HTG Molecular Diagnostics, and More"
SRPT,SRPT:UW,BBG000BCJC58,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO",2016-10-12 12:39:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-alnylam-slumps-123912498.html,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO"
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Skyrocketed 131% in September,2016-10-11 21:18:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mymsv-XDjrw/why-sarepta-therapeutics-skyrocketed-131-in-september-cm692065,Image source Getty Images What happened After the FDA approved its lead drug candidate for the treatment of Duchenne muscular dystrophy DMD on Sept 19 shares in Sarepta Therapeutics NASDAQ SRPT soared an eye popping 131 last month according to S amp P Global
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Skyrocketed 131% in September,2016-10-11 19:41:06 +0000,http://www.fool.com/investing/2016/10/11/why-sarepta-therapeutics-skyrocketed-131-in-septem.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Sarepta Therapeutics Skyrocketed 131% in September
SRPT,SRPT:UW,BBG000BCJC58,Marketplace Roundtable: The State Of Biotech,2016-10-11 18:20:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-dXRuyLW5JM/marketplace-roundtable-the-state-of-biotech-cm687454,By SA Marketplace BySA Marketplace It would be fair to say biotech has had an interesting time of it over the course of the past 15 months Except of course that biotech always has an interesting time of it The go big or go home sector of the market attracts speculators scientists
SRPT,SRPT:UW,BBG000BCJC58,"IYR, PTH: Big ETF Outflows",2016-10-11 16:20:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l-oF84N8xsI/iyr-pth-big-etf-outflows-cm691812,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the iShares U S Real Estate ETF where 7 800 000 units were destroyed or a 12 8 decrease week over week Among the largest underlying components of IYR
SRPT,SRPT:UW,BBG000BCJC58,"XBI, SRPT, IONS, INCY: Large Outflows Detected at ETF",2016-10-11 16:19:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pQG-dTx2-bw/xbi-srpt-ions-incy-large-outflows-detected-at-etf-cm691866,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 39 3 million dollar outflow that s a 1 5 decrease week over week from 39 800 000
SRPT,SRPT:UW,BBG000BCJC58,Health insurers split on coverage of Sarepta’s Duchenne drug,2016-10-11 15:27:53 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/10/health-insurers-split-on-coverage-of-sarepta-s.html?ana=yahoo,Health insurers split on coverage of Sarepta’s Duchenne drug
SRPT,SRPT:UW,BBG000BCJC58,Catabasis Presents Data from DMD study on Edasalonexent,2016-10-11 15:21:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CgJmOAeHPw4/catabasis-presents-data-from-dmd-study-on-edasalonexent-cm691773,Catabasis Pharmaceuticals Inc CATB announced that it has presented results from the part A of the MoveDMD study phase I II on edasalonexent at the congress of the World Muscle Society Edasalonexent a molecule that inhibits a protein called NF kB is being developed for the treatment
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Tumbles After Anthem’s Refusal (SRPT, ANTM)",2016-10-10 20:57:00 +0000,http://www.investopedia.com/news/sarepta-tumbles-after-anthems-refusal-srpt-antm/?partner=YahooSA,"Sarepta Tumbles After Anthem’s Refusal (SRPT, ANTM)"
SRPT,SRPT:UW,BBG000BCJC58,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.",2016-10-10 15:21:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uv8QkimZeNw/better-buy-alnylam-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-cm691031,IMAGE SOURCE GETTY IMAGES You might think that a biotech with a recent FDA regulatory win would automatically be a better investing pick than another biotech with no approved products That s sometimes the case but not always Sarepta Therapeutics NASDAQ SRPT now has
SRPT,SRPT:UW,BBG000BCJC58,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.",2016-10-10 15:00:07 +0000,http://www.fool.com/investing/2016/10/10/better-buy-alnylam-pharmaceuticals-inc-vs-sarepta.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc."
SRPT,SRPT:UW,BBG000BCJC58,"New Anthem policy will cost DMD patients $300,000 or more",2016-10-08 18:46:51 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=217871E2-8CA2-11E6-9FFE-2390D60A01C3&siteid=yhoof2,"New Anthem policy will cost DMD patients $300,000 or more"
SRPT,SRPT:UW,BBG000BCJC58,"Why Tyson Foods, Inc. (TSN), Honeywell International Inc. (HON) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Worst Stocks",2016-10-07 23:44:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TilSXTZVsz8/why-tyson-foods-inc-tsn-honeywell-international-inc-hon-and-sarepta-therapeutics-inc-srpt-are-3-of-todays-worst-stocks-cm690620,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips With another mixed message served up by Friday morning s jobs report for September traders were once again unsure of what to do with stocks The initial selling gave way for strong buying
SRPT,SRPT:UW,BBG000BCJC58,"Noteworthy Friday Option Activity: NLNK, SRPT, BIIB",2016-10-07 20:43:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z23XTZFhmqE/noteworthy-friday-option-activity-nlnk-srpt-biib-cm690520,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in NewLink Genetics Corp Symbol NLNK where a total volume of 2 144 contracts has been traded thus far today a contract volume which is representative of approximately 214
SRPT,SRPT:UW,BBG000BCJC58,Anthem says will not cover Sarepta's approved Duchenne drug,2016-10-07 18:56:51 +0000,http://finance.yahoo.com/news/anthem-says-not-cover-first-173028595.html,Anthem says will not cover Sarepta's approved Duchenne drug
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Therapeutics, Ralph Lauren, Fifth Third Bancorp, and Two Other Stocks Are in Spotlight on Friday",2016-10-07 17:05:54 +0000,http://www.insidermonkey.com/blog/why-sarepta-therapeutics-ralph-lauren-fifth-third-bancorp-and-two-other-stocks-are-in-spotlight-on-friday-479378/,"Why Sarepta Therapeutics, Ralph Lauren, Fifth Third Bancorp, and Two Other Stocks Are in Spotlight on Friday"
SRPT,SRPT:UW,BBG000BCJC58,Anthem won't cover first FDA-approved Duchenne drug,2016-10-07 16:36:58 +0000,http://finance.yahoo.com/news/anthem-wont-cover-first-fda-163658279.html,"[Reuters] - Health insurer Anthem Inc said it would not cover the first U.S. Food and Drug Administration-approved Duchenne muscular dystrophy (DMD) drug, developed by Sarepta Therapeutics Inc, calling it ""investigational and not medically necessary"". Sarepta has to prove that benefit in a subsequent clinical trial."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics (SRPT) Stock Drops, Anthem Says DMD Drug 'Not Medically Necessary'",2016-10-07 16:10:00 +0000,https://www.thestreet.com/story/13846082/1/sarepta-therapeutics-srpt-stock-drops-anthem-says-dmd-drug-not-medically-necessary.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Therapeutics (SRPT) Stock Drops, Anthem Says DMD Drug 'Not Medically Necessary'"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta stock down 4.8% after Anthem signals it won't cover new DMD drug,2016-10-07 15:23:09 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=3A82B0DD-0E81-4BD7-8452-6A464116B843&siteid=yhoof2,Sarepta stock down 4.8% after Anthem signals it won't cover new DMD drug
SRPT,SRPT:UW,BBG000BCJC58,CureDuchenne to Host SareptAssist Webinar on October 11 to Provide an Overview of Sarepta’s Patient Support Program for Duchenne Families,2016-10-06 16:08:00 +0000,http://finance.yahoo.com/news/cureduchenne-host-sareptassist-webinar-october-160800641.html,"[Business Wire] - CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with Sarepta Therapeutics, Inc. on October 11 at 1 p.m."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta’s Exondys 51 Drug May Cost $300,000 (SRPT)",2016-10-05 19:16:00 +0000,http://www.investopedia.com/news/sareptas-exondys-51-drug-may-cost-300000-srpt/?partner=YahooSA,"Sarepta’s Exondys 51 Drug May Cost $300,000 (SRPT)"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations,2016-10-05 17:27:04 +0000,http://finance.yahoo.com/news/sareptas-deal-summit-could-more-172704416.html,Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations
SRPT,SRPT:UW,BBG000BCJC58,Sarepta/Summit Ink Deal for Utrophin Modulator DMD Drugs,2016-10-05 16:47:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eCmz_2tC4aQ/sareptasummit-ink-deal-for-utrophin-modulator-dmd-drugs-cm689254,Sarepta Therapeutics Inc SRPT announced that it has entered into an exclusive license and collaboration agreement with Summit Therapeutics plc SMMT for the rights to the latter s utrophin modulator pipeline for the treatment of Duchenne muscular dystrophy DMD Although Sarepta s
SRPT,SRPT:UW,BBG000BCJC58,"Ignore Market Jitters, Let Price Action Be the Guide",2016-10-05 15:11:00 +0000,http://realmoney.thestreet.com/articles/10/05/2016/ignore-market-jitters-let-price-action-be-guide?puc=yahoo&cm_ven=YAHOO,"Ignore Market Jitters, Let Price Action Be the Guide"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta/Summit Ink Deal for Utrophin Modulator DMD Drugs,2016-10-05 14:06:02 +0000,http://finance.yahoo.com/news/sarepta-summit-ink-deal-utrophin-140602985.html,Sarepta/Summit Ink Deal for Utrophin Modulator DMD Drugs
SRPT,SRPT:UW,BBG000BCJC58,"Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data",2016-10-05 13:29:01 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-summit-soars-132901452.html,"Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data"
SRPT,SRPT:UW,BBG000BCJC58,Blog Coverage Sarepta Announces Collaboration with Summit Therapeutics,2016-10-05 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-sarepta-announces-collaboration-131500077.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / October 5, 2016 / Active Wall St. blog coverage looks at the headline from Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) and Summit Therapeutics PLC (NASDAQ: SMMT ). On October 04th, ..."
SRPT,SRPT:UW,BBG000BCJC58,Blog Coverage Sarepta Announces Collaboration with Summit Therapeutics,2016-10-05 12:57:09 +0000,http://news.investornetwork.com/2016/10/05/blog-coverage-sarepta-announces-collaboration-with-summit-therapeutics/?1=1&1475672229,Blog Coverage Sarepta Announces Collaboration with Summit Therapeutics
SRPT,SRPT:UW,BBG000BCJC58,"CATB Data Pushed Back To Q1, SMMT At Peak, TRIB Pounded, OTIC Hits Right Notes",2016-10-05 01:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qCD762Mut_8/catb-data-pushed-back-to-q1-smmt-at-peak-trib-pounded-otic-hits-right-notes-20161005-00016,"CATB Data Pushed Back To Q1, SMMT At Peak, TRIB Pounded, OTIC Hits Right Notes"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Inks Key DMD Deal (SRPT),2016-10-04 22:00:00 +0000,http://www.investopedia.com/news/sarepta-inks-key-dmd-deal-srpt/?partner=YahooSA,Sarepta Inks Key DMD Deal (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,Close Update: Stocks Slide With Utilities Leading Declines as IMF Cuts Growth Outlook,2016-10-04 21:03:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9Y3Kxu7u41g/close-update-stocks-slide-with-utilities-leading-declines-as-imf-cuts-growth-outlook-cm688806,Stocks in the U S posted a second day of declines on Tuesday as the International Monetary Fund lowered its forecast for growth both globally and domestically Richmond Fed President Jeffrey M Lacker made the case for raising rates to impact inflation and gold prices retreated amid a
SRPT,SRPT:UW,BBG000BCJC58,"Health Care Sector Update for 10/04/2016: CNAT,SMMT,TRIB",2016-10-04 20:43:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T0AfTJAu3mk/health-care-sector-update-for-10042016-cnatsmmttrib-cm688773,Top Health Care StocksTop Health Care Stocks JNJ 0 12 JNJ 0 12 PFE 0 10 PFE 0 10 MRK 1 09 MRK 1 09 ABT 0 31 ABT 0 31 AMGN 0 04 AMGN 0 04 Health care stocks were slightly lower in early afternoon trade with the NYSE Health Care Index dropping about 0 3 while shares of health
SRPT,SRPT:UW,BBG000BCJC58,Sarepta may be the real winner from partnership that lifted Summit Therapeutics stock 50%,2016-10-04 20:09:53 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=36238260-8A38-11E6-B89B-E04BEFEA5B3D&siteid=yhoof2,Sarepta may be the real winner from partnership that lifted Summit Therapeutics stock 50%
SRPT,SRPT:UW,BBG000BCJC58,"Trending Tickers: SDRL, P, SMMT, SRPT",2016-10-04 18:23:00 +0000,http://realmoney.thestreet.com/articles/10/04/2016/trending-tickers-sdrl-p-smmt-srpt?puc=yahoo&cm_ven=YAHOO,"Trending Tickers: SDRL, P, SMMT, SRPT"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics (SRPT) Stock Up on Summit Deal, RBC Bullish",2016-10-04 18:21:00 +0000,https://www.thestreet.com/story/13841169/1/sarepta-therapeutics-srpt-stock-up-on-summit-deal-rbc-bullish.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Therapeutics (SRPT) Stock Up on Summit Deal, RBC Bullish"
SRPT,SRPT:UW,BBG000BCJC58,Midday Update: Stocks On the Fence Ahead of Data Dump,2016-10-04 16:43:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-aES3VY3-l0/midday-update-stocks-on-the-fence-ahead-of-data-dump-cm688609,Stocks were straddling the flatline on Tuesday as Wall Street awaits developments on Deutsche Bank DB Friday s labor market report as well as remarks on U S monetary policy from members of the Federal Reserve Stocks were straddling the flatline on Tuesday as Wall Street awaits
SRPT,SRPT:UW,BBG000BCJC58,​Analyst: Sarepta ‘removes potential competitive threat’ with $562M deal,2016-10-04 16:12:16 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/10/analyst-sarepta-removes-potential-competitive.html?ana=yahoo,​Analyst: Sarepta ‘removes potential competitive threat’ with $562M deal
SRPT,SRPT:UW,BBG000BCJC58,Sarepta partners with UK's Summit on Duchenne drugs,2016-10-04 15:51:04 +0000,http://sg.finance.yahoo.com/news/sarepta-partners-uks-summit-duchenne-155104573.html,Sarepta partners with UK's Summit on Duchenne drugs
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement,2016-10-04 15:48:02 +0000,http://www.publicnow.com/view/77826EECBFC159A52ED749B716A49FF5C159E419,[at noodls] - for European Rights to Summit's Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy Sarepta and Summit collaborate to advance the development of novel therapies for patients with ...
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta's Licensing Deal Makes This Drug Maker An ""Even More Attractive M&A Candidate""",2016-10-04 15:34:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/04/why-sareptas-licensing-deal-makes-this-drug-maker-an-even-more-attractive-ma-candidate/?mod=yahoobarrons&ru=yahoo,"Why Sarepta's Licensing Deal Makes This Drug Maker An ""Even More Attractive M&A Candidate"""
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Stock Gains on Summit Licensing Agreement,2016-10-04 15:17:00 +0000,https://www.thestreet.com/story/13840911/1/sarepta-therapeutics-srpt-stock-gains-on-summit-licensing-agreement.html?puc=yahoo&cm_ven=YAHOO,Sarepta Therapeutics (SRPT) Stock Gains on Summit Licensing Agreement
SRPT,SRPT:UW,BBG000BCJC58,"DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta",2016-10-04 15:00:51 +0000,http://finance.yahoo.com/news/dmd-deal-summit-low-risk-150051898.html,"DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta"
SRPT,SRPT:UW,BBG000BCJC58,Summit Therapeutics Skyrockets on Sarepta Deal,2016-10-04 14:35:14 +0000,http://finance.yahoo.com/news/summit-therapeutics-skyrockets-sarepta-deal-143514363.html,Summit Therapeutics Skyrockets on Sarepta Deal
SRPT,SRPT:UW,BBG000BCJC58,"Early Movers: Darden Lifts Earnings Forecast; Trinity Biotech Plunges, Yanks FDA Applicaiton",2016-10-04 13:46:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/04/early-movers-darden-lifts-earnings-forecast-trinity-biotech-plunges-yanks-fda-applicaiton/?mod=yahoobarrons&ru=yahoo,"Early Movers: Darden Lifts Earnings Forecast; Trinity Biotech Plunges, Yanks FDA Applicaiton"
SRPT,SRPT:UW,BBG000BCJC58,Summit Therapeutics (SMMT) Stock Spikes on Sarepta Licensing Deal,2016-10-04 13:22:00 +0000,https://www.thestreet.com/story/13840554/1/summit-therapeutics-smmt-stock-spikes-on-sarepta-licensing-deal.html?puc=yahoo&cm_ven=YAHOO,Summit Therapeutics (SMMT) Stock Spikes on Sarepta Licensing Deal
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy,2016-10-04 13:18:03 +0000,http://www.publicnow.com/view/9F06B98DD85FC2B583C04CC87E96D1378C9236C5,"[at noodls] - Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophy Summit receives $40 million upfront, with potential future ezutromid-related milestone ..."
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug",2016-10-04 12:37:14 +0000,http://finance.yahoo.com/news/sarepta-wins-exclusive-license-collaboration-123714585.html,"Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug"
SRPT,SRPT:UW,BBG000BCJC58,Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta,2016-10-04 11:58:24 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=0900C5B8-33AF-45A8-8210-C9A582FF4C6C&siteid=yhoof2,Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta
SRPT,SRPT:UW,BBG000BCJC58,BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal,2016-10-04 11:52:55 +0000,http://uk.finance.yahoo.com/news/buzz-summit-therapeutics-best-day-115255208.html,BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal
SRPT,SRPT:UW,BBG000BCJC58,Summit and Sarepta to collaborate on muscular dystrophy drug,2016-10-04 11:29:10 +0000,http://finance.yahoo.com/news/summit-sarepta-collaborate-muscular-dystrophy-112910286.html,Summit and Sarepta to collaborate on muscular dystrophy drug
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E",2016-10-04 11:07:28 +0000,http://biz.yahoo.com/e/161004/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E"
SRPT,SRPT:UW,BBG000BCJC58,Summit Therapeutics (SMMT) Is Spiking To A New High On Sarepta Agreement,2016-10-04 09:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yjgoe5YsdWM/summit-therapeutics-smmt-is-spiking-to-a-new-high-on-sarepta-agreement-20161004-00344,Summit Therapeutics (SMMT) Is Spiking To A New High On Sarepta Agreement
SRPT,SRPT:UW,BBG000BCJC58,"XBI, SRPT, IONS, BLUE: ETF Inflow Alert",2016-10-03 16:43:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i9IER0FKb-Q/xbi-srpt-ions-blue-etf-inflow-alert-cm687842,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 112 7 million dollar inflow that s a 4 5 increase week over week in outstanding
SRPT,SRPT:UW,BBG000BCJC58,6 Best Performing Drug Stocks of September,2016-10-03 12:39:12 +0000,http://finance.yahoo.com/news/6-best-performing-drug-stocks-123912721.html,6 Best Performing Drug Stocks of September
SRPT,SRPT:UW,BBG000BCJC58,Is Sarepta Therapeutics Still a Risky Bet?,2016-10-02 15:43:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ItrrUrl8ZXU/is-sarepta-therapeutics-still-a-risky-bet-cm687528,IMAGE SOURCE GETTY IMAGES Snag a much needed Food and Drug Administration approval Check Increase the company s market cap by over 120 in a matter of days Check Sarepta Therapeutics NASDAQ SRPT managed to do both thanks to a stunning regulatory win for Duchenne
SRPT,SRPT:UW,BBG000BCJC58,Top 6 Biopharma Gainers of the Past Week,2016-10-02 14:05:42 +0000,http://247wallst.com/healthcare-business/2016/10/02/top-6-biopharma-gainers-of-the-past-week/,Top 6 Biopharma Gainers of the Past Week
SRPT,SRPT:UW,BBG000BCJC58,Is Sarepta Therapeutics Still a Risky Bet?,2016-10-02 13:57:16 +0000,http://www.fool.com/investing/2016/10/02/is-sarepta-therapeutics-still-a-risky-bet.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Sarepta Therapeutics Still a Risky Bet?
SRPT,SRPT:UW,BBG000BCJC58,"'Mad Money' Lightning Round: Buy, Buy, Buy Home Depot",2016-10-01 13:00:00 +0000,https://www.thestreet.com/story/13676413/1/mad-money-lightning-round-buy-buy-buy-home-depot.html?puc=yahoo&cm_ven=YAHOO,"'Mad Money' Lightning Round: Buy, Buy, Buy Home Depot"
SRPT,SRPT:UW,BBG000BCJC58,Cramer: We've missed the big move on Sarepta Therapeutics,2016-09-30 23:21:24 +0000,http://www.cnbc.com/id/103983984?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103983984,Cramer: We've missed the big move on Sarepta Therapeutics
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events",2016-09-30 20:16:23 +0000,http://biz.yahoo.com/e/160930/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events"
SRPT,SRPT:UW,BBG000BCJC58,Biotech stocks have plenty of catalysts around the corner,2016-09-30 17:28:21 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=0681569A-8646-11E6-A751-447CDAF369FF&siteid=yhoof2,Biotech stocks have plenty of catalysts around the corner
SRPT,SRPT:UW,BBG000BCJC58,"Kite, Anavex, G.W. Pharma Help Revive Biotech Sector Chemistry",2016-09-30 16:56:03 +0000,http://www.investors.com/research/industry-snapshot/kite-anavex-g-w-pharma-revive-biotech-sector-chemistry/,"Kite, Anavex, G.W. Pharma Help Revive Biotech Sector Chemistry"
SRPT,SRPT:UW,BBG000BCJC58,Shark Bites: Market Responds With 'Deutsche Who?',2016-09-30 16:49:00 +0000,http://realmoney.thestreet.com/articles/09/30/2016/shark-bites-market-responds-deutsche-who?puc=yahoo&cm_ven=YAHOO,Shark Bites: Market Responds With 'Deutsche Who?'
SRPT,SRPT:UW,BBG000BCJC58,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 15:24:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1i38wrWT5co/5-top-performing-stocks-of-the-best-etf-of-q3-cm687111,After a huge sell off at the start of the year the biotech sector has made a strong comeback with BioShares Biotechnology Clinical Trials Fund BBC topping the list of the best performing ETFs of 3Q16 The fund delivered impressive returns of about 29 6 in the quarter and has a Zacks ETF Rank
SRPT,SRPT:UW,BBG000BCJC58,The Crazy Backstory Around Sarepta Therapeutics' Game-Changing Drug Approval,2016-09-30 15:24:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eHIoxSHq6Mo/the-crazy-backstory-around-sarepta-therapeutics-game-changing-drug-approval-cm687099,The FDA s approval of Sarepta Therapeutics NASDAQ SRPT Exondys 51 as a treatment for Duchenne muscular dystrophy was far from an obvious decision A raging debate within the agency regarding the drug s efficacy put the director of the team reviewing Exondys 51 at odds with
SRPT,SRPT:UW,BBG000BCJC58,"One Biotech Crashes, the Other Skyrockets -- Here's Why",2016-09-30 14:54:05 +0000,http://www.fool.com/investing/2016/09/29/one-biotech-crashes-the-other-skyrockets-heres-why.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"One Biotech Crashes, the Other Skyrockets -- Here's Why"
SRPT,SRPT:UW,BBG000BCJC58,The Crazy Backstory Around Sarepta Therapeutics' Game-Changing Drug Approval,2016-09-30 14:28:42 +0000,http://www.fool.com/investing/2016/09/30/the-crazy-backstory-around-sarepta-therapeutics-ga.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Crazy Backstory Around Sarepta Therapeutics' Game-Changing Drug Approval
SRPT,SRPT:UW,BBG000BCJC58,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 13:13:01 +0000,http://finance.yahoo.com/news/5-top-performing-stocks-best-131301185.html,5 Top Performing Stocks of the Best ETF of Q3
SRPT,SRPT:UW,BBG000BCJC58,Close Update: Stocks Unravel as Deutsche Bank Spooks Wall Street,2016-09-29 21:01:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B_aGmyY0dDo/close-update-stocks-unravel-as-deutsche-bank-spooks-wall-street-cm686825,The Dow Jones Industrial Average limped into Thursday s close nearly 200 points lower after a report concerning Deutsche Bank DB spooked Wall Street The Dow Jones Industrial Average limped into Thursday s close nearly 200 points lower after a report concerning Deutsche Bank DB
SRPT,SRPT:UW,BBG000BCJC58,Midday Update: Wall Street Wobbles as Fed-Speak and Data Argues For Higher Rates,2016-09-29 17:41:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nsCKxsR9toc/midday-update-wall-street-wobbles-as-fed-speak-and-data-argues-for-higher-rates-cm686698,Stocks are being dragged lower with the Dow Jones Industrial Average off by more than 160 points as the fallout from Deutsche Bank DB continues to reverberate through Wall Street Stocks are being dragged lower with the Dow Jones Industrial Average off by more than 160 points as the
SRPT,SRPT:UW,BBG000BCJC58,Catabasis Skyrockets on Sarepta Partnership,2016-09-29 16:40:37 +0000,http://finance.yahoo.com/news/catabasis-skyrockets-sarepta-partnership-164037300.html,Catabasis Skyrockets on Sarepta Partnership
SRPT,SRPT:UW,BBG000BCJC58,"One Biotech Crashes, the Other Skyrockets -- Here's Why",2016-09-29 16:25:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SRhkcVl68ok/one-biotech-crashes-the-other-skyrockets-heres-why-cm686632,In a tale of two biotechs Novavax NASDAQ NVAX and Sarepta Therapeutics NASDAQ SRPT shares couldn t have taken more divergent paths recently As 160 billions of dollars in projected sales evaporated because of a key trial failure at Novavax optimism for
SRPT,SRPT:UW,BBG000BCJC58,Sarepta announces Duchenne research partnership with Cambridge's Catabasis,2016-09-29 15:34:14 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/09/sarepta-announces-duchenne-research-partnership.html?ana=yahoo,Sarepta announces Duchenne research partnership with Cambridge's Catabasis
SRPT,SRPT:UW,BBG000BCJC58,Health Care Sector Update for 09/29/2016: CATB,2016-09-29 13:41:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3J6LLA_l6Ao/health-care-sector-update-for-09292016-catb-cm686435,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 1 PFE 0 1 ABT 0 8 ABT 0 8 MRK 0 1 MRK 0 1 AMGN flatAMGN flat Health care shares were mixed in pre market trade on Thursday Health care shares were mixed in pre market trade on Thursday In health care
SRPT,SRPT:UW,BBG000BCJC58,Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy,2016-09-29 13:40:00 +0000,http://www.publicnow.com/view/151624850A4441D5E4103743FD944E743A435442,"[at noodls] - CAMBRIDGE, MA, September 29, 2016 - Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company ('Catabasis'), and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping,2016-09-29 13:40:00 +0000,http://www.publicnow.com/view/47A575EF7F2FC394EA8D85E1876324FE14847875,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 28, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III ..."
SRPT,SRPT:UW,BBG000BCJC58,Biotech Stocks Facing FDA Decision In October,2016-09-29 03:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZnJKegvZeFY/biotech-stocks-facing-fda-decision-in-october-20160929-00092,Biotech Stocks Facing FDA Decision In October
SRPT,SRPT:UW,BBG000BCJC58,"ADHD Doesn''t MEASURE Up, AMGN ARISEs To The Occasion, ITCI Misses Study Goal",2016-09-29 01:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OfY1JuLkPtY/adhd-doesnt-measure-up-amgn-arises-to-the-occasion-itci-misses-study-goal-20160929-00034,"ADHD Doesn''t MEASURE Up, AMGN ARISEs To The Occasion, ITCI Misses Study Goal"
SRPT,SRPT:UW,BBG000BCJC58,Summit (SMMT): Rare Pediatric Disease Status for DMD Drug,2016-09-28 23:21:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ohoDBxtUhhQ/summit-smmt-rare-pediatric-disease-status-for-dmd-drug-cm686274,Summit Therapeutics plc SMMT announced that it has received Rare Pediatric Disease designation from the FDA for one of its pipeline candidates ezutromid utrophin modulator for the treatment of Duchenne muscular dystrophy DMD A rare pediatric disease is one that affects less than 200
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping,2016-09-28 22:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-first-patient-220000350.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A,2016-09-28 20:21:03 +0000,http://www.investors.com/news/technology/sareptas-costly-muscular-dystrophy-drug-flirts-with-big-pharma-ma/,Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A
SRPT,SRPT:UW,BBG000BCJC58,Here’s Why These Five Stocks Are Trading Higher Today,2016-09-28 19:14:18 +0000,http://www.insidermonkey.com/blog/heres-why-these-five-stocks-are-trading-higher-today-5-477407/,Here’s Why These Five Stocks Are Trading Higher Today
SRPT,SRPT:UW,BBG000BCJC58,Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc,2016-09-28 18:22:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S_91qTkPFRY/better-buy-biomarin-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-cm686133,Image source Getty Investing in the biotech industry is risky business The majority of companies from the sector operate at a loss for years on end in the hope that they will eventually create a blockbuster drug That formula that works great when everything goes according to plan
SRPT,SRPT:UW,BBG000BCJC58,Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc,2016-09-28 16:21:00 +0000,http://www.fool.com/investing/2016/09/28/better-buy-biomarin-pharmaceuticals-inc-vs-sarepta.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc
SRPT,SRPT:UW,BBG000BCJC58,Selling Into Strength Can Be a Great Strategic Move,2016-09-28 15:15:00 +0000,http://realmoney.thestreet.com/articles/09/28/2016/selling-strength-can-be-great-strategic-move?puc=yahoo&cm_ven=YAHOO,Selling Into Strength Can Be a Great Strategic Move
SRPT,SRPT:UW,BBG000BCJC58,"RBC Capital Markets more than doubles Sarepta price target, citing 'potential for real upside'",2016-09-28 14:26:01 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=D3B4D706-A378-4ECF-9795-98806A87F5A5&siteid=yhoof2,"RBC Capital Markets more than doubles Sarepta price target, citing 'potential for real upside'"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys",2016-09-28 14:17:00 +0000,https://www.thestreet.com/story/13755087/1/sarepta-therapeutics-srpt-stock-climbs-analysts-bullish-on-exondys.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price'",2016-09-28 14:04:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/28/sarepta-yes-were-aware-our-price-target-is-50-higher-than-the-current-price/?mod=yahoobarrons&ru=yahoo,"Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price'"
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks to Avoid in Healthcare,2016-09-28 13:21:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sZ-YXVngQbk/3-stocks-to-avoid-in-healthcare-cm685768,Image source Getty Images Sometimes it can be just as important to know which stocks you shouldn t buy as it is to know which ones you should To help you separate the good from the bad we asked a team of Fools to highlight a healthcare stock they think should be avoided Read on
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Sep 28, 2016 :  GXP, ARRY, SNY, LN, BBRY, DB, SEED, TWTR, COTY, QQQ, AAPL, SRPT",2016-09-28 12:51:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/umHCRPi5m0A/pre-market-most-active-for-sep-28-2016-gxp-arry-sny-ln-bbry-db-seed-twtr-coty-qqq-aapl-srpt-cm685782,The NASDAQ 100 Pre Market Indicator is up 3 14 to 4 869 85 The total Pre Market volume is currently 8 329 979 shares traded The following are the most active stocks for the pre market session Great Plains Energy Inc GXP is 0 35 at 26 81 with 3 177 250 shares
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks to Avoid in Healthcare,2016-09-28 12:03:00 +0000,http://www.fool.com/investing/2016/09/28/3-stocks-to-avoid-in-healthcare.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks to Avoid in Healthcare
SRPT,SRPT:UW,BBG000BCJC58,Sarepta’s Manufacturing Challenge (SRPT),2016-09-27 18:47:00 +0000,http://www.investopedia.com/news/sareptas-manufacturing-challenge-srpt/?partner=YahooSA,Sarepta’s Manufacturing Challenge (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,"ARRY Hits COLUMBUS Goals, KITE Flies After-hrs, FDA Places Hold On CVM Trial",2016-09-27 02:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KUQnhvR44UY/arry-hits-columbus-goals-kite-flies-afterhrs-fda-places-hold-on-cvm-trial-20160927-00041,"ARRY Hits COLUMBUS Goals, KITE Flies After-hrs, FDA Places Hold On CVM Trial"
SRPT,SRPT:UW,BBG000BCJC58,"BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT)",2016-09-26 16:43:00 +0000,http://www.investopedia.com/news/biomarin-takes-aim-rival-sarepta-bmrn-srpt/?partner=YahooSA,"BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT)"
SRPT,SRPT:UW,BBG000BCJC58,"Why Wells Fargo, Sarepta, Delphi, UPS, and More Are Making Headlines",2016-09-26 13:56:33 +0000,http://www.insidermonkey.com/blog/why-wells-fargo-sarepta-delphi-ups-and-more-are-making-headlines-476764/,"Why Wells Fargo, Sarepta, Delphi, UPS, and More Are Making Headlines"
SRPT,SRPT:UW,BBG000BCJC58,"For Traders, Planning Is More Important Than the Plan",2016-09-25 14:00:00 +0000,http://realmoney.thestreet.com/articles/09/25/2016/traders-planning-more-important-plan?puc=yahoo&cm_ven=YAHOO,"For Traders, Planning Is More Important Than the Plan"
SRPT,SRPT:UW,BBG000BCJC58,"2 Stocks I'd Never Buy, and 1 I'll Consider",2016-09-24 17:24:27 +0000,http://www.fool.com/investing/2016/09/23/2-stocks-id-never-buy-and-1-ill-consider.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"2 Stocks I'd Never Buy, and 1 I'll Consider"
SRPT,SRPT:UW,BBG000BCJC58,The Woman Behind Sarepta Therapeutics' Success,2016-09-24 13:21:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SYjp5zhw9sI/the-woman-behind-sarepta-therapeutics-success-cm684149,Image source Getty Images The FDA finally green lighted Sarepta Therapeutics NASDAQ SRPT Duchenne muscular dystrophy drug Exondys 51 earlier this week and the company and its investors have Janet Woodcock to thank for it Woodcock is the head of the FDA s Center
SRPT,SRPT:UW,BBG000BCJC58,The Woman Behind Sarepta Therapeutics' Success,2016-09-24 11:27:55 +0000,http://www.fool.com/investing/2016/09/24/the-woman-behind-sarepta-therapeutics-success.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Woman Behind Sarepta Therapeutics' Success
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta Still Has Upside,2016-09-24 05:00:00 +0000,http://www.barrons.com/articles/after-more-than-doubling-last-week-sarepta-still-has-upside-1474693207?mod=yahoobarrons&ru=yahoo,[$$] Sarepta Still Has Upside
SRPT,SRPT:UW,BBG000BCJC58,Sarpeta Approval Challenged by FDA (SRPT),2016-09-23 22:50:00 +0000,http://www.investopedia.com/news/sarpeta-approval-challenged-fda-srpt/?partner=YahooSA,Sarpeta Approval Challenged by FDA (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,Sarpeta Raises Offering After FDA Approval (SRPT),2016-09-23 21:45:00 +0000,http://www.investopedia.com/news/sarpeta-raises-offering-after-fda-approval-srpt/?partner=YahooSA,Sarpeta Raises Offering After FDA Approval (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St",2016-09-23 21:29:38 +0000,http://biz.yahoo.com/e/160923/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St"
SRPT,SRPT:UW,BBG000BCJC58,"2 Stocks I'd Never Buy, and 1 I'll Consider",2016-09-23 19:22:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1gDLPxupH9c/2-stocks-id-never-buy-and-1-ill-consider-cm683966,Image source Getty Images Successful investing is all about separating companies that you want to own from those that you don t For that reason I find it helpful to keep a running list of stocks that I d never want to own That way I won t ever be tempted to buy them when
SRPT,SRPT:UW,BBG000BCJC58,"XBI, SRPT, BLUE, IONS: ETF Inflow Alert",2016-09-23 16:21:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4eu9Cset0OI/xbi-srpt-blue-ions-etf-inflow-alert-cm683799,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 203 3 million dollar inflow that s a 8 4 increase week over week in outstanding
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock,2016-09-22 22:31:03 +0000,http://www.publicnow.com/view/0897035EA44F781E8C54FE844AA0B232CDAE8DB8,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 22, 2016-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Proposed Public Offering of Common Stock,2016-09-22 22:31:03 +0000,http://www.publicnow.com/view/5B0724E4B27F7FC896494430503D7D80D0913C39,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 21, 2016-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock,2016-09-22 22:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-pricing-300-220000748.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 5.02 million shares of its common stock at a price to the public of $59.75 per share."
SRPT,SRPT:UW,BBG000BCJC58,3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering,2016-09-22 19:22:43 +0000,http://finance.yahoo.com/news/3-reasons-sarepta-shares-rallied-192243301.html,3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering
SRPT,SRPT:UW,BBG000BCJC58,5 Stocks With Amazon-Like Growth Potential,2016-09-22 18:22:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qr7T3Yni7Jw/5-stocks-with-amazon-like-growth-potential-cm683300,If you re looking for companies with hyper growth trajectories similar to the e commerce giant Amazon NASDAQ AMZN our Foolish contributors think these five stocks should be on your radar right now Read on to find out which growth stocks they recommend and why
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Announces Offering of Common Stock (SRPT),2016-09-22 17:36:00 +0000,http://www.investopedia.com/news/sarepta-announces-offering-common-stock-srpt/?partner=YahooSA,Sarepta Announces Offering of Common Stock (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,"Top trades for the 2nd half: BABA, SRPT & more",2016-09-22 16:59:00 +0000,http://finance.yahoo.com/video/top-trades-2nd-half-baba-165900860.html,"Top trades for the 2nd half: BABA, SRPT & more"
SRPT,SRPT:UW,BBG000BCJC58,"3 Stocks to Watch Thursday: Yahoo! Inc. (YHOO), Red Hat Inc (RHT) and Sarepta Therapeutics Inc (SRPT)",2016-09-22 15:24:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dmef3ZySxp8/3-stocks-to-watch-thursday-yahoo-inc-yhoo-red-hat-inc-rht-and-sarepta-therapeutics-inc-srpt-cm683164,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The Federal Reserve acted as U S market rocket fuel on Thursday after announcing the much expected decision not to raise interest rates this month 160 In response the S amp P 500
SRPT,SRPT:UW,BBG000BCJC58,I Am One of the Underinvested Bulls Right Now,2016-09-22 15:04:00 +0000,http://realmoney.thestreet.com/articles/09/22/2016/i-am-one-underinvested-bulls-right-now?puc=yahoo&cm_ven=YAHOO,I Am One of the Underinvested Bulls Right Now
SRPT,SRPT:UW,BBG000BCJC58,FDA Commish Says Sarepta's DMD Study Should Be Retracted,2016-09-22 14:24:24 +0000,http://finance.yahoo.com/news/fda-commish-says-sareptas-dmd-142424576.html,FDA Commish Says Sarepta's DMD Study Should Be Retracted
SRPT,SRPT:UW,BBG000BCJC58,How Sarepta Is Cashing In on Its FDA Homerun,2016-09-22 13:35:00 +0000,http://247wallst.com/healthcare-business/2016/09/22/how-sarepta-is-cashing-in-on-its-fda-homerun/,How Sarepta Is Cashing In on Its FDA Homerun
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Extending Recent Move To The Upside,2016-09-22 13:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NT_aUBxZSsA/sarepta-therapeutics-extending-recent-move-to-the-upside-20160922-00751,Sarepta Therapeutics Extending Recent Move To The Upside
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Sep 20, 2016 :  ECA, HOT, MAR, MTU, CHK, PBR, CNAT, ASNA, QQQ, WFC, SRPT, TLT",2016-09-22 12:50:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s5PB-46OO6A/pre-market-most-active-for-sep-20-2016-eca-hot-mar-mtu-chk-pbr-cnat-asna-qqq-wfc-srpt-tlt-cm682466,The NASDAQ 100 Pre Market Indicator is up 11 15 to 4 864 9 The total Pre Market volume is currently 30 619 659 shares traded The following are the most active stocks for the pre market session Encana Corporation ECA is 0 63 at 9 23 with 16 210 400 shares traded ECA
SRPT,SRPT:UW,BBG000BCJC58,"Rite Aid Corporation, WCI Communities & Other Stocks in Spotlight Following Earnings, M&A News and More",2016-09-22 12:27:55 +0000,http://www.insidermonkey.com/blog/rite-aid-corporation-wci-communities-other-stocks-in-spotlight-following-earnings-ma-news-and-more-476226/,"Rite Aid Corporation, WCI Communities & Other Stocks in Spotlight Following Earnings, M&A News and More"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Wins Favorable USPTO Decisions (SRPT),2016-09-22 00:58:00 +0000,http://www.investopedia.com/news/sarepta-wins-favorable-uspto-decisions-srpt/?partner=YahooSA,Sarepta Wins Favorable USPTO Decisions (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,"BMRN To Seek Review Of PTAB Ruling, CERC Awaits Phase 2 Data In Nov, OCRX Abuzz",2016-09-22 00:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kl_-7N_Yiuk/bmrn-to-seek-review-of-ptab-ruling-cerc-awaits-phase-2-data-in-nov-ocrx-abuzz-20160922-00007,"BMRN To Seek Review Of PTAB Ruling, CERC Awaits Phase 2 Data In Nov, OCRX Abuzz"
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta to Sell Up to $225 Million of Stock,2016-09-21 21:48:03 +0000,http://www.wsj.com/articles/sarepta-to-sell-up-to-225-million-of-stock-1474494480?mod=yahoo_hs,[$$] Sarepta to Sell Up to $225 Million of Stock
SRPT,SRPT:UW,BBG000BCJC58,"'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs",2016-09-21 20:32:58 +0000,http://www.investors.com/news/technology/blockbuster-franchises-spark-ma-fever-for-sarepta-ariad-biotechs/,"'Blockbuster Franchises' Spark M&A Fever For Sarepta, Ariad, Biotechs"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering,2016-09-21 20:17:00 +0000,https://www.thestreet.com/story/13748050/1/sarepta-srpt-stock-slides-in-after-hours-trading-on-public-offering.html?puc=yahoo&cm_ven=YAHOO,Sarepta (SRPT) Stock Slides in After-Hours Trading on Public Offering
SRPT,SRPT:UW,BBG000BCJC58,Sarepta sales slump after company announces $225 million stock offering,2016-09-21 20:16:15 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CAAA1BA6-0D24-4AE0-A79A-7AA32BB60560&siteid=yhoof2,Sarepta sales slump after company announces $225 million stock offering
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Proposed Public Offering of Common Stock,2016-09-21 20:00:00 +0000,http://finance.yahoo.com/news/sarepta-therapeutics-announces-proposed-public-200000098.html,"[Business Wire] - Sarepta Therapeutics, Inc. , a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in an underwritten public offering."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's New Drug May Make It a Takeover (SRPT),2016-09-21 18:26:00 +0000,http://www.investopedia.com/news/sareptas-new-drug-may-make-it-takeover-srpt/?partner=YahooSA,Sarepta's New Drug May Make It a Takeover (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,Sarepta to Sell Up to $225 Million of Stock,2016-09-21 18:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hLtJ-7DErmo/sarepta-to-sell-up-to-225-million-of-stock-20160921-01016,Sarepta to Sell Up to $225 Million of Stock
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action,2016-09-21 17:34:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/21/sarepta-therapeutics-biomarin-still-wants-a-piece-of-the-action/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action
SRPT,SRPT:UW,BBG000BCJC58,​Sarepta to open Andover manufacturing site soon,2016-09-21 15:58:33 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/09/sarepta-to-open-andover-manufacturing-site-soon.html?ana=yahoo,​Sarepta to open Andover manufacturing site soon
SRPT,SRPT:UW,BBG000BCJC58,Patent Trial And Appeal Board Hands Sarepta Another Big Win,2016-09-21 15:50:39 +0000,http://finance.yahoo.com/news/patent-trial-appeal-board-hands-155039798.html,Patent Trial And Appeal Board Hands Sarepta Another Big Win
SRPT,SRPT:UW,BBG000BCJC58,"Billionaires Have Been Raising Cash In Their Portfolios, Should You?",2016-09-21 14:23:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XHXlmDxCqlY/billionaires-have-been-raising-cash-in-their-portfolios-should-you-cm680773,By Gary Gordon ByGary Gordon According to a Wealth X census the world s billionaires have roughly 22 2 of their total net worth in cash That s the highest percentage since tracking began in 2010 According to aWealth X census the world s billionaires have roughly 22 2 of their
SRPT,SRPT:UW,BBG000BCJC58,"Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug",2016-09-21 12:39:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-tobira-soars-123912296.html,"Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug"
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers",2016-09-21 12:31:54 +0000,http://biz.yahoo.com/e/160921/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers"
SRPT,SRPT:UW,BBG000BCJC58,"At $300,000 a year, Sarepta’s new drug is considered a steal",2016-09-21 12:23:34 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=28444748-7F2E-11E6-A7FF-693D6A707F68&siteid=yhoof2,"At $300,000 a year, Sarepta’s new drug is considered a steal"
SRPT,SRPT:UW,BBG000BCJC58,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT",2016-09-21 02:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AYXMV9I-zTU/mstx-crashes-on-epic-data-mirn-ditches-mrx34-more-good-news-from-srpt-20160921-00036,"MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT"
SRPT,SRPT:UW,BBG000BCJC58,FDA Approval Leads 75% Rise in Sarepta (SRPT),2016-09-20 23:58:00 +0000,http://www.investopedia.com/news/fda-approval-leads-75-rise-sarepta-srpt/?partner=YahooSA,FDA Approval Leads 75% Rise in Sarepta (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,Biotech ETF At Best Level Since January; Are You Braced For Bumps?,2016-09-20 22:20:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wZc1kAUU_Vs/biotech-etf-at-best-level-since-january-are-you-braced-for-bumps-cm681987,Major index ETFs finished flat 160 Tuesday as investors shrugged off weak housing data and awaited the Federal Reserve s decision on interest rates Biotechnology 160 exchange traded funds rose and 160 health care led advancing S amp P 500 sectors Shares of Sarepta
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Favorable USPTO Decisions in Exon 51 and Exon 53 Composition of Matter Patent Interference Cases against BioMarin Pharmaceutical,2016-09-20 21:28:09 +0000,http://www.publicnow.com/view/0E27D2E8BEA1AB9309D2FC8F0ABB65AC2C6F52F1,"[at noodls] - Final refusal of BioMarin's interfering claims facilitates commercialization of EXONDYS 51™ (eteplirsen) in US Key patent protection for EXONDYS 51 and SRP-4053 remains valid CAMBRIDGE, Mass.--(BUSINESS ..."
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-09-20 21:25:46 +0000,http://biz.yahoo.com/e/160920/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
SRPT,SRPT:UW,BBG000BCJC58,"Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday",2016-09-20 21:21:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0JuBz0Ml1Zk/why-ptc-therapeutics-inc-gave-back-as-much-as-10-on-tuesday-cm682273,Image source Getty Images What happened Shares of PTC Therapeutics NASDAQ PTCT a biopharmaceutical company focused on the development of small molecule drugs that target post transcriptional control processes tumbled as much as 10 Tuesday after an analyst at
SRPT,SRPT:UW,BBG000BCJC58,Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm,2016-09-20 20:52:44 +0000,http://www.investors.com/research/ibd-industry-themes/biotech-stocks-stay-hot-as-sarepta-drug-approval-gives-shot-in-arm/,Biotechs Still Hot As Sarepta Drug Approval Provides A Shot In Arm
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Muscular Dystrophy Drug Will Cost $300K; Acquisition Target?,2016-09-20 20:38:23 +0000,http://www.investors.com/news/technology/sarepta-muscular-dystrophy-drug-will-cost-300k-acquisition-target/,Sarepta Muscular Dystrophy Drug Will Cost $300K; Acquisition Target?
SRPT,SRPT:UW,BBG000BCJC58,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy",2016-09-20 20:21:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YawhPysiZmE/forget-sarepta-therapeutics-here-are-3-other-biotech-stocks-to-buy-cm682236,Image source Stockmonkeys com via Flickr When the FDA approved 160 Sarepta Therapeutics NASDAQ SRPT controversial Duchenne muscular dystrophy drug Exondys 51 it caused shares in the company to surge 74 a market cap of 2 4 billion may fairly value it now If so
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta jumps after drugs regulator boost,2016-09-20 20:11:39 +0000,"http://www.ft.com/cms/s/6999827a-7f4d-11e6-8e50-8ec15fb462f4,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Wall Street's bull camp on Sarepta Therapeutics grew on Tuesday, a day after the US drugs regulator approved its treatment for a rare and fatal childhood muscle disorder. Sarepta shares climbed 13.9 per ..."
SRPT,SRPT:UW,BBG000BCJC58,"Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday",2016-09-20 20:07:06 +0000,http://www.fool.com/investing/2016/09/20/why-ptc-therapeutics-inc-gave-back-as-much-as-10-o.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday"
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta Soars 100% in a Week Yet Remains a Buy,2016-09-20 19:12:00 +0000,http://www.barrons.com/articles/sarepta-soars-100-in-a-week-yet-remains-a-buy-1474398772?mod=yahoobarrons&ru=yahoo,[$$] Sarepta Soars 100% in a Week Yet Remains a Buy
SRPT,SRPT:UW,BBG000BCJC58,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy",2016-09-20 19:01:06 +0000,http://www.fool.com/investing/2016/09/20/forget-sarepta-therapeutics-here-are-3-other-biote.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy"
SRPT,SRPT:UW,BBG000BCJC58,"Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again",2016-09-20 18:22:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HKw5xnr16JM/heres-why-sarepta-therapeutics-incs-stock-is-jumping-again-cm682187,Image source Getty Images What happened Investors in Sarepta Therapeutics NASDAQ SRPT are having another great day Shares of the rare disease focused biotech are up more than 12 as of 11 50 a m EDT Tuesday in the wake of catching a handful of analyst upgrades So
SRPT,SRPT:UW,BBG000BCJC58,Was Sarepta's Big Win a Big Mistake for the FDA?,2016-09-20 18:22:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zi6Ie6Hr4Ms/was-sareptas-big-win-a-big-mistake-for-the-fda-cm682186,Image source Getty Images On Monday the FDA approved the first ever treatment for Duchenne muscular dystrophy DMD 160 a rare but crippling disease 160 The highly anticipated decision brought a moment of euphoria for DMD patients and their families But they re not the only
SRPT,SRPT:UW,BBG000BCJC58,"Tuesday's ETF Movers: XBI, ITB",2016-09-20 18:20:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wivqnvesik0/tuesdays-etf-movers-xbi-itb-cm682171,In trading on Tuesday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 2 6 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics SRPT up about 13 1 and shares of Puma Biotechnology PBYI up about 9 7 on
SRPT,SRPT:UW,BBG000BCJC58,Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?,2016-09-20 18:17:07 +0000,http://www.fool.com/investing/2016/09/20/does-sarepta-therapeuticss-fda-win-make-shares-a-b.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?
SRPT,SRPT:UW,BBG000BCJC58,Was Sarepta's Big Win a Big Mistake for the FDA?,2016-09-20 17:49:12 +0000,http://www.fool.com/investing/2016/09/20/was-sareptas-big-win-a-big-mistake-for-the-fda.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Was Sarepta's Big Win a Big Mistake for the FDA?
SRPT,SRPT:UW,BBG000BCJC58,Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?,2016-09-20 17:22:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CVUJmQzjO2s/does-sarepta-therapeutics-incs-fda-win-make-shares-a-buy-cm682141,Image source Getty Images It s been a long 160 and winding road for investors in Sarepta Therapeutics NASDAQ SRPT but shareholders who stuck with the company through thick and thin finally have been rewarded for their patience In a move that stunned the markets the Food
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug,2016-09-20 16:25:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ftq01yLcFy4/sarepta-stock-nearly-doubles-on-fda-approval-for-dmd-drug-cm682077,Shares of Sarepta Therapeutics Inc SRPT shot up 73 9 on Monday after the company announced that it has received accelerated approval for its Duchenne muscular dystrophy DMD drug Exondys 51 eteplirsen in the U S Sarepta s shares hit a new 52 week high of 56 18 on Monday
SRPT,SRPT:UW,BBG000BCJC58,"Company News for September 20, 2016",2016-09-20 16:25:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yHlHNuaOcFQ/company-news-for-september-20-2016-cm682064,Shares of Infoblox Inc BLOX climbed 15 4 on news that Vista Equity Partners Management decided to buy the company for 1 6 billion Avnet Inc s AVT shares gained 6 8 following news that its technology solutions business will be acquired by Tech Data Corp TECD for 2
SRPT,SRPT:UW,BBG000BCJC58,"Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again",2016-09-20 16:22:03 +0000,http://www.fool.com/investing/2016/09/20/heres-why-sarepta-therapeutics-incs-stock-is-jumpi.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta shares jump 13%, extending Monday's surge on drug approval",2016-09-20 15:46:47 +0000,http://www.cnbc.com/id/103954117?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103954117,"Sarepta shares jump 13%, extending Monday's surge on drug approval"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Shares Buoyed by RBC Upgrade,2016-09-20 15:44:00 +0000,http://www.thestreet.com/video/13746000/sarepta-therapeutics-shares-buoyed-by-rbc-upgrade.html?puc=yahoov&cm_ven=YAHOOV,Sarepta Therapeutics Shares Buoyed by RBC Upgrade
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Approval is Good News for BioMarin, Alexion",2016-09-20 15:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/20/why-sarepta-approval-is-good-news-for-biomarin-alexion/?mod=yahoobarrons&ru=yahoo,"Why Sarepta Approval is Good News for BioMarin, Alexion"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics (SRPT) Stock Surges, Cowen Upgrades on FDA Drug Approval",2016-09-20 15:26:00 +0000,https://www.thestreet.com/story/13746003/1/sarepta-therapeutics-srpt-stock-surges-cowen-upgrades-on-fda-drug-approval.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Therapeutics (SRPT) Stock Surges, Cowen Upgrades on FDA Drug Approval"
SRPT,SRPT:UW,BBG000BCJC58,​FDA grants accelerated approval to Sarepta’s Duchenne drug,2016-09-20 15:24:57 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/09/fda-grants-accelerated-approval-to-sarepta-s.html?ana=yahoo,​FDA grants accelerated approval to Sarepta’s Duchenne drug
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform",2016-09-20 15:24:03 +0000,http://finance.yahoo.com/news/sarepta-prices-newly-approved-dmd-152403160.html,"Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform"
SRPT,SRPT:UW,BBG000BCJC58,2022 Will Bring New Questions For Sarepta; Jefferies Raises Price Target From $7 To $50,2016-09-20 14:57:58 +0000,http://finance.yahoo.com/news/2022-bring-questions-sarepta-jefferies-145758141.html,2022 Will Bring New Questions For Sarepta; Jefferies Raises Price Target From $7 To $50
SRPT,SRPT:UW,BBG000BCJC58,"Company News for September 20, 2016",2016-09-20 14:25:02 +0000,http://finance.yahoo.com/news/company-news-september-20-2016-142502745.html,"Company News for September 20, 2016"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug,2016-09-20 14:13:02 +0000,http://finance.yahoo.com/news/sarepta-stock-nearly-doubles-fda-141302133.html,Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
SRPT,SRPT:UW,BBG000BCJC58,Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA,2016-09-20 13:51:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/20/puma-biotechnology-sarepta-isnt-the-only-biotech-getting-a-boost-from-the-fda/?mod=yahoobarrons&ru=yahoo,Puma Biotechnology: Sarepta Isn't the Only Biotech Getting a Boost From the FDA
SRPT,SRPT:UW,BBG000BCJC58,Stocks Open Higher; Housing Starts Miss Views,2016-09-20 13:42:33 +0000,http://www.investors.com/market-trend/stock-market-today/stock-futures-take-a-soft-bounce-lennar-up-on-q3-beat/,Stocks Open Higher; Housing Starts Miss Views
SRPT,SRPT:UW,BBG000BCJC58,Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA,2016-09-20 13:17:00 +0000,http://www.forbes.com/sites/matthewherper/2016/09/20/approving-a-muscular-dystrophy-drug-ignites-civil-war-at-the-fda/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Approving A Muscular Dystrophy Drug Ignites A Civil War At The FDA
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Sep 20, 2016 :  ECA, CHK, CNAT, SRPT, ASNA, F, TLT, QQQ, AAPL, DB, TTM, TSE",2016-09-20 13:00:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yQUI_7ASWMM/pre-market-most-active-for-sep-20-2016-eca-chk-cnat-srpt-asna-f-tlt-qqq-aapl-db-ttm-tse-cm681735,The NASDAQ 100 Pre Market Indicator is up 5 09 to 4 801 16 The total Pre Market volume is currently 10 113 538 shares traded The following are the most active stocks for the pre market session Encana Corporation ECA is 0 67 at 9 19 with 7 287 622 shares traded ECA
SRPT,SRPT:UW,BBG000BCJC58,"Top Analyst Upgrades and Downgrades: American Electric Power, Broadcom, Ford, GM, JD.com, Sarepta, Valeant Pharmaceuticals and More",2016-09-20 12:45:13 +0000,http://247wallst.com/investing/2016/09/20/top-analyst-upgrades-and-downgrades-american-electric-power-broadcom-ford-gm-jd-com-sarepta-valeant-pharmaceuticals-and-more/,"Top Analyst Upgrades and Downgrades: American Electric Power, Broadcom, Ford, GM, JD.com, Sarepta, Valeant Pharmaceuticals and More"
SRPT,SRPT:UW,BBG000BCJC58,Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition,2016-09-20 10:55:00 +0000,https://www.thestreet.com/story/13745109/1/biotech-stock-mailbag-sarepta-therapeutics-approval-edition.html?puc=yahoo&cm_ven=YAHOO,Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition
SRPT,SRPT:UW,BBG000BCJC58,"Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics",2016-09-20 10:00:00 +0000,https://www.thestreet.com/story/13672648/1/jim-cramer-s-top-takeaways-anadarko-petroleum-coach-seres-therapeutics.html?puc=yahoo&cm_ven=YAHOO,"Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics"
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Soars to 150% Q3 Gains, Wal-Mart Closes Jet Deal, SeaWorld Sinks & More",2016-09-20 06:07:28 +0000,http://www.insidermonkey.com/blog/sarepta-soars-to-150-q3-gains-wal-mart-closes-jet-deal-seaworld-sinks-more-475618/,"Sarepta Soars to 150% Q3 Gains, Wal-Mart Closes Jet Deal, SeaWorld Sinks & More"
SRPT,SRPT:UW,BBG000BCJC58,U.S. Stocks Rise as Investors Watch Central Banks,2016-09-20 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TuJUejT39Q8/us-stocks-rise-as-investors-watch-central-banks-20160920-00228,U.S. Stocks Rise as Investors Watch Central Banks
SRPT,SRPT:UW,BBG000BCJC58,U.S. Stocks Inch Up as Investors Watch Central Banks,2016-09-20 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jeTlRmh2cbE/us-stocks-inch-up-as-investors-watch-central-banks-20160920-00599,U.S. Stocks Inch Up as Investors Watch Central Banks
SRPT,SRPT:UW,BBG000BCJC58,[$$] FDA Approves Sarepta’s Muscular Dystrophy Drug,2016-09-20 04:18:45 +0000,http://www.wsj.com/articles/sarepta-wins-fda-approval-for-duchenne-drug-1474297124?ru=yahoo?mod=yahoo_itp,[$$] FDA Approves Sarepta’s Muscular Dystrophy Drug
SRPT,SRPT:UW,BBG000BCJC58,[$$] The Boys Who Beat the FDA,2016-09-20 04:18:39 +0000,http://www.wsj.com/articles/the-boys-who-beat-the-fda-1474328940?ru=yahoo?mod=yahoo_itp,[$$] The Boys Who Beat the FDA
SRPT,SRPT:UW,BBG000BCJC58,Fierce FDA Debate Rages on Whether Drug OK Sets New Standard,2016-09-20 04:00:00 +0000,http://www.bloomberg.com/news/articles/2016-09-20/fierce-debate-at-fda-on-whether-drug-decision-sets-new-standard?cmpid=yhoo.headline,Fierce FDA Debate Rages on Whether Drug OK Sets New Standard
SRPT,SRPT:UW,BBG000BCJC58,"VICL Slumps, FDA Greenlights SRPT's DMD Drug, Domino Effect On PTCT",2016-09-20 02:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9MNsC7JagWY/vicl-slumps-fda-greenlights-srpts-dmd-drug-domino-effect-on-ptct-20160920-00008,"VICL Slumps, FDA Greenlights SRPT's DMD Drug, Domino Effect On PTCT"
SRPT,SRPT:UW,BBG000BCJC58,"VICL Slumps, FDA Greenlights SRPT's DMD Drug, Domino Effect On PTCT",2016-09-20 02:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2amZ7rYDnWI/vicl-slumps-fda-greenlights-srpts-dmd-drug-domino-effect-on-ptct-20160920-00709,"VICL Slumps, FDA Greenlights SRPT's DMD Drug, Domino Effect On PTCT"
SRPT,SRPT:UW,BBG000BCJC58,Why PTC Therapeutics Shares Skyrocketed 20.6% Today,2016-09-20 01:20:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vxL_tif388s/why-ptc-therapeutics-shares-skyrocketed-206-today-cm681662,Image source PTC Therapeutics What happened After competitor Sarepta Therapeutics NASDAQ SRPT won early approval of Exondys 51 a drug for Duchenne muscular dystrophy DMD investors sent 160 PTC Therapeutics NASDAQ PTCT 160 shares soaring 20 6 today So
SRPT,SRPT:UW,BBG000BCJC58,Why PTC Therapeutics Shares Skyrocketed 20.6% Today,2016-09-20 00:01:34 +0000,http://www.fool.com/investing/2016/09/19/why-ptc-therapeutics-shares-skyrocketed-206-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why PTC Therapeutics Shares Skyrocketed 20.6% Today
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Soared 74% Today,2016-09-19 23:21:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DwIO7N00hMo/why-sarepta-therapeutics-soared-74-today-cm681647,Image source Flickr Steve Jurvetson What happened After a comprehensive and at times contentious review process the FDA has given Sarepta Therapeutics NASDAQ SRPT 160 a green light to begin marketing Exondys 51 to Duchenne muscular dystrophy or DMD patients The news
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Pharmaceuticals, Tech Data, and Cliffs Natural Resources Jumped Today",2016-09-19 23:20:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w2z7tRnJClc/why-sarepta-pharmaceuticals-tech-data-and-cliffs-natural-resources-jumped-today-cm681633,Image source Cliffs Natural Resources The stock market got off to a good start on Monday although the day s gains evaporated throughout the trading session to leave major market benchmarks unchanged by the market close For the most part investors have appeared reluctant to
SRPT,SRPT:UW,BBG000BCJC58,"Why Infoblox Inc (BLOX), Isle of Capri Casinos (ISLE) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Best Stocks",2016-09-19 23:20:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5VrAkVfv_U4/why-infoblox-inc-blox-isle-of-capri-casinos-isle-and-sarepta-therapeutics-inc-srpt-are-3-of-todays-best-stocks-cm681632,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Ahead of some big central bank meetings later this week including the Federal Reserve on Wednesday it was not surprising to see stocks start the week in sluggish fashion
SRPT,SRPT:UW,BBG000BCJC58,Cramer Remix: Another speculative biotech with tremendous...,2016-09-19 23:00:00 +0000,http://finance.yahoo.com/video/cramer-remix-another-speculative-biotech-230000729.html,Cramer Remix: Another speculative biotech with tremendous...
SRPT,SRPT:UW,BBG000BCJC58,How To Predict The Next Sarepta (FDA Approval Stock) And Win Big,2016-09-19 22:56:00 +0000,http://www.forbes.com/sites/bryanrich/2016/09/19/how-to-predict-the-next-sarepta-fda-approval-stock-and-win-big/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,How To Predict The Next Sarepta (FDA Approval Stock) And Win Big
SRPT,SRPT:UW,BBG000BCJC58,FDA Grants Accelerated Approval To Sarepta' Drug For Duchenne Muscular Dystrophy,2016-09-19 22:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zoocZX9ij58/fda-grants-accelerated-approval-to-sarepta-drug-for-duchenne-muscular-dystrophy-20160919-01249,FDA Grants Accelerated Approval To Sarepta' Drug For Duchenne Muscular Dystrophy
SRPT,SRPT:UW,BBG000BCJC58,FDA Grants Accelerated Approval To Sarepta' Drug For Duchenne Muscular Dystrophy,2016-09-19 22:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PAaNPZKRZjM/fda-grants-accelerated-approval-to-sarepta-drug-for-duchenne-muscular-dystrophy-20160919-01115,FDA Grants Accelerated Approval To Sarepta' Drug For Duchenne Muscular Dystrophy
SRPT,SRPT:UW,BBG000BCJC58,"Final Trade: GM, SRPT & more",2016-09-19 21:59:00 +0000,http://finance.yahoo.com/video/final-trade-gm-srpt-more-215900883.html,"Final Trade: GM, SRPT & more"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's big FDA win,2016-09-19 21:51:00 +0000,http://finance.yahoo.com/video/sareptas-big-fda-win-215100535.html,Sarepta's big FDA win
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Pharmaceuticals, Tech Data, and Cliffs Natural Resources Jumped Today",2016-09-19 21:46:05 +0000,http://www.fool.com/investing/2016/09/19/why-sarepta-pharmaceuticals-tech-data-and-cliffs-n.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Sarepta Pharmaceuticals, Tech Data, and Cliffs Natural Resources Jumped Today"
SRPT,SRPT:UW,BBG000BCJC58,Cause For Celebration In The Duchenne Muscular Dystrophy Community,2016-09-19 21:30:00 +0000,http://www.forbes.com/sites/kenkam/2016/09/19/cause-for-celebration-in-the-duchenne-muscular-dystrophy-community/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Cause For Celebration In The Duchenne Muscular Dystrophy Community
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Soared 74% Today,2016-09-19 21:29:40 +0000,http://www.fool.com/investing/2016/09/19/why-sarepta-therapeutics-soared-74-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Sarepta Therapeutics Soared 74% Today
SRPT,SRPT:UW,BBG000BCJC58,[$$] FDA Approves Sarepta's Dystrophy Drug,2016-09-19 21:15:54 +0000,http://www.wsj.com/articles/sarepta-wins-fda-approval-for-duchenne-drug-1474297124?mod=yahoo_hs,[$$] FDA Approves Sarepta's Dystrophy Drug
SRPT,SRPT:UW,BBG000BCJC58,Sarepta shares leap 90% after FDA approves drug,2016-09-19 21:04:45 +0000,http://www.cnbc.com/id/103950615?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103950615,Sarepta shares leap 90% after FDA approves drug
SRPT,SRPT:UW,BBG000BCJC58,Close Update: Stocks Return Gains as Oil Falls Off Highs,2016-09-19 21:00:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uR7FUSdov6I/close-update-stocks-return-gains-as-oil-falls-off-highs-cm681597,Stocks gave back all of Monday s gains and closed in the red for a second day as oil retreated off its intra day high and as investors braced for Wednesday s Federal Open Market Committee decision After last week s underwhelming consumer spending and inflation data Wall Street is betting
SRPT,SRPT:UW,BBG000BCJC58,Biotech stock explodes 73% after the FDA approves the first drug to treat a rare muscle disorder,2016-09-19 20:34:00 +0000,http://finance.yahoo.com/news/biotech-stock-explodes-80-fda-141141554.html,Biotech stock explodes 73% after the FDA approves the first drug to treat a rare muscle disorder
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Stock Soars On FDA OK For Muscular Dystrophy Drug,2016-09-19 20:10:18 +0000,http://www.investors.com/news/technology/sarepta-stock-soars-on-fda-ok-for-muscular-dystrophy-drug/,Sarepta Stock Soars On FDA OK For Muscular Dystrophy Drug
SRPT,SRPT:UW,BBG000BCJC58,Biotechnology ETFs Rally on Sarepta FDA Drug Approval,2016-09-19 20:09:37 +0000,http://finance.yahoo.com/news/biotechnology-etfs-rally-sarepta-fda-200937927.html,Biotechnology ETFs Rally on Sarepta FDA Drug Approval
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta Still a Buy After Expedited FDA Approval,2016-09-19 20:05:00 +0000,http://www.barrons.com/articles/sarepta-still-a-buy-after-expedited-fda-approval-1474315522?mod=yahoobarrons&ru=yahoo,[$$] Sarepta Still a Buy After Expedited FDA Approval
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc Corporate Update on Accelerated Approval of EXONDYS 51TM Call scheduled for 4:00 pm ET today,2016-09-19 20:00:00 +0000,http://biz.yahoo.com/cc/7/153807.html,Sarepta Therapeutics Inc Corporate Update on Accelerated Approval of EXONDYS 51TM Call scheduled for 4:00 pm ET today
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's very good day,2016-09-19 18:45:00 +0000,http://finance.yahoo.com/video/sareptas-very-good-day-184500661.html,Sarepta's very good day
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval,2016-09-19 18:27:35 +0000,http://finance.yahoo.com/news/sarepta-analysts-turn-bullish-duchenne-182735102.html,Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval
SRPT,SRPT:UW,BBG000BCJC58,Why the Recent Volatility Is a GOOD Thing,2016-09-19 18:21:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pyd8VVjjRpM/why-the-recent-volatility-is-a-good-thing-cm681471,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips While the recent increase in volatility has resulted in some wild trading swings the S amp P 500 is down just over 2 from its closing high Source Craig Lloyd via Flickr Modified A pullback of
SRPT,SRPT:UW,BBG000BCJC58,"Monday's ETF Movers: XBI, XLF",2016-09-19 18:19:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xw9CbZjY99Y/mondays-etf-movers-xbi-xlf-cm681457,In trading on Monday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 2 9 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics SRPT up about 89 2 and shares of Novavax NVAX up about 10 8 on the
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51",2016-09-19 17:58:02 +0000,http://www.publicnow.com/view/E29C99EBA785880E4336B7EA512D646D3E04A35D,"[at noodls] - -- EXONDYS 51™ the first DMD treatment approved in the US, targets dystrophin deficiency, the underlying cause of Duchenne -- --U.S. Commercial Launch planned to commence immediately-- --Conference call ..."
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-09-19 17:44:20 +0000,http://biz.yahoo.com/e/160919/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
SRPT,SRPT:UW,BBG000BCJC58,Short Hills Capital CIO Weiss Discusses Sarepta Therapeutic (SRPT) Stock Surge Today,2016-09-19 17:32:00 +0000,https://www.thestreet.com/story/13744431/1/short-hills-capital-cio-weiss-discusses-sarepta-therapeutic-srpt-stock-surge-today.html?puc=yahoo&cm_ven=YAHOO,Short Hills Capital CIO Weiss Discusses Sarepta Therapeutic (SRPT) Stock Surge Today
SRPT,SRPT:UW,BBG000BCJC58,Here’s Why Sarepta Therapeutics Inc Is Up 80% Today (SRPT),2016-09-19 17:21:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h8e9k2HMqHo/heres-why-sarepta-therapeutics-inc-is-up-80-today-srpt-cm681383,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Sarepta Therapeutics Inc 160 NASDAQ SRPT shot up 80 on Monday to lead just about everything else on Wall Street The catalyst for the move is the U S Food and
SRPT,SRPT:UW,BBG000BCJC58,Perceptive's Joe Edelman on Sarepta: I Always Believed Exondys Would Be Approved,2016-09-19 16:54:00 +0000,https://www.thestreet.com/story/13744432/1/perceptive-s-joe-edelman-on-sarepta-i-always-believed-exondys-would-be-approved.html?puc=yahoo&cm_ven=YAHOO,Perceptive's Joe Edelman on Sarepta: I Always Believed Exondys Would Be Approved
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta shares surge 90% on FDA approval,2016-09-19 16:53:21 +0000,"http://www.ft.com/cms/s/e26128d6-7e7e-11e6-bc52-0c7211ef3198,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - The US drugs watchdog has approved a contentious treatment for a type of Duchenne muscular dystrophy, a rare and fatal childhood disorder, sending shares in the company developing the medicine up by more ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta’s controversial Duchenne muscular dystrophy drug was contested right up to approval,2016-09-19 16:48:31 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=D8A1E762-7E75-11E6-97D7-DACB26147418&siteid=yhoof2,Sarepta’s controversial Duchenne muscular dystrophy drug was contested right up to approval
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: When Bears Become Bulls,2016-09-19 16:00:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/19/sarepta-therapeutics-when-bears-become-bulls/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: When Bears Become Bulls
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics Inc (SRPT), PTC Therapeutics, Inc. (PTCT) and More: Here’s Why These Stocks Are on Investors’ Radars Today",2016-09-19 15:45:59 +0000,http://www.insidermonkey.com/blog/sarepta-therapeutics-inc-srpt-ptc-therapeutics-inc-ptct-and-more-heres-why-these-stocks-are-on-investors-radars-today-475481/,"Sarepta Therapeutics Inc (SRPT), PTC Therapeutics, Inc. (PTCT) and More: Here’s Why These Stocks Are on Investors’ Radars Today"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch,2016-09-19 15:16:00 +0000,http://www.forbes.com/sites/arleneweintraub/2016/09/19/sarepta-wins-fda-nod-for-embattled-dmd-drug-but-with-a-catch/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Sarepta Wins FDA Nod For Embattled DMD Drug -- But With A Catch
SRPT,SRPT:UW,BBG000BCJC58,Seeing the Same Old Patterns Ahead of Fed News,2016-09-19 14:55:00 +0000,http://realmoney.thestreet.com/articles/09/19/2016/seeing-same-old-patterns-ahead-fed-news?puc=yahoo&cm_ven=YAHOO,Seeing the Same Old Patterns Ahead of Fed News
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Soars as FDA Grants Accelerate Approval,2016-09-19 14:31:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/19/sarepta-therapeutics-soars-as-fda-grants-accelerate-approval/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics Soars as FDA Grants Accelerate Approval
SRPT,SRPT:UW,BBG000BCJC58,FDA approves Sarepta drug,2016-09-19 14:18:00 +0000,http://finance.yahoo.com/video/fda-approves-sarepta-drug-141800815.html,FDA approves Sarepta drug
SRPT,SRPT:UW,BBG000BCJC58,Sarepta stock jumps 82% on approval of controversial Duchenne muscular dystrophy drug,2016-09-19 14:14:17 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=D4DB75F4-197D-4F8A-9107-828F40413514&siteid=yhoof2,Sarepta stock jumps 82% on approval of controversial Duchenne muscular dystrophy drug
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Secures FDA Approval for Duchenne Drug After Long Fight,2016-09-19 14:13:00 +0000,https://www.thestreet.com/story/13673965/1/sarepta-secures-fda-approval-for-duchenne-drug-after-long-fight.html?puc=yahoo&cm_ven=YAHOO,Sarepta Secures FDA Approval for Duchenne Drug After Long Fight
SRPT,SRPT:UW,BBG000BCJC58,Biotech stock explodes 80% after the FDA approves a key drug,2016-09-19 14:11:41 +0000,http://finance.yahoo.com/news/biotech-stock-explodes-80-fda-141141529.html,Biotech stock explodes 80% after the FDA approves a key drug
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Wins Approval for Duchenne Drug After Long FDA Review,2016-09-19 13:58:33 +0000,http://www.bloomberg.com/news/articles/2016-09-19/sarepta-wins-approval-for-duchenne-drug-after-long-fda-review?cmpid=yhoo.headline,Sarepta Wins Approval for Duchenne Drug After Long FDA Review
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Remains Sharply Higher After Early Jump,2016-09-19 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YiiZ58q_U0Q/sarepta-therapeutics-remains-sharply-higher-after-early-jump-20160919-00725,Sarepta Therapeutics Remains Sharply Higher After Early Jump
SRPT,SRPT:UW,BBG000BCJC58,FDA Approves Sarepta's Dystrophy Drug,2016-09-19 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3hl0ydXKLTM/fda-approves-sareptas-dystrophy-drug-20160919-01208,FDA Approves Sarepta's Dystrophy Drug
SRPT,SRPT:UW,BBG000BCJC58,FDA Approves Sarepta's Dystrophy Drug,2016-09-19 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7LSVv2Uj7s8/fda-approves-sareptas-dystrophy-drug-20160919-01016,FDA Approves Sarepta's Dystrophy Drug
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Has Suddenly Spiked To The Upside,2016-09-19 09:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BUeGxoNss3g/sarepta-therapeutics-srpt-has-suddenly-spiked-to-the-upside-20160919-00490,Sarepta Therapeutics (SRPT) Has Suddenly Spiked To The Upside
SRPT,SRPT:UW,BBG000BCJC58,"Why Monsanto Company (MON), Sarepta Therapeutics Inc (SRPT) and VF Corp (VFC) Are 3 of Today’s Worst Stocks",2016-09-16 17:17:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EqEaFA6dIGg/why-monsanto-company-mon-sarepta-therapeutics-inc-srpt-and-vf-corp-vfc-are-3-of-todays-worst-stocks-cm680308,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Between tepid retail sales and sub par industrial activity for August it was easy for investors to presume that even the remote possibility of a September rate hike had been
SRPT,SRPT:UW,BBG000BCJC58,Sarepta's Drug Is Stuck in the FDA Quagmire (SRPT),2016-09-16 15:22:00 +0000,http://www.investopedia.com/news/sareptas-drug-stuck-fda-quagmire-srpt/?partner=YahooSA,Sarepta's Drug Is Stuck in the FDA Quagmire (SRPT)
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Shares Soar on News of Key Drug Critic FDA Exit,2016-09-15 23:18:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d-CLSMcV7Lo/sarepta-shares-soar-on-news-of-key-drug-critic-fda-exit-cm680285,Shares of Sarepta Therapeutics Inc SRPT rose around 27 on Wed Sep 14 on news that a key critic Farkas of its lead pipeline candidate eteplirsen has left his job at the FDA raising hopes of approval of the drug The biopharmaceutical company is looking to get eteplirsen approved for
SRPT,SRPT:UW,BBG000BCJC58,"Why Apogee Enterprises, Ferrellgas Partners, and Sarepta Therapeutics Slumped Today",2016-09-15 23:17:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7M5fjaaDS74/why-apogee-enterprises-ferrellgas-partners-and-sarepta-therapeutics-slumped-today-cm680284,Thursday brought a return to volatility for the stock market but most investors were pleased with the sizable gains that they saw Hopes that the Federal Reserve would be slower to raise interest rates than many had feared were a major contributor to the improvement in sentiment
SRPT,SRPT:UW,BBG000BCJC58,"Why Apogee Enterprises, Ferrellgas Partners, and Sarepta Therapeutics Slumped Today",2016-09-15 21:54:00 +0000,http://www.fool.com/investing/2016/09/15/why-apogee-enterprises-ferrellgas-partners-and-sar.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Apogee Enterprises, Ferrellgas Partners, and Sarepta Therapeutics Slumped Today"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Shares Soar on News of Key Drug Critic FDA Exit,2016-09-15 21:18:09 +0000,http://finance.yahoo.com/news/sarepta-shares-soar-news-key-211809758.html,Sarepta Shares Soar on News of Key Drug Critic FDA Exit
SRPT,SRPT:UW,BBG000BCJC58,Aerie Pharmaceuticals Skyrockets On Eye Drug News,2016-09-15 20:42:19 +0000,http://www.investors.com/news/technology/aerie-pharmaceuticals-skyrockets-on-eye-drug-news/,Aerie Pharmaceuticals Skyrockets On Eye Drug News
SRPT,SRPT:UW,BBG000BCJC58,Here's Why Sarepta Therapeutics Inc. is Falling Today,2016-09-15 17:42:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2YnHz0ka2N0/heres-why-sarepta-therapeutics-inc-is-falling-today-cm680149,Image source Getty Images What happened Rare disease focused Sarepta Therapeutics NASDAQ SRPT fell by as much as 10 in early morning trading Thursday after a Wall Street analyst issued a bearish note on the company s stock So what Sarepta s shares
SRPT,SRPT:UW,BBG000BCJC58,Here's Why Sarepta Therapeutics Inc. is Falling Today,2016-09-15 17:02:32 +0000,http://www.fool.com/investing/2016/09/15/heres-why-sarepta-therapeutics-inc-is-falling-toda.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why Sarepta Therapeutics Inc. is Falling Today
SRPT,SRPT:UW,BBG000BCJC58,"Company News for September 15, 2016",2016-09-15 16:19:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1ghiGFLmPD0/company-news-for-september-15-2016-cm680037,160 160 160 Shares of Monsanto Co MON increased 0 6 after Bayer AG BAYN raised its offer for Monsanto to 128 per share 160 160 160 Shares of Vitae Pharmaceuticals Inc VTAE soared more than 100 after Allergan plc AGN agreed to buy Vitae
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News?",2016-09-15 15:49:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/15/sarepta-therapeutics-wait-i-thought-turmoil-at-the-fda-was-good-news/?mod=yahoobarrons&ru=yahoo,"Sarepta Therapeutics: Wait, I Thought Turmoil at the FDA Was Good News?"
SRPT,SRPT:UW,BBG000BCJC58,"Thursday’s Vital Data: Apple Inc. (AAPL), Wells Fargo & Co (WFC) and Sarepta Therapeutics Inc (SRPT)",2016-09-15 15:19:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IzfhGS3lrm0/thursdays-vital-data-apple-inc-aapl-wells-fargo-co-wfc-and-sarepta-therapeutics-inc-srpt-cm679966,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips U S stock futures are set for a sharply higher open as Wall Street looks forward to a wealth of economic data slated for release later this morning Headlining today s
SRPT,SRPT:UW,BBG000BCJC58,"Company News for September 15, 2016",2016-09-15 14:10:02 +0000,http://finance.yahoo.com/news/company-news-september-15-2016-141002007.html,"Company News for September 15, 2016"
SRPT,SRPT:UW,BBG000BCJC58,"Stocks to Watch: Pandora, Aerie, AcelRx, Sarepta, Goodyear, Apogee, GE",2016-09-15 13:28:27 +0000,http://blogs.wsj.com/moneybeat/2016/09/15/stocks-to-watch-pandora-aerie-acelrx-sarepta-goodyear-apogee-ge/?mod=yahoo_hs,"Stocks to Watch: Pandora, Aerie, AcelRx, Sarepta, Goodyear, Apogee, GE"
SRPT,SRPT:UW,BBG000BCJC58,"Top Analyst Upgrades and Downgrades: Apple, AT&T, Autodesk, Bluebird Bio, Monsanto, Sarepta and More",2016-09-15 12:55:09 +0000,http://247wallst.com/investing/2016/09/15/top-analyst-upgrades-and-downgrades-apple-att-autodesk-bluebird-bio-monsanto-sarepta-and-more/,"Top Analyst Upgrades and Downgrades: Apple, AT&T, Autodesk, Bluebird Bio, Monsanto, Sarepta and More"
SRPT,SRPT:UW,BBG000BCJC58,Does This News Make Sarepta Therapeutics a Buy?,2016-09-15 02:14:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-v1WcNnUXtI/does-this-news-make-sarepta-therapeutics-a-buy-cm679752,Image source Stockmonkeys com via Flickr Short sellers have been betting against an FDA approval of Sarepta Therapeutics NASDAQ SRPT Duchenne muscular dystrophy DMD drug eteplirsen and I can t say I blame them Sarepta Therapeutics has been hoping for accelerated
SRPT,SRPT:UW,BBG000BCJC58,Does This News Make Sarepta Therapeutics a Buy?,2016-09-15 00:40:05 +0000,http://www.fool.com/investing/2016/09/14/does-this-news-make-sarepta-therapeutics-a-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Does This News Make Sarepta Therapeutics a Buy?
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Therapeutics, Advanced Micro Devices, and Vonage Jumped Today",2016-09-15 00:18:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ANorl1hHy4U/why-sarepta-therapeutics-advanced-micro-devices-and-vonage-jumped-today-cm679699,Image source Sarepta Therapeutics The stock market took a well deserved break on Wednesday from its recent volatility trading in a fairly tight range and finishing the day with mixed results The Nasdaq Composite posted solid gains of about a third of a percent but the S amp P
SRPT,SRPT:UW,BBG000BCJC58,"Why Apple Inc. (AAPL), Sarepta Therapeutics Inc (SRPT) And Twitter Inc (TWTR) Are 3 of Today’s Best Stocks",2016-09-15 00:16:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6Kp_3HWS1hY/why-apple-inc-aapl-sarepta-therapeutics-inc-srpt-and-twitter-inc-twtr-are-3-of-todays-best-stocks-cm679645,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips With oil falling for a second day stocks joined as investors again eschewed riskier assets Bonds rose while the energy sector was the worst performing group in the U S
SRPT,SRPT:UW,BBG000BCJC58,"Close Update: Stocks Lose Early Gains as Data Deluge Looms, Oil Retreats",2016-09-14 23:34:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZDmdoeOP4mE/close-update-stocks-lose-early-gains-as-data-deluge-looms-oil-retreats-cm679632,Stocks closed mixed on Wednesday with the Dow and S amp P 500 returning early gains but the Nasdaq Composite reversing Tuesday s loss All three benchmark indices retreated from their session highs late in the day as oil extended earlier losses and investors braced for Thursday s deluge
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta Therapeutics, Advanced Micro Devices, and Vonage Jumped Today",2016-09-14 21:47:00 +0000,http://www.fool.com/investing/2016/09/14/why-sarepta-therapeutics-advanced-micro-devices-an.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Sarepta Therapeutics, Advanced Micro Devices, and Vonage Jumped Today"
SRPT,SRPT:UW,BBG000BCJC58,Why This FDA Departure Is Huge for Sarepta,2016-09-14 20:37:30 +0000,http://247wallst.com/healthcare-business/2016/09/14/why-this-fda-departure-is-huge-for-sarepta/,Why This FDA Departure Is Huge for Sarepta
SRPT,SRPT:UW,BBG000BCJC58,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar",2016-09-14 20:27:26 +0000,http://www.investors.com/research/ibd-industry-themes/bevy-of-biotech-stocks-healthy-sarepta-bluebird-exelixis-soar/,"Bevy Of Biotech Stocks Healthy; Sarepta, Bluebird, Exelixis Soar"
SRPT,SRPT:UW,BBG000BCJC58,"Watch Oracle, Casinos, Biotechs For Thursday's Investing Action Plan",2016-09-14 20:22:14 +0000,http://www.investors.com/research/investing-action-plan/watch-oracle-casinos-biotechs-for-thurdays-investing-action-plan/,"Watch Oracle, Casinos, Biotechs For Thursday's Investing Action Plan"
SRPT,SRPT:UW,BBG000BCJC58,SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen,2016-09-14 19:27:53 +0000,http://finance.yahoo.com/news/suntrust-sarepta-therapeutics-fda-likely-192753383.html,SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics shares jump on news of critic’s departure from FDA,2016-09-14 19:02:53 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=57ECEA36-7A6F-11E6-AA97-CF05589A95D8&siteid=yhoof2,Sarepta Therapeutics shares jump on news of critic’s departure from FDA
SRPT,SRPT:UW,BBG000BCJC58,4 Big Stocks to Add to Your Buy List -- Plus 3 to Avoid,2016-09-14 18:09:00 +0000,https://www.thestreet.com/story/13733520/1/4-big-stocks-to-add-to-your-buy-list-plus-3-to-avoid.html?puc=yahoo&cm_ven=YAHOO,4 Big Stocks to Add to Your Buy List -- Plus 3 to Avoid
SRPT,SRPT:UW,BBG000BCJC58,[$$] Sarepta Rally Has Legs as FDA Critic Leaves Agency,2016-09-14 17:59:00 +0000,http://www.barrons.com/articles/sarepta-rally-has-legs-as-fda-critic-leaves-agency-1473874326?mod=yahoobarrons&ru=yahoo,[$$] Sarepta Rally Has Legs as FDA Critic Leaves Agency
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics' Shares Are Skyrocketing 25% Today,2016-09-14 17:46:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jtt38RSGR0I/why-sarepta-therapeutics-shares-are-skyrocketing-25-today-cm679522,Image source Getty Images What happened Optimism that the departure of Ronald Farkas from the FDA 160 will clear a path to an important drug approval has sent Sarepta Therapeutics NASDAQ SRPT 160 shares soaring 25 as of 12 15 p m EDT So what In April a key
SRPT,SRPT:UW,BBG000BCJC58,"Wednesday Sector Leaders: Biotechnology, Drugs",2016-09-14 17:46:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-LxdYAC7uGI/wednesday-sector-leaders-biotechnology-drugs-cm679535,In trading on Wednesday biotechnology shares were relative leaders up on the day by about 2 2 Leading the group were shares of Vitae Pharmaceuticals up about 158 and shares of Sarepta Therapeutics up about 22 8 on the day Also showing relative strength are drugs shares up on the
SRPT,SRPT:UW,BBG000BCJC58,"Wednesday's ETF Movers: XBI, XOP",2016-09-14 17:45:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9CB9WPSnDQ/wednesdays-etf-movers-xbi-xop-cm679523,In trading on Wednesday the SPDR S amp P Biotech ETF is outperforming other ETFs up about 1 9 on the day Components of that ETF showing particular strength include shares of Sarepta Therapeutics up about 24 7 and shares of Exelixis up about 5 5 on the day And underperforming
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Drug Critic Departs FDA, Raising Hope for Approval",2016-09-14 16:55:00 +0000,https://www.thestreet.com/story/13728022/1/sarepta-drug-critic-departs-fda-raising-hope-for-approval.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Drug Critic Departs FDA, Raising Hope for Approval"
SRPT,SRPT:UW,BBG000BCJC58,"4 Stocks, 4 trades: F, CBRL & more",2016-09-14 16:50:00 +0000,http://finance.yahoo.com/video/4-stocks-4-trades-f-165000465.html,"4 Stocks, 4 trades: F, CBRL & more"
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics' Shares Are Skyrocketing 25% Today,2016-09-14 16:35:14 +0000,http://www.fool.com/investing/2016/09/14/why-sarepta-therapeutics-shares-are-skyrocketing-2.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Sarepta Therapeutics' Shares Are Skyrocketing 25% Today
SRPT,SRPT:UW,BBG000BCJC58,"Why Sarepta, Glu Mobile, Harmony Gold and 2 Other Stocks Are On The Move Today",2016-09-14 16:08:15 +0000,http://www.insidermonkey.com/blog/why-sarepta-glu-mobile-harmony-gold-and-2-other-stocks-are-on-the-move-today-474605/,"Why Sarepta, Glu Mobile, Harmony Gold and 2 Other Stocks Are On The Move Today"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics spike amid news of critic's FDA departure,2016-09-14 15:21:59 +0000,http://www.cnbc.com/id/103939579?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103939579,Sarepta Therapeutics spike amid news of critic's FDA departure
SRPT,SRPT:UW,BBG000BCJC58,Jim Cramer -- Sarepta May Finally Have Some Good News,2016-09-14 14:14:00 +0000,https://www.thestreet.com/story/13728616/1/jim-cramer-sarepta-may-finally-have-some-good-news.html?puc=yahoo&cm_ven=YAHOO,Jim Cramer -- Sarepta May Finally Have Some Good News
SRPT,SRPT:UW,BBG000BCJC58,Farkas' FDA Departure Could Signal 'Imminent Decision' For Eteplirsen,2016-09-14 14:08:52 +0000,http://finance.yahoo.com/news/farkas-fda-departure-could-signal-140852106.html,Farkas' FDA Departure Could Signal 'Imminent Decision' For Eteplirsen
SRPT,SRPT:UW,BBG000BCJC58,"Stocks Edge Higher; Apple, Macy's, Sarepta Rise",2016-09-14 14:00:56 +0000,http://www.investors.com/market-trend/stock-market-today/stock-futures-bounce-early-risers-apple-macys-sarepta/,"Stocks Edge Higher; Apple, Macy's, Sarepta Rise"
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Has Soared 20%,2016-09-14 13:58:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/14/why-sarepta-therapeutics-has-soared-20/?mod=yahoobarrons&ru=yahoo,Why Sarepta Therapeutics Has Soared 20%
SRPT,SRPT:UW,BBG000BCJC58,Cramer's Mad Dash: Sarepta surges,2016-09-14 13:22:00 +0000,http://finance.yahoo.com/video/cramers-mad-dash-sarepta-surges-132200616.html,Cramer's Mad Dash: Sarepta surges
SRPT,SRPT:UW,BBG000BCJC58,JMP On Sarepta: 'We Maintain Our 10% Chance Of First-Cycle Approval For Eteplirsen',2016-09-14 12:56:26 +0000,http://finance.yahoo.com/news/jmp-sarepta-maintain-10-chance-125626493.html,JMP On Sarepta: 'We Maintain Our 10% Chance Of First-Cycle Approval For Eteplirsen'
SRPT,SRPT:UW,BBG000BCJC58,"Pre-Market Most Active for Sep 14, 2016 :  MON, F, AZN, MT, AEG, VTAE, AAPL, FCX, XIV, SRPT, QQQ, TVIX",2016-09-14 12:55:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tpZlu6QtADE/pre-market-most-active-for-sep-14-2016-mon-f-azn-mt-aeg-vtae-aapl-fcx-xiv-srpt-qqq-tvix-cm679230,The NASDAQ 100 Pre Market Indicator is up 10 53 to 4 733 37 The total Pre Market volume is currently 12 147 057 shares traded The following are the most active stocks for the pre market session Monsanto Company MON is 0 35 at 106 45 with 4 494 093 shares traded
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Soars After FDA Staffer’s Exit Lifts Approval Hopes,2016-09-14 11:49:07 +0000,http://www.bloomberg.com/news/articles/2016-09-14/sarepta-soars-after-reports-of-fda-drug-reviewer-s-departure?cmpid=yhoo.headline,Sarepta Soars After FDA Staffer’s Exit Lifts Approval Hopes
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc. (SRPT) Is Rising On Hopes For Ateplirsen Approval,2016-09-14 09:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0kDkf7HMp-8/sarepta-therapeutics-inc-srpt-is-rising-on-hopes-for-ateplirsen-approval-20160914-00593,Sarepta Therapeutics Inc. (SRPT) Is Rising On Hopes For Ateplirsen Approval
SRPT,SRPT:UW,BBG000BCJC58,What's driving biotech?,2016-09-12 19:43:00 +0000,http://finance.yahoo.com/video/whats-driving-biotech-194300495.html,What's driving biotech?
SRPT,SRPT:UW,BBG000BCJC58,5 Questions and Answers Take a Measure of Biotech Investor Sentiment,2016-09-12 12:35:00 +0000,https://www.thestreet.com/story/13702897/1/five-questions-and-answers-take-a-measure-of-biotech-investor-sentiment.html?puc=yahoo&cm_ven=YAHOO,5 Questions and Answers Take a Measure of Biotech Investor Sentiment
SRPT,SRPT:UW,BBG000BCJC58,3 All-or-Nothing Biotechs I'm Watching Like a Hawk,2016-09-12 12:24:20 +0000,http://www.fool.com/investing/2016/09/11/3-all-or-nothing-biotechs-im-watching-like-a-hawk.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 All-or-Nothing Biotechs I'm Watching Like a Hawk
SRPT,SRPT:UW,BBG000BCJC58,3 All-or-Nothing Biotechs I'm Watching Like a Hawk,2016-09-11 13:30:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HFGYnW_YJeU/3-all-or-nothing-biotechs-im-watching-like-a-hawk-cm677438,Image source Getty Images Every small cap biotech stock whose future depends on the success of a single compound will eventually face a binary event Whether that event is the release of data from an important clinical trial or a yes no decision from regulators a single news item
SRPT,SRPT:UW,BBG000BCJC58,Cramer: One of the highest risk stocks in the world,2016-09-08 23:18:49 +0000,http://www.cnbc.com/id/103925062?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103925062,Cramer: One of the highest risk stocks in the world
SRPT,SRPT:UW,BBG000BCJC58,Insiders Bullish on Certain Holdings of XBI,2016-09-08 15:18:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yntYrCtZgos/insiders-bullish-on-certain-holdings-of-xbi-cm676157,A look at the weighted underlying holdings of the SPDR S amp P Biotech ETF XBI shows an impressive 12 3 of holdings on a weighted basis have experienced insider buying within the past six months Sarepta Therapeutics Inc Symbol SRPT which makes up 3 14 of the SPDR S amp P
SRPT,SRPT:UW,BBG000BCJC58,"XBI, DDG: Big ETF Outflows",2016-09-07 16:18:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JcBn4KEzaus/xbi-ddg-big-etf-outflows-cm675607,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the SPDR S amp P Biotech ETF where 2 900 000 units were destroyed or a 8 0 decrease week over week Among the largest underlying components of XBI in
SRPT,SRPT:UW,BBG000BCJC58,Better Buy: ACADIA Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc.,2016-09-04 11:50:42 +0000,http://www.fool.com/investing/2016/09/03/better-buy-acadia-pharmaceuticals-vs-sarepta-thera.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: ACADIA Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc.
SRPT,SRPT:UW,BBG000BCJC58,Better Buy: ACADIA Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc.,2016-09-03 13:17:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NLJ30vxH-ZM/better-buy-acadia-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-cm674435,Image source Getty Images ACADIA Pharmaceuticals NASDAQ ACAD and Sarepta Therapeutics NASDAQ SRPT 160 are both cash burning biotech stocks that offer huge upside if everything goes according to plan However shareholders in each company face a real risk of being
SRPT,SRPT:UW,BBG000BCJC58,SPDR S&P Biotech ETF Experiences Big Inflow,2016-08-30 16:12:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y1JhmdUSg6E/spdr-sp-biotech-etf-experiences-big-inflow-cm672265,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $97.6 million dollar inflow"
SRPT,SRPT:UW,BBG000BCJC58,Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.,2016-08-26 15:30:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bRd1jNkw7j4/mallinckrodt-dmd-drug-gets-fast-track-status-in-the-us-cm670703,Mallinckrodt Public Limited CompanyMNK announced that it has received Fast Track designation in the U.S. for its Investigational New Drug (IND) application for Synacthen Depot for the treatment of patients with Duchenne muscular dystrophy (DMD).  We
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks With Explosive Upside Potential,2016-08-23 21:46:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5_y8QCugfBI/3-biotech-stocks-with-explosive-upside-potential-cm669231,Image source  Getty Images.  The biotech sector is a great hunting ground for investors who are after stocks that offer massive upside. If you buy shares in a company that goes on to create
SRPT,SRPT:UW,BBG000BCJC58,3 Biotech Stocks With Explosive Upside Potential,2016-08-23 19:41:00 +0000,http://www.fool.com/investing/2016/08/23/3-biotech-stocks-with-explosive-upside-potential.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks With Explosive Upside Potential
SRPT,SRPT:UW,BBG000BCJC58,What's behind put volume in Sarepta,2016-08-23 17:36:18 +0000,http://finance.yahoo.com/news/whats-behind-put-volume-sarepta-173618076.html,What's behind put volume in Sarepta
SRPT,SRPT:UW,BBG000BCJC58,"Notable Monday Option Activity: SRPT, ALNY, SWFT",2016-08-22 17:40:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sxy8D3vYGks/notable-monday-option-activity-srpt-alny-swft-cm668569,"Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sarepta Therapeutics Inc (Symbol SRPT), where a total volume of 24,954 contracts has been traded thus far today, a contract volume"
SRPT,SRPT:UW,BBG000BCJC58,"XBI, IONS, SRPT, BLUE: ETF Outflow Alert",2016-08-22 16:40:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qy3_oguYklg/xbi-ions-srpt-blue-etf-outflow-alert-cm668478,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $160.7 million dollar outflow"
SRPT,SRPT:UW,BBG000BCJC58,"XBI, IONS, SRPT, BLUE: ETF Inflow Alert",2016-08-12 16:49:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/--DhNSXf-v4/xbi-ions-srpt-blue-etf-inflow-alert-cm664745,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $216.8 million dollar inflow"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: Patience Will Not Be Rewarded,2016-08-10 19:12:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/10/sarepta-therapeutics-patience-will-not-be-rewarded/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: Patience Will Not Be Rewarded
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines'",2016-08-10 14:37:00 +0000,https://www.thestreet.com/story/13671174/1/sarepta-therapeutics-srpt-stock-falls-janney-stay-on-the-sidelines.html?puc=yahoo&cm_ven=YAHOO,"Sarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines'"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics: Here We Go Again,2016-08-10 13:57:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/10/sarepta-therapeutics-here-we-go-again/?mod=yahoobarrons&ru=yahoo,Sarepta Therapeutics: Here We Go Again
SRPT,SRPT:UW,BBG000BCJC58,[$$] Heart of Bureaucratic Darkness,2016-08-10 04:07:27 +0000,http://www.wsj.com/articles/heart-of-bureaucratic-darkness-1470784233?ru=yahoo?mod=yahoo_itp,[$$] Heart of Bureaucratic Darkness
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report",2016-08-09 20:10:33 +0000,http://biz.yahoo.com/e/160809/srpt10-q.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report"
SRPT,SRPT:UW,BBG000BCJC58,Is Sarepta Therapeutics Still a Buy After Surging Higher in July?,2016-08-09 14:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FZw-6Ixjcs4/is-sarepta-therapeutics-still-a-buy-after-surging-higher-in-july-cm662434,"Image source  Getty Images.  What Sarepta Therapeutics (NASDAQ  SRPT) , an RNA based therapeutics company, saw its shares rise by almost 25% last month, according to data from S&P Global Market Intelligence ."
SRPT,SRPT:UW,BBG000BCJC58,"XBI, IONS, SRPT, TSRO: Large Outflows Detected at ETF",2016-08-04 16:56:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3thRB6csAlg/xbi-ions-srpt-tsro-large-outflows-detected-at-etf-cm660498,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol XBI) where we have detected an approximate $215.5 million dollar outflow"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta (SRPT) Stock Advances on Phase III Trial Recruitment,2016-08-03 16:30:00 +0000,https://www.thestreet.com/story/13663409/1/sarepta-srpt-stock-advances-on-phase-iii-trial-recruitment.html?puc=yahoo&cm_ven=YAHOO,Sarepta (SRPT) Stock Advances on Phase III Trial Recruitment
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics is Soaring,2016-08-03 15:51:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/03/why-sarepta-therapeutics-is-soaring/?mod=yahoobarrons&ru=yahoo,Why Sarepta Therapeutics is Soaring
SRPT,SRPT:UW,BBG000BCJC58,How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company,2016-07-28 12:30:00 +0000,http://www.forbes.com/sites/matthewherper/2016/07/28/from-rare-to-great/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoomag,How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks Wall Street Hates,2016-07-26 16:23:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oZYC6EsQLPM/3-stocks-wall-street-hates-cm654879,"Image source  Getty Images.  Wall Street is in love with the stock market. According to an analysis by the Bespoke Investment Group, of the 12,122 analyst ratings on companies in the S&P 500,"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments,2016-07-26 15:28:04 +0000,http://www.publicnow.com/view/9AE0181E5A68692CBFC5172BF9EA252175FE6E88,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 19, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three and six ..."
SRPT,SRPT:UW,BBG000BCJC58,3 Stocks Wall Street Hates,2016-07-26 15:06:00 +0000,http://www.fool.com/investing/2016/07/26/3-stocks-wall-street-hates.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks Wall Street Hates
SRPT,SRPT:UW,BBG000BCJC58,"Health Care Sector Update for 07/22/2016: SRPT,PBYI,CFRX",2016-07-22 20:43:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mQgPhg1Dl-8/health-care-sector-update-for-07222016-srptpbyicfrx-cm653608,"Top Health Care Stocks JNJ 0.15% PFE +0.05% MRK +0.22% ABT +0.08% AMGN +0.88% Health care stocks were finishing moderately higher, with the NYSE Health Care Index rising about 0.4% while shares of health care companies in the S&P"
SRPT,SRPT:UW,BBG000BCJC58,Why Investors Flocked to Sarepta Therapeutics This Week,2016-07-21 20:14:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z4TxQdxOwjc/why-investors-flocked-to-sarepta-therapeutics-this-week-cm652904,"Image source  Getty Images.  What   Sarepta Therapeutics (NASDAQ  SRPT) investors have been in a holding pattern since the FDA delayed a decision on the company's Duchenne muscular dystrophy (DMD) drug,"
SRPT,SRPT:UW,BBG000BCJC58,SRPT Makes Bullish Cross Above Critical Moving Average,2016-07-21 17:13:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fT6bHGmtSiw/srpt-makes-bullish-cross-above-critical-moving-average-cm652750,"In trading on Thursday, shares of Sarepta Therapeutics Inc (Symbol SRPT) crossed above their 200 day moving average of $22.77, changing hands as high as $23.41 per share. Sarepta Therapeutics Inc shares are currently trading up about 3.1% on"
SRPT,SRPT:UW,BBG000BCJC58,Why Investors Flocked to Sarepta Therapeutics This Week,2016-07-21 15:02:00 +0000,http://www.fool.com/investing/2016/07/21/why-investors-flocked-to-sarepta-therapeutics-last.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Investors Flocked to Sarepta Therapeutics This Week
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus",2016-07-20 15:18:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G8JjAZ4robs/sarepta-srpt-posts-yy-wider-q2-loss-eteplirsen-in-focus-cm651887,"Sarepta Therapeutics, Inc.SRPT reported a loss of $1.34 per share in the second quarter of 2016, wider than both the Zacks Consensus Estimate of a loss of $1.19 and the year ago loss of $1.01. The company did not"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss,2016-07-20 13:47:00 +0000,https://www.thestreet.com/story/13645844/1/sarepta-therapeutics-srpt-stock-falls-on-q2-earnings-loss.html?puc=yahoo&cm_ven=YAHOO,Sarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus",2016-07-20 12:57:12 +0000,http://finance.yahoo.com/news/sarepta-srpt-posts-y-y-125712342.html,"Sarepta (SRPT) Posts Y/Y Wider Q2 Loss, Eteplirsen in Focus"
SRPT,SRPT:UW,BBG000BCJC58,Morning Movers: Morgan Stanley Jumps on Earnings; Valeant Pharmaceuticals Climbs on Drug Approval,2016-07-20 12:26:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/07/20/morning-movers-morgan-stanley-jumps-on-earnings-valeant-pharmaceuticals-jumps-on-drug-approval/?mod=yahoobarrons&ru=yahoo,Morning Movers: Morgan Stanley Jumps on Earnings; Valeant Pharmaceuticals Climbs on Drug Approval
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics reports 2Q loss,2016-07-19 20:06:34 +0000,http://sg.finance.yahoo.com/news/sarepta-therapeutics-reports-2q-loss-200634829.html,Sarepta Therapeutics reports 2Q loss
SRPT,SRPT:UW,BBG000BCJC58,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an",2016-07-19 20:05:27 +0000,http://biz.yahoo.com/e/160719/srpt8-k.html,"SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD,2016-07-14 20:14:48 +0000,http://www.investors.com/news/technology/sarepta-stock-slides-as-fda-sends-another-bad-signal-for-dmd/?ven=YahooCP&src=AURLLED&ven=yahoo,Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD
SRPT,SRPT:UW,BBG000BCJC58,Is There Hope for Sarepta?,2016-07-14 16:50:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/07/14/is-there-hope-for-sarepta/?mod=yahoobarrons&ru=yahoo,Is There Hope for Sarepta?
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics stock slumps 3.5% after other DMD drug is denied accelerated approval,2016-07-14 15:35:18 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=465EFEE2-A9B0-4DC0-AF45-2277A14E5D01&siteid=yhoof2,Sarepta Therapeutics stock slumps 3.5% after other DMD drug is denied accelerated approval
SRPT,SRPT:UW,BBG000BCJC58,Duchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay,2016-07-14 12:46:00 +0000,https://www.thestreet.com/story/13639641/1/duchenne-drug-developer-not-sarepta-hit-with-lengthy-fda-delay.html?puc=yahoo&cm_ven=YAHOO,Duchenne Drug Developer (Not Sarepta) Hit With Lengthy FDA Delay
SRPT,SRPT:UW,BBG000BCJC58,3 Risky Biotech Stocks That Could Make You Rich,2016-07-12 21:49:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9m0zO4G9r1U/3-risky-biotech-stocks-that-could-make-you-rich-cm648245,"Image Source  Getty Images  If you're looking for stocks that offer unusual growth opportunities, clinical stage biotechs are fertile ground. Even among this select group, though, there are only a handful of companies"
SRPT,SRPT:UW,BBG000BCJC58,3 Risky Biotech Stocks That Could Make You Rich,2016-07-12 20:25:00 +0000,http://www.fool.com/investing/2016/07/12/3-risky-biotech-stocks-that-could-make-you-rich.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Risky Biotech Stocks That Could Make You Rich
SRPT,SRPT:UW,BBG000BCJC58,Why Sarepta Therapeutics Shares Slipped 10.9% in June,2016-07-09 15:38:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KxA_IsHpYDY/why-sarepta-therapeutics-shares-slipped-109-in-june-cm646822,"Image source  Getty Images.  What  In May, Sarepta Therapeutics (NASDAQ  SRPT)  shares notched double digit gains in hopes that the Food and Drug Administration would disregard a key advisory committee vote"
SRPT,SRPT:UW,BBG000BCJC58,Catabasis' DMD Drug in Phase II Open-Label Extension Study,2016-07-08 16:41:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XKBXqnoO1iI/catabasis-dmd-drug-in-phase-ii-open-label-extension-study-cm646449,"Catabasis Pharmaceuticals, Inc.CATB announced that it has initiated an open label extension (Part C) of the phase II portion of its MoveDMD study (phase I II) on edasalonexent (CAT 1004). Edasalonexent, a molecule that inhibits a protein called NF"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Inc's Stock Has Plunged 47% in 2016. Here's Why.,2016-07-04 13:46:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MemOTwVoQpk/sarepta-therapeutics-incs-stock-has-plunged-47-in-2016-heres-why-cm644353,Image source  Getty Images.  What   It's been a rough couple of months to be an investor in Sarepta Therapeutics (NASDAQ  SRPT) . A series of positive and negative news items have
SRPT,SRPT:UW,BBG000BCJC58,141 Reasons to Love Biotech Stocks,2016-06-30 23:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_XYP8-9lWfU/141-reasons-to-love-biotech-stocks-cm643557,"Image source  Getty Images.  The biotech sector has taken a bit of a beating, down about 24% this year as measured by the iShares NASDAQ Biotechnology Index ETF , and down about 35%"
SRPT,SRPT:UW,BBG000BCJC58,3 Tempting Stocks to Avoid,2016-06-26 15:26:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ET15srVdgY/3-tempting-stocks-to-avoid-cm640837,"You might regret buying these stocks. Image source  Getty Images.  The stock market hasn't done much over the past year. Adjusted for dividends, The S&P 500 is up a mere 1%. That paltry"
SRPT,SRPT:UW,BBG000BCJC58,Fake Tweets Sink Stocks: What Happens When Scammers Impersonate Research Firms,2016-06-22 00:56:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8bEjQ_cmFo0/fake-tweets-sink-stocks-what-happens-when-scammers-impersonate-research-firms-cm638767,"Image source  Getty images.  In recent years, more and more people have turned to social media, and Twitter in particular, for investing news and intelligence. The trend is in part supported by the"
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Proposed Offering,2016-06-09 09:09:04 +0000,http://www.publicnow.com/view/A65BCFB0D9D805E0FFDA94268FA8E4F442BCF3AA,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2016-- Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA,2016-06-08 20:48:01 +0000,http://www.publicnow.com/view/4373784AAD2202235194414393C332CD77DC3374,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration ..."
SRPT,SRPT:UW,BBG000BCJC58,"ADMP Snubbed Again, OCUL, DNAI Skid On Trial Data, AGN Gets FDA Nod. SRPT Abuzz",2016-06-07 01:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R0lid86hsxY/admp-snubbed-again-ocul-dnai-skid-on-trial-data-agn-gets-fda-nod-srpt-abuzz-20160607-00028,"ADMP Snubbed Again, OCUL, DNAI Skid On Trial Data, AGN Gets FDA Nod. SRPT Abuzz"
SRPT,SRPT:UW,BBG000BCJC58,"No Pain, Only Gain For INNL, FDA Panel Backs SNY, Wait Continues For SRPT",2016-05-25 23:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DNmIUDzwdF0/no-pain-only-gain-for-innl-fda-panel-backs-sny-wait-continues-for-srpt-20160525-01241,"No Pain, Only Gain For INNL, FDA Panel Backs SNY, Wait Continues For SRPT"
SRPT,SRPT:UW,BBG000BCJC58,FDA delay raises slim hope for muscular dystrophy drug,2016-05-25 16:23:54 +0000,http://sg.finance.yahoo.com/news/fda-delays-high-stakes-decision-141838845.html,FDA delay raises slim hope for muscular dystrophy drug
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Holding On To Strong Gain After Initial Jump,2016-05-25 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L4-9m6YyLb0/sarepta-holding-on-to-strong-gain-after-initial-jump-20160525-00775,Sarepta Holding On To Strong Gain After Initial Jump
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date,2016-05-25 11:26:05 +0000,http://www.publicnow.com/view/A1AD678B2CCEEB84981D3E029EF764F745DF148F,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 25, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics (SRPT) Is Up Sharply After FDA Delays Eteplirsen Review,2016-05-25 09:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8gJdM2I8jHI/sarepta-therapeutics-srpt-is-up-sharply-after-fda-delays-eteplirsen-review-20160525-00580,Sarepta Therapeutics (SRPT) Is Up Sharply After FDA Delays Eteplirsen Review
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: FDA''s Decision on Dystrophy Drug Delayed,2016-05-25 09:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Aztl6yCcft8/sarepta-fdas-decision-on-dystrophy-drug-delayed-20160525-00557,Sarepta: FDA''s Decision on Dystrophy Drug Delayed
SRPT,SRPT:UW,BBG000BCJC58,Sarepta: FDA's Decision on Dystrophy Drug Delayed,2016-05-25 09:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8pDrybpEKY4/sarepta-fdas-decision-on-dystrophy-drug-delayed-20160525-01070,Sarepta: FDA's Decision on Dystrophy Drug Delayed
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Says FDA Will Not Complete Review Of Eteplirsen NDA By PDUFA Date,2016-05-25 07:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7QS-ZTO4TFQ/sarepta-says-fda-will-not-complete-review-of-eteplirsen-nda-by-pdufa-date-20160525-00221,Sarepta Says FDA Will Not Complete Review Of Eteplirsen NDA By PDUFA Date
SRPT,SRPT:UW,BBG000BCJC58,D-Day For Sarepta As FDA Decision Looms,2016-05-24 23:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SVvSCxvu21A/dday-for-sarepta-as-fda-decision-looms-20160524-01246,D-Day For Sarepta As FDA Decision Looms
SRPT,SRPT:UW,BBG000BCJC58,CORRECTING and REPLACING Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2016-05-14 08:08:01 +0000,http://www.publicnow.com/view/D200C88ABB1B1694523328ED820E8E217B76AE03,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2016-- Please replace the release dated February 2, 2016 with the following corrected version due to multiple revisions. ... This is an abstract of the original ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Developments,2016-05-05 17:01:05 +0000,http://www.publicnow.com/view/DE3ED10E7A0E066387664CAE0A6DBD2B2704AAAA,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2016-- Sarepta Therapeutics, Inc.(NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months ended ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics reports 1Q loss,2016-05-05 11:24:25 +0000,http://sg.finance.yahoo.com/news/sarepta-therapeutics-reports-1q-loss-112425373.html,Sarepta Therapeutics reports 1Q loss
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy,2016-05-05 11:21:08 +0000,http://www.publicnow.com/view/CAED9833BAE6AC8851DFBA21152F624899E63BDE,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 25, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced that the U.S. Food and Drug Administration's ..."
SRPT,SRPT:UW,BBG000BCJC58,Muscular dystrophy drug falls short at high-stakes meeting,2016-04-26 00:36:09 +0000,http://sg.finance.yahoo.com/news/muscular-dystrophy-drug-falls-short-234059043.html,Muscular dystrophy drug falls short at high-stakes meeting
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2016-04-02 03:49:16 +0000,http://www.publicnow.com/view/D407D9772B4B2905F12700BB4784294767E8C3D2,"[at noodls] - --Advisory Committee Meeting Rescheduled for April 25, 2016-- --PDUFA date for eteplirsen is May 26, 2016-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 14, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics reports 4Q loss,2016-02-25 23:21:45 +0000,http://sg.finance.yahoo.com/news/sarepta-therapeutics-reports-4q-loss-232145251.html,Sarepta Therapeutics reports 4Q loss
SRPT,SRPT:UW,BBG000BCJC58,FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area,2016-01-21 01:05:04 +0000,http://www.noodls.com/view/8A0904D6F44AA1C60E4C0E175388FB27D261F598,"[at noodls] - --(BUSINESS WIRE)--Jan. 20, 2016-- (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration's () meeting scheduled for has been postponed ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta plunges on negative FDA drug review,2016-01-15 19:34:23 +0000,http://sg.finance.yahoo.com/news/sarepta-plunges-negative-fda-drug-193423340.html,Sarepta plunges on negative FDA drug review
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),2016-01-04 22:00:08 +0000,http://www.noodls.com/view/618F3C6A5513C0610BDA1774E2554CD1DC5E1C6F,"[at noodls] - --(BUSINESS WIRE)--Jan. 4, 2016-- , Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, granted equity awards on , that were previously approved by the Compensation Committee of its ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments,2015-11-17 14:11:44 +0000,http://www.noodls.com/view/5BB4E9696B72D9479BE57487822D969EDBD76745,"[at noodls] - Well capitalized with $111 million in cash and other investments at quarter end, with an additional $120 million raised post-quarter end CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2015-- Sarepta Therapeutics, ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics reports 3Q loss,2015-11-05 13:05:57 +0000,http://sg.finance.yahoo.com/news/sarepta-therapeutics-reports-3q-loss-130557806.html,Sarepta Therapeutics reports 3Q loss
SRPT,SRPT:UW,BBG000BCJC58,"Sarepta Therapeutics to Announce Third Quarter 2015 Financial Results and Recent Corporate Developments on November 5, 2015",2015-10-27 12:55:17 +0000,http://www.noodls.com/view/96D3CF5FD34BF267258591189062A746BD8AE95F,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 27, 2015-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, will report third quarter 2015 financial results before ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy,2015-10-25 23:12:12 +0000,http://www.noodls.com/view/D164CBDDE01B8E4C75E588BAA04636D427E4FD46,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 14, 2015-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the Peripheral and Central Nervous System ..."
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock,2015-10-09 15:47:10 +0000,http://www.noodls.com/view/BA98A1B069CBB15633A4EACE81C3EA237ACB683C,[at noodls] - Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Pricing of $127 Million Public Offering of Common Stock,2015-10-06 13:34:10 +0000,http://www.noodls.com/view/51F3B479C531B475A0B370EC8EF0CBE70E952144,[at noodls] - Sarepta Therapeutics Announces Pricing of $127 Million Public Offering of Common Stock
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Proposed Public Offering of Common Stock,2015-10-05 21:04:09 +0000,http://www.noodls.com/view/F597C27A3B4BC73CBEAA560349BD15E142F7F5FB,[at noodls] - Sarepta Therapeutics Announces Proposed Public Offering of Common Stock
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers Steve Wilton and Sue Fletcher,2015-10-01 20:58:03 +0000,http://www.noodls.com/view/839D0BBA02514550EE11C009FBFE7CB87FD1868B,[at noodls] - Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers Steve Wilton and Sue Fletcher
SRPT,SRPT:UW,BBG000BCJC58,BUZZ-Sarepta news lifts other muscular distrophy stocks,2015-05-20 19:18:50 +0000,http://uk.finance.yahoo.com/news/buzz-sarepta-news-lifts-other-191850656.html,BUZZ-Sarepta news lifts other muscular distrophy stocks
SRPT,SRPT:UW,BBG000BCJC58,FDA panel to discuss Ebola vaccine development in May,2015-03-18 12:16:20 +0000,http://uk.finance.yahoo.com/news/fda-panel-discuss-ebola-vaccine-121620395.html,FDA panel to discuss Ebola vaccine development in May
SRPT,SRPT:UW,BBG000BCJC58,Medicago wins contract to develop Ebola treatments,2015-02-24 15:47:20 +0000,http://uk.finance.yahoo.com/news/medicago-wins-contract-develop-ebola-154720596.html,Medicago wins contract to develop Ebola treatments
SRPT,SRPT:UW,BBG000BCJC58,Sarepta Therapeutics tops 3Q profit forecasts,2014-11-06 12:51:53 +0000,http://sg.finance.yahoo.com/news/sarepta-therapeutics-tops-3q-profit-125153932--finance.html,Sarepta Therapeutics tops 3Q profit forecasts
SRPT,SRPT:UW,BBG000BCJC58,Sarepta tumbles on new delay for key drug,2014-10-27 14:54:27 +0000,http://sg.finance.yahoo.com/news/sarepta-tumbles-delay-key-drug-145427827--finance.html,Sarepta tumbles on new delay for key drug
SRPT,SRPT:UW,BBG000BCJC58,Ahead of the Bell: Sarepta Therapeutics climbs,2014-10-17 11:39:45 +0000,http://sg.finance.yahoo.com/news/ahead-bell-sarepta-therapeutics-climbs-113945455--finance.html,Ahead of the Bell: Sarepta Therapeutics climbs
